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aspects. For Paper IV, Associate Professor of University of Bergen and consultant 
paediatrician at Stavanger University Hospital Ingvild Bruun Mikalsen has been 
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Knut Øymar, Professor at the Department of Clinical Science, University of Bergen 
has been the main supervisor of this thesis. As a PhD candidate I have been affiliated 
to the Department of Clinical Science, University of Bergen.  
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Paediatric Department of Stavanger University Hospital as part of everyday clinical 
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insights into aspects of childhood growth. He provided the idea of writing the second 
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writing. 
I would like to specially thank my colleague and friend, Ingvild Mikalsen, who was 
the second author and who contributed substantially to my last paper. She has seen 
the project from the outside and provided several critical questions that led to 
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I would like to extend my warmest gratitude to Professor and Biostatistician Geir Egil 
Eide from the Centre of Clinical Research at Haukeland University Hospital. Despite 
his busy schedule and involvement in several research projects, he has provided 
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extensive answers to all my questions. 
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Summary of thesis 
Background 
An adverse intrauterine environment may affect offspring immunology, 
including allergies, asthma and lung function, as well as offspring metabolism, 
including growth and development. A few studies have been reported on the 
associations between preeclampsia and these outcomes, but they have shown 
conflicting results. Furthermore, a possible association between childhood excessive 
weight/obesity and physical activity with allergies, asthma and lung function has been 
suggested, but, again, previous studies show conflicting results, and few longitudinal 
studies exist. 
Objectives 
(1) To study the associations of preeclampsia exposure with atopic 
sensitization, allergic rhinoconjunctivitis, atopic dermatitis, asthma and lung function 
in late childhood. (2) To study the associations of preeclampsia exposure with 
length/height, weight and body mass index (BMI) at several ages from birth to late 
childhood and waist circumference, waist-to-height ratio and skinfolds in late 
childhood. (3) To study the associations of weight-related anthropometric 
measurements at several ages from birth to late childhood and physical activity with 
allergies and asthma in late childhood. (4) To study the associations of weight-related 
anthropometric measurements at several ages from birth to late childhood with lung 
function in late childhood. 
Methods 
In a nested case control study, 229 children were exposed to preeclampsia 
(mild/moderate: n = 164, severe: n = 54, unknown severity: n = 11) and 385 were 
unexposed. Length/height were abstracted from medical records at birth, 3 and 6 
months, 1 and 4 years, and measured along with waist circumference and skinfolds at 
10.8 years (girls), 11.8 years (boys) and 12.8 years (both genders). Questionnaires on 
maternal and child data were administered to the mothers when the children were at 
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the age of 10.8/11.8 years (girls/boys) and to the children at the age of 12.8 years 
(both genders). Specific IgE in serum and lung function were measured at the age of 
12.8 years (both genders). Multiple regression analyses were performed to analyse 
the associations of mother’s preeclampsia, child weight, child BMI, and childhood 
physical activity with childhood growth, atopic sensitization, allergic 
rhinoconjunctivitis, asthma, atopic dermatitis and lung function. 
Results 
 Severe preeclampsia exposure was associated with high-level atopic 
sensitization (sum of specific IgE in serum  3.9 kU/l; the lower quartile of all 
sensitized children in the study) and with allergic rhinoconjunctivitis in the offspring. 
We did not find any association of preeclampsia with allergic rhinoconjunctivitis, 
atopic dermatitis or lung function. 
 In boys, mild/moderate preeclampsia exposure was positively associated with 
length/height after 0.5 years; however, severe preeclampsia exposure was negatively 
associated with length/height at all ages. In girls, preeclampsia was negatively 
associated with length/height until 12 years of age. In both genders, preeclampsia 
exposure was in general negatively associated with weight and BMI during infancy 
and early childhood, but the association became positive in later childhood, except 
that for boys exposed to severe preeclampsia the negative association remained 
throughout childhood. Severe preeclampsia exposure was positively associated with 
waist-to-height ratio at 10.8/11.8 (girls/boys) years of age. We did not find any 
associations of preeclampsia exposure with skinfolds or waist circumference. 
 BMI at 1 year of age and low physical activity at 3–6 years of age were 
positively associated with atopic sensitization at 12.8 years of age. Change in BMI 
from 1 to 4 years, BMI at 4 years and high physical activity at 6–10 years of age were 
positively associated with ever being diagnosed with atopic dermatitis at the age of 
10.8/11.8 years (girls/boys). Low physical activity at 3–6 and 6–10 years of age were 
positively associated with ever being diagnosed with asthma at the age of 10.8/11.8 
years (girls/boys). We did not find any associations of weight, BMI and physical 
activity with ever being diagnosed with allergic rhinoconjunctivitis at the age of 
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10.8/11.8 years (girls/boys), and current asthma at the age of 12.8 years (both 
genders), nor did we find any non-straight-line associations of the predictors with any 
of the outcomes of atopic sensitization, allergic rhinoconjunctivitis, atopic dermatitis 
or asthma. 
 Birthweight and BMI at different ages throughout childhood were positively 
associated with forced vital capacity in percent of predicted (FVC %) and forced 
expiratory volume in the first second of predicted (FEV1 %) at 12.8 years of age. 
BMI, waist circumference, waist-to-height ratio and skinfolds at 12.8 years of age 
and the change in BMI from early to late childhood were positively associated with 
FVC % and FEV1 % and negatively associated with FEV1/FVC and forced expiratory 
flow at 25–75% of FVC/FVC. Interaction analyses showed that positive associations 
between anthropometrics other than BMI and lung function were mostly present in 
girls. Inverse U-shaped associations were found between BMI at the ages of 
10.8/11.8 (girls/boys) and 12.8 years (both genders) and FVC % and FEV1 % at 12.8 
years of age. 
Conclusions 
Preeclampsia exposure was positively associated with atopic sensitization and 
allergic rhinoconjunctivitis in late childhood, but not with atopic dermatitis, asthma 
or lung function. From birth to adolescence, length/height, weight and BMI 
trajectories differed between the genders depending on the severity of preeclampsia 
exposure. In general, preeclampsia exposure was negatively associated with 
length/height, and in girls positively associated with weight and BMI. BMI and 
physical activity in early childhood were positively associated with atopic 
sensitization, atopic dermatitis and asthma in late childhood. Body composition 
through childhood may influence lung function in late childhood, which may be 
physiological or associated with air flow limitation. Non-straight-line associations 
suggest a differential impact on lung function in normal-weighted and overweight 
children. 
Our results suggest that foetal life is a particularly sensitive period for 
subsequent growth and development of the immune system, and that growth during 
18 
childhood may further influence allergic disease and lung function in late childhood. 
Understanding the impact of early life risk factors may enable preventing the 
development of allergic disease and unfavourable lung function and promote healthy 
growth. 
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Allergy and allergic diseases are becoming increasingly common worldwide (1-3). 
They represent the most common chronic medical conditions in children, and they 
impose a considerable burden on the involved children and their families. Today, 
more than one-third of all Norwegian school children have at least one allergic 
sensitization (4). 
Allergies seem to have affected humans since ancient times. The earliest medical 
description of allergy is of King Menses of Egypt, who died of anaphylaxis in 2641 
BC; furthermore, Emperor Octavianus Augustus (born in 63 BC) was the most 
famous allergic individual of this era, with the whole allergic triad including allergic 
rhinitis, asthma and eczema and positive family history of allergy (5). 
One of the milestones in the understanding of allergic diseases is the simultaneous 
discovery of IgE by Johansson and Bennich in Uppsala, Mrs and Mr Ishizaka in 
Denver and Humphrey and Stanworth in the UK in 1967 (6-8). IgE is the 
immunoglobulin involved in hypersensitivity type 1, and it manifests in allergy and 
allergic diseases (9). During the past few decades, as increasing knowledge has been 
gained about allergies, an epidemic of allergy and allergic diseases has also been 
seen, especially in the developed world. 
Over the last 2000 years, various terms have been used for describing allergies. 
However, only in 1906 did Clemens von Pirquet introduce the term ‘allergy’ (from 
the Greek ‘allos’ meaning ‘other’ and ‘ergon’ meaning ‘reaction’) to describe a 
hypersensitivity reaction. In 1923, the American allergists Coca and Cooke 
introduced the term atopy to characterize familial-type hypersensitivity reactions such 
as asthma, seasonal allergic rhinitis and others (10). 
The worldwide allergy epidemic cannot be explained by inheritance alone. 
Increasingly, environmental factors are being studied to find an explanation. In 
particular, early-life factors, both in utero and during the first years of life, seem to 
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play an important role. Increasing evidence suggests that pregnancy and early 
childhood are sensitive periods for environmental risk factors for the development of 
allergy and allergic disease (11). 
A hostile intrauterine environment could potentially affect the developing foetus, 
especially in terms of lung development and the immune system, which develop both 
in utero and in early childhood (12, 13). 
Preeclampsia affects 3%–5% of pregnancies, and it may create a hostile intrauterine 
environment (14). Associations between preeclampsia exposure in utero and 
subsequent allergic sensitization and allergic disease have been suggested (15-17). 
Adaptive responses to low birth weight due to a hostile intrauterine environment 
could be a risk factor for subsequent obesity and metabolic diseases (18). The 
prevalence of obesity has increased in parallel with allergy and allergic diseases, and 
an association has been suggested (19). The association between obesity and asthma 
in adults has been established, and some studies indicate the same for children (20, 
21). However, studies on the association between obesity and allergy in childhood 
show conflicting results (22, 23). 
A possible association between preeclampsia exposure and allergic sensitization, 
allergic disease and lung function could be mediated through a changed growth 
pattern in affected children. It is already known that children exposed to preeclampsia 
(especially of the severe type) have low birthweight, and at least some of them have 
an increased risk of overweight in adolescence (24, 25).  However, how preeclampsia 
exposure affects growth between birth and adolescence remains unknown, and the 
effect on height has not been studied according to the severity of preeclampsia. To 
address these issues could improve the understanding of the complex relations of 
early life predictors and outcomes in the other papers of this thesis. 
After the submission of the first paper of in this thesis in February 2014, new studies 
about preeclampsia, growth, allergic sensitization, allergic diseases and lung function 
have been published. Our study aimed to address questions based on the current 
knowledge at that time. Consequently, when addressing topics related to our 
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hypotheses, the general introduction will refer to articles published before our papers. 
More recent knowledge will be addressed in the discussion section. 
1.2 Preeclampsia 
Preeclampsia is a maternal disorder of pregnancy occurring after 20 weeks of 
gestation. It can either be of severe type with onset at early pregnancy or with slowly 
developing, milder symptoms later during pregnancy. The mother shows 
hypertension, renal involvement, coagulation disturbances and reduced organ 
perfusion. The most severe form often results in preterm delivery, intrauterine growth 
restriction or even foetal death. Preeclampsia is the most common cause of maternal 
and foetal morbidity and mortality in the developed world (14). 
1.2.1 Definition 
The word preeclampsia is derived from the words ‘pre’ and ‘eclampsia’. ‘Eclampsia’ 
is a Greek noun meaning a ‘light burst’, and it is used metaphorically in this context 
to mean ‘sudden occurrence’.  
Preeclampsia may be defined in various ways, and it could probably be characterised 
as a syndrome rather than as one disorder. However, most preeclampsia cases have 
some common features, and in this study, we have used the criteria of the 
Collaborative Low-dose Aspirin Study in Pregnancy (CLASP) (26), which is 
described in greater detail in Chapter 3.  
1.2.2 Epidemiology 
Despite advancements in perinatal care, the incidence of preeclampsia has increased 
during the last two decades (27), and it is seen globally in 3%–5% of all pregnancies 
(14). However, the increased incidence has not been accompanied by any increased 
risk of maternal and infant morbidity and mortality. In healthy nulliparous women, 
this condition is mostly mild and near-term, and it poses a negligible risk of adverse 
outcomes for the offspring. However, the prevalence and risk is higher in women 
with multifetal gestation, hypertension, previous preeclampsia, diabetes mellitus and 
24 
thrombophilia (14). Obesity is a risk factor for preeclampsia, and the worldwide 
increase in obesity is likely to increase the prevalence of preeclampsia (14). 
1.2.3 Pathophysiology 
The causes of preeclampsia are largely unknown. It may be caused by a faulty 
maternal response to placentation, in which inflammatory signals (depending on the 
foetal genes) and the maternal response to these signals (depending on maternal 
genes) lead to the maternal syndrome (14). 
Lam et al. described the difference between abnormal placentation in preeclampsia 
and normal placentation, and it is illustrated in Figure 1 (28).  
Figure 1 Abnormal placentation in preeclampsia. With permission from Lam et al, Hypertension, 2005. In 
normal placental development, invasive cytotrophoblasts of foetal origin invade the maternal spiral arteries, 
transforming them from small-calibre resistance vessels capable of providing adequate placental perfusion to 
sustain the growing foetus. During vascular invasion, the cytotrophoblasts differentiate from an epithelial 
phenotype to an endothelial phenotype (upper panel). In preeclampsia, cytotrophoblasts fail to adopt an invasive 
endothelial phenotype. Instead, invasion of the spiral arteries is shallow, and they remain small-calibre 
resistance vessels (lower panel). 
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Impaired remodelling of the spiral artery has been considered an early event in the 
development of preeclampsia (Figure 2). Vascular changes occur in the inner 
myometrium followed by trophoblast invasion with associated remodelling. The 
interaction of trophoblasts with uterine natural killer cells and/or dendritic cells is 
considered important in the regulation of invasion. The intervillous flow starting at 8 
weeks of gestation in connecting channels appears between spiral arteries and lacunae 
Figure 2 Two possible pathophysiological stages of preeclampsia. Modified from 
Steegers et al., Lancet, 2010, with permission.
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in the wall of the implanted blastocyst, and the embryo is protected from high oxygen 
concentrations by early trophoblast plugging. The premature loss or insufficient 
lateral spread of these plugs could result in extensive chorionic regression, a small 
placenta and intrauterine growth restriction and/or preeclampsia depending on the 
timing (29).  
Impaired invasion of myometrial spiral arteries in preeclampsia might result from 
maternal flow defects. 
The first stage of preeclampsia might be an excessive or atypical maternal immune 
response to trophoblasts and thus a failed interaction between two genetically 
different organisms (Figure 2). Consequently, very shallow placentation occurs. 
The second stage (Figure 2) involves exaggerated endothelial activation and a 
hyperinflammatory state. The components of the intervillous space are released into 
the systemic maternal circulation, thereby producing the maternal inflammatory 
response. These components include anti-angiogenic factors (29). 
The two types of preeclampsia might actually be two different phenotypes, where the 
severe type is mostly early onset whereas the mild/moderate types are mostly late 
onset. The mechanisms linking these two stages of faulty placentation in 
preeclampsia vary between the different phenotypes. Severe (or early onset) 
preeclampsia is more common in normal-weight mothers, and it is characterized by a 
small placenta owing to angiogenic imbalance, with a higher degree of inflammation. 
Mild/moderate (or late onset) preeclampsia is characterized by normal placentation, 
in which cardiovascular and metabolic syndromes might still set off a cascade of 
placental inflammation (29, 30). 
1.2.4 Clinical characteristics and treatment 
Maternal organ systems susceptible to excessive inflammation and endothelial 
damage include the central nervous system, lungs, liver, kidneys, systemic 
vasculature, heart and the blood coagulation mechanism. The placenta and foetus are 
also at risk. The numbers of complications for the mother and foetus depend on the 
number of organ systems involved. Maternal symptoms may be mild ones like nausea 
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and vomiting even at the onset of severe preeclampsia. Significant maternal 
morbidity is encountered in ~15% of women with severe preeclampsia, which may be 
accompanied by complications including retinal detachment, cerebrovascular 
bleeding and haemolysis, elevated liver enzymes, and low platelet count (HELLP 
syndrome). In particular, early-onset, or severe-type, preeclampsia is associated with 
foetal growth restriction. Eclampsia occurs in 1%–2% of severe preeclampsia cases, 
and causes tonic-clonic seizures either during pregnancy or shortly after delivery 
(29). 
Commonly, the following signs or symptoms might be present: hypertension, 
proteinuria, headache, visual disturbance, epigastric pain, vomiting, reduced foetal 
movements and an infant that is small for the gestational age. 
There is no universal standard of care for mothers with preeclampsia, although 
standardized assessment and surveillance, avoidance and management of severe 
hypertension, prevention and treatment of seizures and avoidance of overhydration 
help reduce morbidity/mortality risk. Women at term are best managed by induction 
of labour, whereas for those remote from term, expectant management could be 
attempted, although the definite treatment is delivery of the baby (29). 
Preeclampsia is the most common indication for premature delivery (23%), with 
several consequences for the offspring (31). 
The timing of delivery depends on foetal well-being as assessed by ultrasound and 
cardiotocography. 
1.2.5 Associations between preeclampsia and subsequent disease 
in the child 
The epigenetic modification of foetal vascular tissue owing to mother’s preeclampsia 
might have consequences for the child’s future cardiovascular and reproductive 
health. Individuals exposed to preeclampsia in utero have an increased risk of having 
(or fathering) a future pregnancy with preeclampsia. Children exposed to 
preeclampsia have an increased risk of hypertension, altered start of puberty, 
metabolic syndrome and cardiovascular disease (29, 32-34). Preeclampsia exposure 
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may have a negative effect on intellectual development in children, and it is 
positively associated with mental, mood or anxiety disorders; epilepsy and lower 
motor competence (35). 
Microchimerism refers to a small number of cells or DNA harboured by one 
individual that originate in a genetically different individual. The most common 
source is from maternal-foetal trafficking across the placenta during pregnancy (36). 
Microchimerism may have an impact on the long-term health of both the mother and 
the offspring. The offspring may have maternal cells and DNA in their body; this is 
called maternal microchimerism, and it is positively associated with inflammatory 
conditions during the entire life. Maternal cells have proliferative potential (37). 
During preeclampsia, the transfer of cells between the mother and the foetus is higher 
than during normal pregnancies, and an increased risk of the mother harbouring foetal 
microchimerism has been found (38). Therefore, the foetus could also have an 
increased risk of maternal microchimerism after pregnancies with preeclampsia. 
Maternal microchimerism is also a risk factor for autoimmune diseases; therefore, it 
could also give rise to other non-communicable diseases like atopy. To the best of our 
knowledge, no publications exist on the possible association between maternal 
microchimerism and atopy; however, one report suggests a negative association 
between maternal microchimerism and asthma in children (39). 
The risk of some types of cancer is suggested to be affected by preeclampsia. Women 
born after preeclamptic pregnancies have a reduced risk of breast cancer (40). Men 
born after pregnancies with severe and mild preeclampsia have a reduced and 
increased risk of testicular cancer, respectively (41). 
A few studies have assessed the associations of preeclampsia with allergy, 
asthma and lung function before the submission of our first paper in the beginning of 
2014. Further details are introduced in Chapters 1.5–1.6. 
1.3 Childhood growth 
It is estimated that up to 80% of the final height of individuals is dependent on their 
genetic potential (42); however, normal endocrine function and adequate nutrition are 
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also prerequisites for normal growth and development (43). Generally, childhood 
growth is a sensitive parameter of general health, and chronic diseases and 
psychosocial deprivation may negatively affect linear growth (44). Additionally, as 
stated by Tanner, children’s growth reflects prevalent conditions in society (45).  
Secular trends in childhood growth in Norway were summarized from the Bergen 
Growth Study in the Journal of the Norwegian Medical Association in 2009 (46). The 
authors found that Norwegian school children were generally taller than children 30 
years ago; overweight had increased in children above five years of age, and those in 
the upper percentiles were mainly affected; toddlers had the same growth as 20 years 
ago; and Norwegian children had higher birthweight, childhood length/height, head 
circumference and weight than the World Health Organization international standard 
(46). 
1.3.1 Normal childhood growth 
Genotype and maternal factors are most important for foetal growth (47, 48). 
Placental function is crucial, and pregnancy disorders weakening the placenta will 
affect foetal growth negatively (49). The placenta exerts endocrine functions by 
producing growth-regulating hormones. Normal foetal growth also depends on an 
adequate supply of nutrients, oxygen and insulin (48, 50). 
Postnatal growth is divided into three stages: infancy, childhood, and puberty, also 
called the ICP model (Figure 3) (51). The first stage, infancy, is characterized by a 
fast but decelerating growth during the first 2–3 years of life. Foetal growth factors 
are most important in this period. The second stage, childhood, starts at ½–1 year of 
age, and it adds to infant growth. From 3 years of age, the childhood stage is the most 
important, with the main growth factors being the thyroid and growth hormones. The 
third and last stage, puberty, adds to childhood growth at puberty, and it adds up to 
20–25 cm for girls and 25–30 cm for boys, independent of ethnicity and age of 
puberty onset. As childhood growth wanes, the total growth in puberty is lower the 
later puberty starts. The earlier puberty starts, the larger will be the total growth 
during puberty. The final height in children with early- or late-onset puberty therefore 
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remains normal as the actual height at puberty onset is either higher or lower 
compared to that of children entering puberty at an average age. Growth during 
puberty is regulated by sex hormones, both directly and through the modification of 
the secretion and effect of growth hormone. The maximal growth velocity is 
frequently seen 2 years after puberty onset (51). 
The crossing of percentiles during the first 2 years of life is frequently normal, and 
the child usually finds its new growth channel during this period (52). Crossing 
percentiles is almost universal in puberty, but it is especially prominent in 
constitutionally delayed growth and development (52). 
1.3.2 Catch-up growth 
The definition of catch-up growth varies, but it is typically characterized by above-
normal height velocity for 1 year following a period of less growth. The change in 
height standard deviation score of 0.67 is frequently used, as it corresponds to the 
distance between two lines in the growth curve. Complete catch-up results in a mean 
final height close to the mean target height (53). 
Figure 3 Karlberg et al., with permission from 
John Wiley and Sons. Height for a typical 
male from birth to maturity. The basic 
hormones involved in the regulation of linear 
growth are also indicated. 
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Small for gestational age (SGA) is usually defined as a birthweight <-2 standard 
deviation scores (SDS) (54). However, intrauterine growth retardation is defined as a 
failure to achieve the growth potential of a foetus that is promised by the genetic 
constitution (49).  
Most, but not all, children show catch-up growth following intrauterine growth 
retardation. Catch-up seen in children born SGA is associated with being overweight 
and obese later in life. Although only 14 % of children born SGA remain short at 18 
years of age (54), these children frequently show more catch-up in weight than in 
height (55). The unfavourable metabolic consequence of being born SGA and/or 
experiencing catch-up growth is indicated by the association with increased 
abdominal adiposity (56). 
1.3.3 Overweight epidemic 
The prevalence of overweight and obese children has increased worldwide during the 
last few decades (57). However, there are large variations across countries. For 
example, the following numbers have been reported in Europe. In England, 
overweight in 4- to 11-year-old boys increased from 7.8% in 1974 to 21.4% in 2002, 
and in Spain, overweight in 6- to 7-year-old boys increased from 21% in 1985 to 34% 
in 1996, with a similar increase being found in girls (58). The annual increases in 
overweight and obesity prevalence in Europe increased from below 0.5% in the 
1980s to over 1.0% in the late 1990s (58). In the Bergen Growth Study from Norway, 
the prevalence of overweight and obesity was found to increase from 1971 to 2007, 
with an overall mean increase in weight for height of 0.48 kg/m (boys) and 0.92 kg/m 
(girls) (59). The prevalence of overweight including obesity found in the Bergen 
Growth Study in 2009 was 13.8% in all children (60). 
The importance of early-life risk factors in the development of childhood obesity is 
increasingly emphasized, and obesity is a risk factor for excessive morbidity across 
the life course for those affected (61).  
Overweight and obesity are due to an energy imbalance, with excess energy stored as 
fat. However, genes, metabolism, behaviour and environment influence body weight 
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and composition (42). Sleep disturbances and social risks are associated with obesity 
(62, 63). A sedentary, modern lifestyle is a risk for overweight/obesity. Medication, 
diet and lifestyle could influence gut flora and thus play a role in obesity, allergy and 
allergic diseases (64, 65) 
Cut-off points for BMI (unit: kg/m2) for thinness grades 1, 2 and 3 and overweight 
and obesity in children between 2 and 18 years by gender for exact age corresponding 
to BMI of 25 and 30 kg/m2 at 18 years of age are shown in Figures 4–5 (46, 66). 
However, BMI is not an accurate measurement of obesity; it is actually influenced by 
both lean and fat mass. Therefore, other measurements of body composition are also 
used. Waist circumference and waist-to-height ratio are strongly related to BMI and 
cardiovascular risk factors, whereas measurements of skinfold thickness do predict 
the percentage of body fat better than BMI (67). However, it is not certain whether 
skinfolds predict health risks better than BMI does (68).  
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Figure 4. Juliusson et al., Bergen Growth Study. Body mass index curves for boys (upper panel) and girls (lower panel). The limits for 
thinness grade 1 and 2 are respectively indicated by the top and bottom of the lower grey area and those for obesity and overweight, by the 
top and bottom of the upper grey areas.
Figure 5. Cole & Lobstein 2012, with permission from John Wiley and Sons. Original international cut-offs (red solid lines) 
and those as derived from the more recent L, M and S curves (blue dotted lines).  
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1.3.4 Developmental origins of health and disease 
The developmental origins of adult disease (DOAD) or the Barker hypothesis is 
based on many studies providing evidence for the hypothesis that birth weight is 
related to disease risk later in life (18, 69). The more modern term, Developmental 
Origins of Health and Disease (DOHaD) is now used, because several early stressors 
in life increase disease risk later in life, and it has been discovered that chronic 
malnutrition, changes in social condition and adverse early-life experiences may 
epigenetically change phenotypes and contribute to long-lasting risk of disease (70). 
Foetal growth is generally limited by maternal constraints, and it is aggravated by 
small placental size or poor perfusion, short maternal stature, young or old maternal 
age, first pregnancy or multiple pregnancies, unbalanced maternal diet or excessive 
maternal thinness or fatness. Furthermore, foetal development is impaired by poor 
placental function or maternal disease. Subsequent rapid childhood growth appears to 
have negative effects on later health. The relation between prenatal nutrition and later 
metabolic disease is likely to be U-shaped, with increased risks at both ends of the 
birth-weight curve. Genetic expressions seem to be modified by prenatal factors. 
These epigenetic modifications involve a small set of enzymes, and they may include 
changes in the methylation of nucleotides in promoter regions of specific genes (71). 
Intrauterine growth restriction, severely preterm birth and food restriction in utero are 
associated with increased appetite and carbohydrate intake and lower physical 
activity, and these food preferences persist into adulthood (72). 
1.3.5 Preeclampsia and growth 
Severe preeclampsia frequently results in poor nutrient supply or, in the most severe 
cases, poor perfusion, and therefore, it may influence foetal growth (73, 74). 
Preeclampsia is the most frequent indication of preterm delivery (31). As intrauterine 
growth restriction and preterm birth may affect the appetite of the offspring (72), 
preeclampsia could, via epigenetics, affect appetite (71) and even the growth of the 
offspring in the long term. 
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Some studies have been conducted on preeclampsia exposure in utero and its 
association with subsequent growth. 
Odegard et al. found that preeclampsia is negatively associated with foetal growth 
(25). Ogland et al. found that preeclampsia exposure in girls is associated with higher 
BMI and larger waist circumference in late childhood, but only if the mothers had 
high BMI (24). In a study of 90 children exposed to preeclampsia (differentiated by 
early or late onset) and 50 controls, the height and weight of exposed children at 7–11 
years of age did not differ from those of the controls (75). Similarly, in a study of 
>9000 16-year-old adolescents in Finland, preeclampsia exposure (not differentiated 
by severity) was not associated with BMI or waist circumference (76). However, in 
another Finnish study of 144 individuals who were born SGA, men who were 
exposed to preeclampsia (not differentiated by severity) in utero had higher weight 
and BMI at 20–25 years of age than unexposed men; however, no difference in height 
was found (77). In the same publication, 139 individuals born to term were studied, 
and preeclampsia exposure was not associated with height, weight or BMI at 20–25 
years of age (77). In a Norwegian study of 23 children exposed to preeclampsia and 
17 controls at 5–8 years of age, no significant differences in BMI, waist 
circumference, hip circumference and waist-to-height ratio were found (78). Larger 
studies have shown that preeclampsia exposure (not differentiated by severity) was 
associated with low birthweight, catch-up growth in infants (79) and high weight and 
BMI in adolescence (32, 80). However, no studies have focused on growth 
trajectories or length/height in children after preeclampsia exposure. Furthermore, 
few studies on preeclampsia and growth have differentiated by the severity of 
preeclampsia. 
1.3.6 Growth and atopy 
The prevalence of obesity and allergies/allergic diseases has increased in parallel 
worldwide (57), and studies have been conducted on the associations between these 
conditions. The associations between obesity and allergy, asthma and lung function 
are described in further detail in Chapters 1.5.6 and 1.6.1. 
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1.4 Physical activity 
Physical activity in children consists of spontaneous and everyday movement, as well 
as targeted exercise. Everyday activity plays the most important part in the youngest 
age groups. Children’s activity level is closely linked to their body composition and is 
also associated with various health aspects (81). The recommended minimum of 
activity, for example, during play, is 60 min per day for children. Most Norwegian 
children aged 6–9 years, but only half of those aged15years, achieved the 
recommended levels of physical activity in 2012 (82). The levels of physical activity 
for 9-year-old children was increased from 2000–2005, but those in 15-year-olds 
remained constant (83). 
Exercise has been suggested to diminish the unfavourable metabolic profile of 
children who have experienced intrauterine growth retardation (84). The favourable 
effects of physical activity may be due to the negative association with leptin (thus 
regulating appetite) (85). On the other hand, activity behaviour may be influenced by 
in utero conditions, as suggested by animal experiments, where poor nourishment in 
utero was associated with sedentary behaviour in postnatal life, despite adequate 
nutrition postnatally (86). 
Physical activity increases growth hormone levels and improves bone strength (87). 
A sedentary lifestyle in children is strongly associated with obesity (88); thus the 
effects of physical activity and obesity on general health could be difficult to 
distinguish. Tremblay et al. reviewed the role of a sedentary lifestyle in children (81), 
and they found that it was positively associated with concerns about body shape, 
depressive symptoms, behavioural problems, poorer academic achievements, serum 
cholesterol levels, blood pressure, glycated haemoglobin, fasting insulin, insulin 
resistance and metabolic syndrome. Furthermore, a sedentary lifestyle was negatively 
associated with musculoskeletal, cardiovascular and aerobic fitness; self-esteem; and 
perceptions of self-worth. The authors reported that a decrease in sedentary time in 
favour of more physical activity reversed several of the negative health effects 
described above (81).  
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Several studies have suggested the immunological effects of physical activity; for 
example, acute exercise increases the levels of natural killer cells and 
proinflammatory cytokines, before they decrease shortly thereafter (89-91). Studies 
have shown that after a long period of exercise, proinflammatory cytokines are 
reduced whereas natural killer cells are increased (92, 93). Furthermore, in a small 
study of allergic individuals, circulating levels of IgE were reported to be 
significantly altered by the acute steady state of moderate exercise (94). 
Asthmatic subjects experienced better disease control after aerobic training (95). 
Further studies on the association between physical activity and atopy are described 
in the chapters about atopy. 
1.5 Atopy 
1.5.1 Definitions 
Johansson et al. published a nomenclature for allergy in a position statement for the 
European Academy of Allergy and Clinical Immunology (EAACI) in 2001 (96). It is 
presented in Table 2 along with the definition of asthma from the 2014 Global 




Current definitions of allergy 
Hypersensitivity Objectively reproducible symptoms or signs initiated by exposure to a defined stimulus at 
a dose tolerated by normal persons. Hypersensitivity reactions include several phenomena, 
as summarized in Figure 6. 
Atopy Personal and/or familial tendency, usually in childhood or adolescence, to become 
sensitized and produce IgE antibodies in response to ordinary exposures to allergens, 
usually proteins. Consequently, these persons can develop typical symptoms of asthma, 
rhinoconjunctivitis or eczema. 
Atopic Allergic symptoms in a person with an atopic constitution, as in atopic rhinoconjunctivitis. 
Allergy A hypersensitivity reaction initiated by immunologic mechanisms. This could be IgE-
mediated or non-IgE-mediated (cell-mediated), but only those who produce IgE towards 
an allergen could be atopic (Figure 7). 
Allergens Antigens stimulating hypersensitivity mediated by allergy. These are mostly proteins, but 
in certain circumstances, pure carbohydrates could be allergens. In rare instances, low-
molecular-weight chemicals could work as allergens for IgE antibodies, and certain drugs 
are recognized by T cells. 
Allergic diseases Asthma, allergic rhinoconjunctivitis and atopic eczema/dermatitis. 
Asthma According to the latest GINA guidelines; ‘a heterogeneous disease, usually characterized 
by chronic airway inflammation. It is defined by a history of respiratory symptoms such as 
wheezing, shortness of breath, chest tightness and cough that vary over time and in 
intensity, together with variable expiratory airflow limitation’. 
Allergic rhinitis Symptoms resulting from an immunologically mediated hypersensitivity reaction in the 
nose (Figure 8) 
Allergic 
conjunctivitis 
Similar to allergic rhinitis, but occurs in the conjunctiva. It often accompanies allergic 
rhinitis, then it is called allergic rhinoconjunctivitis (Figure 9) 
Atopic dermatitis  
or atopic  
eczema/dermatitis 
syndrome 
Eczematous hypersensitivity reactions of the skin, analogous to rhinitis in the nose and 
asthma in the lung. The term ‘atopic dermatitis’ allows for the definition of one distinct 
form of dermatitis (skin inflammation) where ‘atopic’ has a different meaning than 
‘atopy’ as defined above, because it is actually possible to select patients with atopic 
dermatitis in whom no IgE-associated mechanism is involved (Figure 10) 
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1.5.2  Epidemiology 
The prevalence of atopic sensitization has increased worldwide during the last 50 
years. In 2005–2006, the prevalence of atopic sensitization in USA was 36.2% in 
preschool children and 44.6% in schoolchildren (98). The prevalence was higher than 
that in 1976–80, when 23.6% of individuals aged 6–24 years had atopic sensitization 
Figure 6. From Johansson 
et.al., Allergy, 2008, with 
permission from John Wiley 
and Sons. 
Figures 7–10: From Johansson et al., Allergy, 2008, 
with permission from John Wiley and Sons. 
Fig. 7
Fig. 8 
Fig. 9 Fig. 10 
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(99). Similarly, the prevalence of atopic sensitization in Swedish schoolchildren 
increased from 21% in 1996 to 30% in 2006 (100). 
The prevalence of asthma, allergic rhinoconjunctivitis and atopic eczema increased 
worldwide from 1995 to 2003; according to the International Study of Asthma and 
Allergies in Childhood (ISAAC), it varies from 20- to 60-fold across countries (101, 
102). In countries with the highest prevalence rates, there was little change or even a 
decrease in prevalence in all three conditions (102). In a metaanalysis from 2015 
based on ISAAC questionnaires (103), the prevalence of atopy and allergic diseases 
worldwide was reported, and with large differences were observed between centres. 
The mean prevalence of childhood asthma, atopic dermatitis and allergic rhinitis 
worldwide was reported to be approximately 12%, 8% and 13%, respectively (103).  
The prevalence of asthma has also increased worldwide in the last 50 years. For 
children in developed countries, the prevalence has increased from 4%–5% in 1955 to 
approximately15% in 2010, although with great variation (104). In Scotland, the 
prevalence of wheezing in school children doubled from 10% to 20% between 1965 
and 1989 (3). The World Health Organisation estimates that with the current global 
trend of asthma increase, the number of affected individuals will increase from 300 
million in 2013 to 400 million by 2025 (3). A publication from the ISAAC phase III 
study showed that the worldwide differences in asthma symptom prevalence are 
decreasing, and that the prevalence is decreasing in English-speaking countries but 
increasing in countries with lower prevalence (105). In the ISAAC phase I study, the 
prevalence of asthma varied 15-fold from 2.1% to 32.2% between countries, and in 
the ISAAC phase III study, the differences between countries had decreased (3). The 
prevalence of asthma ever in northern Norwegian schoolchildren was 7.3%–9.3% in 
1985, and it increased to13.8% in 2000 and 17.6% in 2008 (106, 107). Asthma is now 
the most common chronic non-communicable disease among children (108). 
Epidemiological studies show that the prevalence of allergic rhinoconjunctivitis 
continues to increase worldwide. In the USA and Europe, the prevalence is 3%–19 %, 
and 4%–32%, respectively (3). In northern Norwegian schoolchildren, the prevalence 
of allergic rhinoconjunctivitis was 15.9%–16.5% in 1985, and it increased to 29.6% 
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in 2000 and decreased to 24.5% in 2008 (106, 107). In Trondheim, Norway, 3% of 2-
year-old children had allergic rhinoconjunctivitis in 2003–2005 (109).  
Generally, the incidence of atopic dermatitis has increased two-to three-fold during 
the past 30 years (3). In northern Norwegian schoolchildren, the prevalence of atopic 
dermatitis was 12.2%–13.4% in 1985, and it increased to 20.8% in 2000 and 
decreased to 19.3% in 2008 (106, 107). In Trondheim, Norway, 17% of 2-year-old 
children had atopic dermatitis in 2003–2005 (109). In 45% of children, the onset of 
atopic dermatitis occurred during the first 6 months of life; 60% of children were 
affected during the first year and 85%, before 5 years of age (3). 
The prevalence of atopy is higher in boys until puberty, after which it is higher in 
girls; this indicates that sex hormones influence the development of atopy (110, 111). 
Allergic rhinitis, atopic dermatitis and asthma are global health problems affecting 
people of all ages and ethnic and socioeconomic groups, and they cause major illness 
and disability, thereby affecting social life, sleep, school and work and having a 
major economic impact (101, 112). 
The increased prevalence of atopy must be attributable to non-genetic factors, as 
described in Chapter 1.5.5. 
1.5.3 The atopic march 
Atopy starts early in life, and therefore, early-life factors play an important role in its 
development. Sometimes, the term ‘the atopic march’ is used, meaning that there is a 
progression from atopic dermatitis to food allergy, and, subsequently, allergic rhinitis 
and asthma (113). Approximately half of the children with atopic dermatitis develop 
asthma, and two-thirds develop allergic rhinoconjunctivitis (114). The associations 
with atopic dermatitis are probably due to concomitant atopic dermatitis and atopic 
sensitization, and not due to atopic dermatitis without sensitization (115). Atopic 
dermatitis is suggested to increase the risk of food sensitization, and food 
sensitization may occur through the skin (113). The oral route is considered more 
tolerogenic (113). The Dual- Allergen Exposure hypothesis suggests that allergic 
sensitization to foods occurs through cutaneous exposure, whereas tolerance occurs 
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as a result of oral exposure to food (116). It is unknown whether food allergy is 
actually a step in the atopic march (113). 
When allergic rhinitis develops in the ‘atopic march’, the risk of asthma is present. 
Many patients with allergic rhinitis also have lower airway hyperreactivity. Nasal 
symptoms, airflow and inflammation markers correlate with lower airway markers 
like forced expiratory volume in 1 second. Allergic rhinitis and asthma have very 
common pathogeneses, and three-fourths of patients with asthma report having 
allergic rhinitis (113). 
1.5.4 Pathophysiology of atopy 
According to the T-helper (Th) 1/Th2 paradigm, atopy is a decreased Th1 response to 
antigens that skews the balance of Th1/Th2 cells in favour of Th2 cells. Atopy is 
associated with a Th2–type inflammation, as described below (117). Several subsets 
of CD4+ Th lymphocytes have been discovered after the Th1/Th2 paradigm was 
established; including T regulatory cells (Tregs) and the proinflammatory Th17 and 
Th9 cells. Tregs regulate the induction of allergen-specific T-cells and suppress the 
effector cells of allergy (Figure 11) (118). 
The phase of allergic sensitization begins with the allergen captured by the antigen-
presenting cells of the epidermis, gut and airway mucosa, which in turn migrate to 
lymph tissues and promote Th2 immunity. Furthermore, Th2 cells produce cytokines 
that lead to B-cell immunoglobulin E (IgE) production, and IgE binds to high-affinity 
receptors (Fc RI) on the surface of mast cells and basophils in the skin, gut and 
respiratory and cardiovascular systems, thereby readying them for reactivity the next 
time exposure to the allergen occurs (Figure 11). The next phase, elicitation, occurs 
within minutes after allergen exposure when mast cells with IgE become activated 
(Figure 11) (113, 119), and it causes symptoms in all the mentioned organ systems 
through the release of various mediators (112, 120). 
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IgE, which was discovered in 1967, is the fifth and final class of human antibody(8). 
Gould and Sutton reviewed the role of IgE in allergy in 2008 (121). The activity of 
IgE is associated with a network of proteins, especially Fc RI, CD23, galectin-3 and 
several co-receptors for CD23, CD21 and various integrins. IgE and mast cells are 
concentrated in the mucosal membranes. Thus, IgE is among the first defence 
molecules that an invading pathogen may encounter; however, it plays an important 
role in allergy. The cross-linking of IgE-Fc RI on mast cells leads to the elicitation 
phase of allergy, involving mast cell degranulation and synthesis of lipid mediators. 
Cytokines and chemokines liberated in this early phase initiate the late phase, which 
peaks some hours later and involves the recruitment and activation of inflammatory 
cells at sites sensitive to the allergen. Allergens also activate IgE-sensitive antigen 
presenting cells (APC), which in turn promote IgE production by B cells to replenish 
the IgE consumed in the allergic reaction, thereby maintaining mast-cell and APC 
sensitization. Fc RI is upregulated by IgE from local B cells, and is only expressed 
on mucosal mast cells. Any excess IgE is mostly directed into secretions, rather than 
into the circulation (121). Figure 12 shows the steps involved in the allergic response, 
Figure 11. From Jutel, Current Allergy and Asthma Reports 2011, with permission from Springer. The figure shows the differentiation 
of naïve T-cells. Depending on the adjuvanticity of the substances co-exposed with the antigen and status of the cells and cytokines in 
the microenvironment, naïve T-cells can differentiate into T-helper (Th) 1, Th2, Th9, Th17 and Th22 T cells. Based on their respective 
cytokine profiles, responses to chemokines and interactions with other cells, these T-cell subsets can promote different types of 
inflammatory responses. IFN: interferon, IL: interleukin, TGF: transforming growth factor, TNF: tumour necrosis factor.
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with an emphasis on the role of IgE. It shows that IgE is synthesized and secreted by 
B cells that have switched from producing IgM. (121). 
1.5.5 Early-life risk factors 
As reviewed by Prescott et al. in 2013 (122), studies have shown that allergy may 
occur during the first months of life in some individuals. Therefore, non-genetic risk 
factors for allergy may play a role early in infancy or in utero; these include diet, 
pollutants, microbial patterns and stress, all of which promote inflammation (Figure 
12). The environment, both during pregnancy and in early childhood, can determine 
Figure 12. Modified from Gould, 2008, 
with permission from Nature Publishing 
Group. IgE binds to Fc RI on mast cells 
and APCs (a) and sensitizes these cells to 
allergens. Allergen binding to IgE 
triggers mast-cell degranulation to cause 
an allergic response (c). Allergen binding 
to the APC leads to the presentation of 
allergenic peptides to Th2 cells (d). The 
allergen-activated Th2 cells secrete 
interleukin-4 (IL-4) (e) to maintain the 
Th2 –cell lineage and recruit more Th 
cells into this lineage (e). The Th2 cells 
also secrete IL-13 and express CD40 
ligand (CD40L), which, together with IL-
4, stimulates switching to IgE (f). The 
allergen-activated mast cells contribute to 
the production of IL-4 and IL-13 (and 
express CD40L), which may also 
stimulate the expression of CD23 and the 
release of soluble CD23 (h). Soluble 
CD23 may upregulate IgE synthesis and 
secretion through interaction with CD21 
(i). Thus, the allergen plays a role in the 
pump-priming of the allergic response. 
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the physiologic, structural, immune, metabolic and behavioural development and 
modify the response patterns influencing future disease susceptibility. Evidence 
suggests that the effects on the immune system that lead to atopy must begin in utero.  
Supplements of omega-3 fatty acids (with anti-inflammatory properties) to pregnant 
women and infants aged 0–6 months are negatively associated with allergic 
sensitization and atopic dermatitis in offspring. 
The manipulation of gut microbiota can prevent allergy and obesity, and there 
is evidence that these effects are mediated through the immune system (Figure 13). 
The positive effects of exercise on general health are partly mediated through the 
same pathways (122). 
Figure 12. From Prescott, 2013, with permission from Elsevier. The figure shows that inflammation is a 
common element in many non-communicable diseases (NCD). HPA: hypothalamic-pituitary-adrenal axis. 
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The hygiene hypothesis suggests that lack of exposure to microorganisms skews the 
Th1/Th2 balance towards an immune response to allergens with Th2 overweight 
(123). The dermal microbiome in atopic dermatitis probably plays an important role 
in creating an immune response with Th2 overweight (113). Studies have shown that 
growing up on a farm is protective against atopy, and this mechanism is suggested to 
act via bacterial endotoxins from farm animals suppressing the Th2 response toward 
allergens via specific enzyme induction (124). Studies have shown that gut 
microbiota play an important role in protection against the development of atopy, and 
they are influenced by factors such as the mode of birth (exposure to maternal vaginal 
microbiota), feeding (breastmilk promotes healthy gut microbiota), maternal exposure 
to pets or livestock during pregnancy and maternal exposure to antimicrobials during 
pregnancy (125). 
Childhood diet is probably an important environmental factor related to the 
development of atopy. A Mediterranean diet seems to protect against atopy 
development (126), and a positive association between fast food and atopy has been 
reported (127). In a study of cord blood omega-3 fatty acids, negative associations 
with atopy were reported (128). In the LEAP study, the early introduction of peanuts 
Figure 13. From Prescott, 2013, with permission from Elsevier. This figure shows the central role of 
the immune system in mediating the multisystem effects of diet, physical activity, and microbiota.
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in high-risk infants was negatively associated with the development of a peanut 
allergy even if the children avoided peanuts for a longer period at a later age, further 
underlining the tolerogenic role of the oral route for introducing allergens (129). 
Positive associations between outdoor air pollution in utero and later atopy have been 
reported (130), and poor indoor air quality, including stuffy odour, mould 
contamination, and exposure to environmental tobacco smoke during the first two 
years of life, could contribute to atopy development (131). 
1.5.6 Risk factors for atopy in the current studies
The following risk factors for atopy are studied: preeclampsia exposure in utero, 
weight and BMI from birth to late childhood, physical activity in early childhood and 
weight-related anthropometrics in late childhood. Previous studies have reported on 
these associations before our articles did, as described in this chapter. 
Nafstad et al. reported positive associations between complications during 
pregnancies (but not preeclampsia) and both childhood asthma and allergic 
rhinoconjunctivitis (15, 16). In a study of 378 children delivered by caesarean 
section, Keski-Nisula et al. reported a positive association between preeclampsia 
exposure in utero and adolescent allergic sensitization (17). Furthermore, Gagliardi et 
al. reported positive associations between preeclampsia and both respiratory distress 
syndrome and bronchopulmonary dysplasia in preterm children, and wheezing in 
preschool children (132). To the best of our knowledge, no further studies have 
focused on preeclampsia exposure, especially not according to severity, and 
subsequent allergic diseases. Furthermore, the long-term effect of preeclampsia 
exposure on lung function in the offspring was unknown. 
Positive associations have been found between obesity and asthma in several studies, 
where obesity precedes asthma (133), although the causal pathway of this association 
remains unclear (134). On the other hand, the association between obesity and allergy 
was less consistent (135-137). 
Positive associations have been reported between an accelerated weigh gain in early 
childhood and atopic sensitization, allergic rhinitis (12) and asthma (138, 139); 
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however, no associations with atopic dermatitis have been found. Childhood physical 
activity may be associated with atopy either directly or through an effect on body 
composition. In the ISAAC phase III study, positive associations were reported 
between vigorous physical activity and a sedentary lifestyle and childhood asthma, 
allergic rhinoconjunctivitis and atopic dermatitis (135). Although childhood obesity 
and physical activity and associations with atopy have been studied, few longitudinal 
studies apart from register studies exist (133, 140, 141). Furthermore, it is not known 
whether accelerated weight gain from birth is associated with an increased risk of 
atopy or whether the positive association between BMI and asthma is limited to 
atopic children. 
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1.6 Lung function 
Figure 14 shows how the various volumes of the lung can be measured by 
plethysmography. 
Total lung capacity (TLC) is the volume in the lungs at maximal inflation; it is the 
sum of the residual volume (RV) and the vital capacity (VC). The RV is the 
remaining volume in the lungs after maximum expiration. The VC is the volume 
inspired starting from maximum expiration up to maximum inspiration. The 
functional residual capacity (FRC) is the lung volume at the end of a normal 
expiration, that is, under the mechanical equilibrium of the opposite forces exerted by 
the lung tissue and thorax. The inspiratory capacity (IC) is the volume of air that can 
be maximally inspired starting from FRC. The expiratory reserve volume (ERV) is 
the volume of air exhaled by maximum expiration starting from FRC, and it is used to 
derive RV from FRC. The tidal volume (TV) is the volume of air moved during 
normal breathing. The inspiratory reserve volume (IRV) is the maximal volume that 
can be inhaled from the end-inspiratory level (142). 
Figure 14. Total lung capacity and its subdivisions. Reprinted from Wikimedia Commons. 
50 
Spirometry is used to measure the volume of air exhaled from the lungs during a 
maximal expiratory manoeuvre, and it is usually shown as a flow-volume curve 
(Figure 15). Forced vital capacity (FVC) is the maximal volume of air exhaled with 
maximally forced effort from a position of maximal inspiration, that is, the VC, with 
a maximally forced expiratory effort, and it is expressed in litres. The forced 
expiratory volume during the first second of FVC (FEV1) is the volume of air exhaled 
during the first second of the performance of FVC. The peak expiratory flow (PEF) is 
the largest expiratory flow achieved with a maximally forced effort from a position of 
maximal inspiration, and it is expressed in litres/second (143). FEF25% is the forced 
expiratory flow after the first 25% of the FVC has been expired, and it is expressed in 
litres/second. FEF50% and FEF75% are the FEFs after 50%, and 75% of the FVC, 
respectively, has been expired. FEF25-75% is the average of the flow when 25% to 75% 
of the VC has been expired, and it represents the flow in the mid-portion of the VC 
(144). The curve below the x-axis of the flow-volume curve represents the inspiratory 
curve, where the forced inspiratory flow (FIF) measurements correspond to the FEF 
measurements above the x-axis. 
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The use of predicted values for lung function measurements yields standardized 
values relative to gender, age, height and ethnicity. Several types of reference 
equations have been published, with the most recent one being the Global Lung 
Function Initiative (GLI) references (145). 
Figure 15. Flow-volume loop as measured by spirometry, reprinted from Wikimedia Commons.
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Obstructive lung function can be assessed using spirometry, and it may be graded 
according to severity as described by Paton (144): Mild: FEV1 in percent of predicted 
(%) =70–100; Moderate: FEV1 % = 50–70; Severe: FEV1 % = 34–50; Very severe: 
FEV1 % < 34. The maximal expiratory airflow rates reduce in the presence of an 
obstruction, and there is a reduction of the maximal airflow from the lung compared 
to the FVC, which is usually expressed as a reduction in the FEV1/FVC ratio. 
The earliest change with flow limitation in small airways is shown as a slowing in the 
terminal portion of the flow volume curve, and it gives an increasingly convex curve 
(convex to the x-axis) in late expiration. 
Flow measurements in small airways (FEF25%, FEF50% and FEF75%) are sensitive to 
inadequate patient effort, as they measure the flow at specific moments. However, 
FEF25-75%, as the mean between the two, is more robust, and therefore, it is used more 
often to describe small airway obstruction; it may be more sensitive in children than 
FEV1/FVC (144). 
1.6.1 Associations between growth and lung function
Lung function is dependent on normal development from foetal life and onwards. 
Sonnenschein-van der Voort et al. recently found that foetal length, infant weight 
development and lower infant length growth were positively associated with airway 
resistance (146). These authors also reported a positive association between faster 
weight gain across childhood and FVC and FEV1 values (139). 
In a recent metaanalysis, Den Dekker et al. reported that children with younger 
gestational age at birth had lower FEV1, FEV1/FVC ratio and FEF75%; whereas those 
who were born SGA had lower FEV1 but higher FEV1/FVC ratio. Greater infant 
weight gain was associated with higher FEV1 but with lower FEV1/FVC ratio and 
lower FEF75% in childhood (147). 
Several studies have reported that birth weight is positively associated with lung 
function (148-150). Barker suggested that an adverse environment and poor growth in 
utero may lead to impaired growth of the airways and subsequently reduced airway 
calibre (151). Cross-sectional studies in children and adolescents have shown that 
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weight-related anthropometrics are positively associated with FEV1 and FVC but 
negatively associated with FEV1/FVC ratio (152-155). Studies on the association 
between change in weight over time and lung function have reported different results 
at different ages (139, 156, 157). 
Some studies have shown that reduced lung volume is related to the degree of obesity 
(158). Others have noted negative associations between weight-related 
anthropometrics and lung function (154). However, a review has noted discrepancies 
among studies (159). 
In prematurely born children, increased soluble antiangiogenic factor might influence 
future lung function (160). Furthermore, infants with intrauterine growth restriction 
may have a congenital reduction in airway calibre and compliance, leading to poor 
lung function (150).  
Preeclampsia is the most frequent medical indication for delivering a baby 
prematurely. Although preeclampsia has been shown to be positively associated with 
respiratory distress syndrome and bronchopulmonary disease in preterm infants and 
with recurrent wheezing in preschool children (132), no studies exist on a possible 
long-term association between preeclampsia exposure and lung function. 
1.7 Summary  
The prevalence of atopy has increased substantially worldwide during recent decades 
(98), and early-life environmental factors and lifestyle may be important risk factors 
for this increase (122). Preeclampsia is, like atopy, a condition characterized by 
inflammation (29, 113). The incidence of preeclampsia is also increasing (27). 
Previous studies on the association between preeclampsia exposure and atopy and 
lung function in early childhood have been assessed in a few studies, (15-17, 132). 
However, the role of preeclampsia exposure in atopy and lung function development 
until late childhood is not known. 
There is an increased focus of the impact of early childhood lifestyle on atopy (122). 
The incidence of obesity is also increasing (57), and prospective studies have shown 
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an association with asthma (133). However, studies on the association between 
obesity and atopy show conflicting results (135-137). Furthermore, cross-sectional 
studies have focused on the association between obesity and atopy, and existing 
longitudinal studies are mostly from registers; however, to the best of our knowledge, 
clinical studies have not been reported. 
Obesity is possibly associated with asthma, and it may also be associated with altered 
lung function. Studies in adults suggest such an association (161), whereas those in 
children and adolescents show conflicting results (159). Studies indicate that at an 
early age, increasing BMI is associated with larger lung volumes and better lung 
function (139, 157). In comparison, at a later age in childhood, BMI is associated 
with a more obstructive lung function pattern; however, the age at which this 
transition occurs is not known (157). 
The participants included in the thesis are from a nested case control study, called the 
Stavanger Study, of 614 children, of whom one-third were exposed to preeclampsia 
and two-thirds were unexposed (24). This thesis includes studies on the early-life risk 
factors; preeclampsia, growth and physical activity and the outcomes of allergy, 
allergic diseases and lung function in later childhood. The studies in this thesis are 
part to the lung-atopy branch of ‘the Stavanger Study’. 
As the cohort consisted of children exposed to preeclampsia and controls, any 
potential effect of preeclampsia exposure status on the outcomes of atopy and lung 
function via a possible effect on childhood growth might be of importance. However, 
during our work, we discovered that little is known about preeclampsia exposure and 
subsequent growth across childhood. Previous publications from the Stavanger Study 
showed that preeclampsia exposure was negatively associated with birthweight (25) 
and positively associated with BMI and waist circumference at puberty onset in girls 
(24). Seven other published studies on preeclampsia exposure and growth showed 
conflicting results (32, 75-80); however, no studies examined growth trajectories 
across childhood. To further explore this issue, the thesis also includes a study on the 
association between preeclampsia exposure and subsequent growth during childhood. 
This does not directly address the association between early life risk factors and 
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allergic disease, but may illuminate the associations between childhood growth and 




2. Aims of the thesis 
The overall aim of this thesis was to study early-life risk factors for atopy and lung 
function in a historical cohort. Specifically, the main early-life factors investigated 
were preeclampsia, weight-related anthropometrics and physical activity. We also 
aimed to study whether preeclampsia could have any effect on childhood growth 
from a longitudinal perspective. 
The objectives of this study were as follows. 
Preeclampsia as a risk factor for atopy and changed lung function by late childhood:  
To study the associations between preeclampsia exposure according to severity and 
various outcomes including atopic sensitization, allergic rhinoconjunctivitis, atopic 
dermatitis asthma and lung function in late childhood. 
Preeclampsia and childhood growth: 
To study the associations of preeclampsia exposure according to severity with 
length/height, weight and BMI at several time-points from birth to late childhood and 
waist circumference and skinfolds in late childhood, and to analyse whether these 
associations are gender-dependent. 
Weight-related anthropometrics and activity level as risk factors for atopy by late 
childhood: 
To study the associations of birth weight, BMI at several time-points in childhood, 
changes in weight and BMI, late childhood waist circumference and skinfolds and 
physical activity level with various outcomes including atopic sensitization, allergic 
rhinoconjunctivitis, atopic dermatitis and asthma by late childhood. 
Weight-related anthropometrics as risk factors for changed lung function in late 
childhood: 
To study the associations of birth weight, BMI at several time-points in childhood, 
changes in weight and BMI, late childhood waist circumference and skinfolds with 
FVC, FEV1, FEV1/FVC ratio and FEF25-75%/FVC ratio in late childhood. 
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Based on these objectives, we hypothesized the following: 
1. Preeclampsia exposure in utero is positively associated with atopic sensitization 
and atopic disease and negatively associated with lung function in late childhood 
2. Preeclampsia exposure in utero affects linear growth. Preeclampsia exposure is 
positively associated with accelerated weight gain during childhood, especially in 
girls. 
3. Childhood BMI and weight-related anthropometrics, accelerated weight gain and 
sedentary lifestyle are positively associated with atopic sensitization and atopic 
disease. 
4. Childhood BMI and weight-related anthropometrics are negatively associated with 
lung function in late childhood. 
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3. Subjects and methods 
3.1 Participants and study design 
A population-based cohort including 12 804 deliveries during 1993-1995 at 
Stavanger University Hospital served as the basis of this study. The Medical Birth 
Registry of Norway was used to identify mothers from this cohort with preeclampsia 
(n = 366) and controls (n = 659) to conduct a nested case control study finished in 
2002. The study design was as follows. For each case, two matched controls were 
selected: one was the next delivery in the hospital (i.e., a birth date match) and one 
was the next born matched on maternal age (i.e., a risk factor for preeclampsia) (25). 
This nested case control study was conducted to study maternal risk factors for 
preeclampsia and foetal growth in relation to preeclampsia. The Stavanger Study (24) 
was a follow-up of the nested case control study conducted to study anthropometry, 
blood pressure and reproductive development in children after preeclampsia exposure 
in utero. The 1025 children (366 cases and 659 controls) were invited to participate in 
late childhood in a first follow-up study at 10.8 years (girls) and 11.8 years (boys), 
and a second follow-up at 12.8 years (both genders) (24) (Paper I, Figure 1). The ages 
at follow-up were selected to coincide with the age of pubertal onset (first follow-up) 
and menarche (second follow-up) of the children (24, 32). 
Invitations for follow-ups were sent to the mothers at addresses identified through 
public registries. Exposed non-responders received a written reminder, and if 
necessary, a telephone message or phone call. Unexposed non-responders did not 
receive a reminder. 
The study was a part of the Stavanger Study, of which Papers I, III and IV are called 
the ‘Lung-atopy arm of the Stavanger Study’. This study was conducted according to 
the original study design as a follow-up of the nested case control study described in 
Papers I and II. The study was conducted as a historical cohort in Papers III and IV 
and adjusted for preeclampsia as a potential confounder. The original matching of 
maternal age and birth date were ignored in the analyses owing to more missing 
participants in the unexposed group than in the exposed one, thus the analyses were 
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adjusted for maternal age. The analytic samples included all the children who 
participated in both follow-ups. 
3.2 Questionnaires 
Questionnaires were distributed to consenting parents and children at the first and 
second follow-ups of the Stavanger Study (Appendix to this thesis). The 
questionnaires included questions about diet, work, leisure time activities and health. 
The lung-atopy arm of the Stavanger Study included validated questions related to 
lung function and asthma (an ISAAC questionnaire) (101) at the second follow-up, 
and they were completed by the children. Questions and responses relevant for the 
studies of this thesis were extracted; these are explained further in Chapters 3.4.1 and 
3.5.3. At the first follow-up, the mothers also answered questions about the health of 
their child, and at the second follow-up, the children answered questions about their 
own health. If the questionnaires were answered but specific yes/no questions had 
missing responses, the response was interpreted as ‘no’. 
3.3 Clinical examinations 
Clinical examinations of participants were performed at birth and at the first and 
second follow-ups. The examinations relevant to the studies of this thesis are 
described below. Anthropometric measurements from well-baby visits during infancy 
and pre-school age were collected when the children attended the first follow-up. A 
second collection was performed for missing anthropometric data in 2014 after newly 
obtaining written consent from the participants. 
3.4 Outcomes 
Only the outcomes of the studies are described in this section. Anthropometric 
measurements were outcomes in Paper II, and predictors in Papers III and IV and are 
described in Chapter 3.5.2. 
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3.4.1 Atopy 
Allergic rhinoconjunctivitis, atopic dermatitis and asthma ever were assessed at the 
first follow-up. Atopic sensitization and current asthma were assessed at the second 
follow-up. 
Atopic sensitization 
Definition: Blood specific IgE  0.35 kU/l for at least one common allergen. At the 
second follow-up, blood was drawn from the children, centrifuged and aliquoted, and 
the serum was stored at -80°C. Specific IgE antibodies were measured using 
Phadiatop® and fx5E® (ImmunoCAP® 250, Phadia AB, Uppsala, Sweden). If 
Phadiatop® was positive, the serum was further analysed for specific IgE against 
Dermatophagoides pteronyssinus, cat, horse, dog, timothy, common silver birch, 
mugwort and Cladosporidum herbarum. If fx5E® was positive, the serum was 
further analysed for specific IgE against egg white, milk, fish (cod), wheat, peanut 
and soya bean. The included allergens are shown in Paper III, Figure 1. The levels of 
specific IgE  0.35 kU/l were added, and high grade sensitization was defined as a 
sum > 3.9 kU/l: above the lower quartile of all children being sensitized. The ordinal 
outcome variable atopic sensitization was categorized as no, low-grade and high-
grade sensitization. 
Atopic disease: Asthma ever, allergic rhinoconjunctivitis or atopic 
dermatitis 
At the first follow-up, questions about atopic diseases of the child were asked to the 
mothers: ‘Has your child ever had doctor-diagnosed asthma or ever been diagnosed 
with allergy in nose/eyes (hay fever) or atopic dermatitis (childhood eczema)?’ A 
‘yes’ response was classified as having the respective diagnosis at any age up to and 
including 10.8/11.8 years (girls/boys). 
Current asthma 
At the second follow-up, the children answered a questionnaire on reported asthma 
symptoms and medication during the last year according to ISAAC (101) and asthma 
ever was recorded. Current asthma at 12.8 years of age was defined as a positive 
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answer to the question of doctor-diagnosed ‘asthma ever’, in addition to a positive 
answer to at least one of the two questions about asthma symptoms 
(wheezing/whistling/chest tightness) or the use of asthma medication during the last 
12 months. 
3.4.2 Lung function tests 
At the second follow-up, lung function was measured by spirometry according to 
established guidelines (143) by using a Vmax Encore Spirometer (Sensor Medics 
Inc., Anaheim, USA), and FVC, FEV1 and FEF25-75% were recorded. In Paper I, 
reference values from 1995 were used (162). In Paper IV, measurements were 
compared to the values predicted by the more recent 2012 European Respiratory 
Society (ERS) Task Force standard reference equations from GLI relative to age, 
gender, height and ethnicity (145). The values for FVC, FEV1 and FEV1/FVC ratio 
were reported as percentages of predicted (%). The FEF25-75%/FVC ratio was given as 
a percentage as no predicted values were available.
3.5 Exposures and predictors 
3.5.1 Preeclampsia 
Preeclampsia was diagnosed according to the CLASP criteria (26), which define 
preeclampsia as a condition occurring after 20 weeks of gestation as a diastolic blood 
pressure increase of 25 mmHg to a persistent pressure of 90 mmHg and proteinuria 
with dipstick +1 present in 1 urine sample. In the Stavanger Study, preeclampsia 
was further defined according to severity, and severe preeclampsia was defined as 
proteinuria with dipstick +3 and diastolic blood pressure 110 mmHg; moderate 
preeclampsia, as proteinuria with dipstick +2 and mild preeclampsia, as any other 
condition of preeclampsia. 
3.5.2 Anthropometry 
Anthropometry means the scientific study of the measurements and proportions of the 
human body (163). 
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These measurements are used as either predictors or outcomes in the papers 
depending on the research question. In Paper I, selected anthropometric 
measurements were used in descriptive analyses of the participants and as potential 
confounders in regression analyses. Anthropometric measurements were outcomes in 
Paper II and predictors in Papers III and IV. 
Birth length and weight were abstracted from hospital records for consenting 
participants. In Norway, all children receive healthcare at well-child clinics with 
routine measurements of recumbent length before 2 years of age, standing height 
from 2 years of age, and weight from infancy to school age. At the first follow-up, 
length/height and weight measurements from the routine well-child visits at the target 
ages of 3, 6 and 12 months and 4 years were abstracted from clinical records. If a 
measurement was missing, the value from the closest visit in time was used, and the 
exact age was recorded for all visits. Three experienced and trained paediatric nurse 
researchers measured height, weight, triceps skinfold and waist circumference in the 
offspring two times at each follow-up and subscapular skinfold two times at the 
second follow-up, with the average used in the analyses. Skinfolds were measured 
using a Harpenden Skinfold Calliper ®. The consistency of the measurements was 
ensured by regular audits by a paediatrician (24). Body weight was measured using a 
Seca 770 electronic scale (Seca, Hamburg, Germany), and height was measured using 
a Holtain stadiometer (Holtain, Crosswell, Crymych, Wales, UK). 
The waist-to-height ratio was calculated as the ratio of waist circumference (cm) to 
body height (cm). 
In premature children, growth was corrected for prematurity in the first two years of 
life by evaluating the child as if it was born at the due date and not by chronological 
age. 
3.5.3 Physical activity 
The questionnaire distributed to mothers at the first follow-up included questions 
extracted from the ‘Stanford Brief Activity Survey’ (164), a questionnaire that has 
been validated for adults, and it requested responses about the child’s physical 
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activity levels. Specifically, the answers to the following questions were extracted: 
‘How active was your child at 3–6 years?’ and ‘How active was your child at 6–10 
years?’ The response categories were passive, not so active, active and very active. 
The categories ‘passive’ and ‘not so active’ were combined and recoded as ‘low 
activity’, ‘active’ as ‘normal’ and ‘very active’ as ‘high activity’. 
3.6 Statistics 
Due to the inclusion of children who were either exposed or unexposed to 
preeclampsia, there was a wide range of gestational ages at birth and a wide age range 
at later well-child visits. The actual anthropometric values would therefore not be 
appropriate for most analyses. For birth weight in Paper I, z-scores calculated from 
Scandinavian references were used when adjusting for birth weight (165). In the last 
three papers, SDS based on anthropometric values and actual ages and gender were 
computed from validated references (166-169). Conversions to SDS were performed 
using R version 2.6.2 (R Development Core Team, Vienna, Austria). 
The results and demographic data were presented as numbers and percentages, means 
with standard deviations (SD) or 95% confidence intervals (CI) and medians with 
lower and upper quartiles (Q1, Q3). Categorical variables were compared using 
Pearson’s chi-square exact test with Bonferroni-correction of P-values for multiple 
testing. Group comparisons for normally distributed continuous variables were 
performed using independent t-tests (Gosset’s t-test, Student 1908) and one-way 
analysis of variance. The Kruskal-Wallis one way analysis of variance and Mann-
Whitney U-test were used for continuous variables that were not normally distributed. 
Multiple logistic and linear regression was used to analyse the associations between 
predictors and outcomes. 
Generalized Estimating Equations (GEE) were used for multiple linear regression 
analyses of growth over time according to the severity of preeclampsia. Multiple 
Fractional Polynomial Regression (MFPR) was used to study possible non-straight-
line associations between anthropometric measurements and outcomes of atopy and 
lung function, and MFPR in combination with GEE was used to identify possible 
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non-straight-line effects of preeclampsia on growth. The identified fractional 
polynomials in Paper II were plotted using R version 3.2.1 (R Development Core 
Team, Vienna, Austria). 
Causal diagrams called directed acyclic graphs (DAGs) were used to select 
adjustment set variables for the regression analyses in Papers II, III and IV using the 
DAGitty program (170). 
In the analyses in Papers I, II and III, a backward stepwise selection of confounders at 
P <0.05 was performed: First, each variable was entered into simple regression 
models. Next, all potential confounders were included in fully adjusted models. 
Backward stepwise selections were performed to remove non-significant 
confounders. Ultimately, the final models included all remaining confounders and 
different variables forced into the final model. 
Owing to missing values, the number of participants varied between the different 
analyses. 
For each predictor, estimated coefficients (b) (linear regressions), odds ratios (OR) 
(logistic regressions) and 95% CIs were reported. For linear regression, P-values 
from the F-test (for variables of all types) or Wald’s chi-square-test (for each b in the 
model and for GEE) were reported. For logistic regression, likelihood ratio (LR) test 
P-values were reported. Interactions between predictors and potential confounders 
were tested for all regression analyses for all Papers, and they were presented if 
significant. 
All statistical tests were two-tailed, and P <0.05 was considered statistically 
significant. The latest version of SPSS statistical package and STATA SE14 
(StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: 
StataCorp LP) were used for the analyses. 
3.7 Ethics 
The study was approved by the Norwegian Data Inspectorate, the Regional 
Committee for Ethics in Medical Research Western Norway (Reference Numbers: 
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First: 078-03, Second: 2010/1375) and the Institutional Review Boards of the 
National Cancer Institute (Reference Number: LAB09-0139) and University of Texas 
at Austin, United States (Reference Number: 2013-04-0036). At follow-up, 
participating mothers and children signed an informed consent/assent form. When 
new research questions including outcomes of atopy and lung function were planned, 
The Regional Committee for Ethics in Medical Research Western Norway was 
applied to for approval, and it gave the second reference number. 
3.8 Funding 
The Stavanger Study was funded by an internal grant from the National Cancer 
Institute, National Institute of Health (RO3 grant number: 1R03CA137754), and it is 
a part of the MD Anderson Global Programme. The lung-atopy arm of the Stavanger 
Study was further funded by a PhD grant from the Western Norway Regional Health 
Authority for the first author (grant number: 911835). 
The funders played no role in the study design, data collection and analysis, decision 




This chapter provides a complete overview of participation in the present studies in 
more detail than in each of the papers. 
A complete flow-chart of participation is shown in Paper I, Figure 1. The number of 
participants who had information about preeclampsia severity and each outcome are 
shown in Paper I, Table 2. These were the children who were included in the 
statistical analyses in Paper I. 
Of 1025 invited children, 614 assented to the first follow-up and 468 to the second 
follow-up. 
An overview of information about preeclampsia severity for each follow-up is shown 
in Table 3. Only children with information about preeclampsia severity were included 
in the analyses in Papers I-IV, 603 children at the first follow-up and 459 children at 
the second follow-up. 
Table 3. Participation in the two follow-ups according to preeclampsia severity 
Numbers of children 
 Preeclampsia severity 
 Total Missing No Mild/moderate Severe 
First follow-up 614 11 385 164 54 
Second follow-up 468 9 286 127 46 
In Paper II, children with information about anthropometry and preeclampsia severity 
were included in the analyses, as shown in Table 4. In Paper II, GEE analyses were 
used. Therefore, the analytic sample included all children participating at each visit 
age, and it was not limited to the number of children at the follow-ups. 
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Table 4. Participation according to type of anthropometric measurement, and number of visiting children with 
information about preeclampsia severity in Paper II. 
Visit age (n) 
Variable Birth 3 months 6 months 1 year 4 years 10.8/11.8 yearsa) 12.8 years 
Length/height SDS 937 542 557 558 478 600 443 
Weight SDS 942 553 558 559 477 595 443 
BMI SDS  541 557 558 477 595 443 
WC SDS      593 443 
WHtR SDS      593 443 
TSF SDS      589 442 
SSF SDS       430 
Abbreviations: n = number of participants; BMI = body mass index; WC = waist circumference; SDS= 
standard deviation score; WHtR = waist-to-height ratio; TSF = triceps skinfold; SSF = subscapular skinfold. 
a) 10.8 years in girls, 11.8 years in boys 
Paper III, Table 1 shows the number of participants available for the analysis for each 
predictor and outcome, irrespective of preeclampsia status information. The analytic 
sample in Paper III consisted of the children for whom we had information about 
preeclampsia severity. The number of children with information about anthropometry 
and physical activity, and the different outcomes in Paper III are shown in Table 5. 
The table includes only children with information about preeclampsia severity, 
because preeclampsia severity was included in the adjustment set of the regression 
analyses. 
Table 5. Number of children with information about anthropometric measurements, physical activity and 
outcomes of atopy in Paper III, among those with information about preeclampsia severity in Paper III.
Outcome (n) 




Asthma ever Current asthma Atopic 
sensitization 
Birthweight SDS 580 581 575 448 380 
BMI SDS       
     3 months 521 522 517 415 353 
     6 months 537 538 533 429 363 
     1 year 537 538 533 428 363 
     4 years 460 462 457 385 329 
     10.8/11.8 yearsa) 573 574 568 436 367 
     12.8 years    436 368 
Physical activity      
  3–6 years 575 576 570 434 367 
  6–10 years 569 570 564 431 363 
Abbreviations: n = number of participants; SDS = standard deviation score. 
a) 10.8 years in girls, 11.8 years in boys
The percentage of children sensitized to airborne allergens varied between 2% and 
21%, and that to food allergens varied between 1% and 6%. Of these, 21% were 
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sensitized to timothy; 20% to house dust mite; and 14% to birch pollen (Paper III, 
Figure 1). 
In total, 463 children performed lung function tests, and 456 also responded to the 
ISAAC questionnaire (Paper IV). 
In all regression analyses, the response rate for each potential confounder varies 
owing to missing data from the questionnaires and antenatal visits. 
In Paper IV, the clinical characteristics (anthropometry) are shown only for children 
who performed lung function tests, and thus, n is lower than that in Paper III, where 
clinical characteristics for all assenting children are shown. 
In total, 468 children consented to participate at the second follow-up, but 
information about preeclampsia severity was available for only 459. The outcomes of 
lung function were measured at the second follow-up. Of the 459 children with 
information about preeclampsia severity, 453 performed lung function tests, and they 
constituted the analytic sample in Paper IV. Of these 453 children, 446 completed the 
ISAAC questionnaire. 
In Paper IV, the extended International Obesity Task Force (IOTF) BMI classes of 
the participating children are shown, and the BMI of the participants was within the 
normal range when compared to other studies of Norwegian children (60). 
The actual age of the participants at both follow-ups was the intended target age. At 
the first follow-up, the age of the girls was 10.8 (±0.22) years (mean, SD) and that for 
boys was 11.8 (±0.18) years. At the second follow-up, the age of the children was 
12.8 (±0.19) years. 
The average BMI for the girls who participated in the first follow-up but not the 
second follow-up was higher than that for the girls who participated in both follow-
ups. There were more children with atopic dermatitis among those who assented only 
to the first follow-up than for those who assented to both follow-ups (Paper I). 
Maternal age at delivery was higher in children who did than did not assent to the 
second follow-up (Paper II). 
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Otherwise, the baseline characteristics were similar between those who assented to 
the first follow-up only and those who assented to both follow-ups (Paper I). 
Furthermore, there were no significant differences in perinatal characteristics between 
children who did and did not assent to the first and the second follow-ups (Paper II). 
4.2 Results from the four papers 
The answers to the objectives are presented in this section. The relation between the 
four studies is illustrated in figure 16. 
Figure 16: overview of studies 
4.2.1 Preeclampsia and associations with atopy and lung function 
(Paper I) 
Among children with any atopic sensitization, 50% had symptoms of allergic 
rhinoconjunctivitis. Atopic sensitization was found in 94.4% of children diagnosed 
with allergic rhinoconjunctivitis. Furthermore, 5.6% of children reported allergic 
rhinoconjunctivitis without being sensitized. 
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In adjusted regression analyses, severe preeclampsia was positively associated with 
high-level atopic sensitization (OR: 4.05; 95% CI: 1.62, 10.1) and allergic 
rhinoconjunctivitis (OR: 2.23; 95% CI: 1.20, 4.17).
We found that increasing severity of preeclampsia was associated with high-level 
atopic sensitization (OR. 1.88; 95 % CI: 1.23, 2.86; likelihood ratio (LR)-p = 0.003) 
and allergic rhinoconjunctivitis (OR: 1.42; 95 % CI: 1.07, 1.89; LR-p = 0.018). 
We did not find any associations of preeclampsia with atopic dermatitis, asthma or 
changes in lung function. 
4.2.2 Preeclampsia and childhood growth (Paper II) 
Paper II shows the median gestational age in weeks (Q1, Q3) of children exposed to 
severe, mild/moderate and no preeclampsia: 36.1 (32.0, 38.6); 39.1 (37.6, 40.1); and 
40.1 (39.3, 41.0), respectively. 
The associations between preeclampsia and childhood growth yielded the predictive 
model shown in Paper II, Figures 1–2, and the equations for the predictive curves are 
shown in Paper II, Table 1. 
In boys and girls, preeclampsia exposure was negatively associated with 
length/height SDS (linear growth). However, in boys, exposure to mild/moderate 
preeclampsia was positively associated with linear growth after 0.5 years of age. 
In boys, exposure to severe preeclampsia was negatively associated with weight SDS 
and BMI SDS throughout childhood. Otherwise, preeclampsia exposure (for both 
genders and severity categories) was negatively associated with weight and BMI 
during infancy, but positively associated with weight and BMI thereafter. 
Exposure to severe preeclampsia was positively associated with waist-to-height ratio 
SDS in late childhood in both genders. At the first follow-up: b = 0.47, 95% CI (0.15, 
0.79). At second follow-up: b = 0.44, 95% CI (0.12, 0.75). Preeclampsia exposure 
was not associated with waist circumference or skinfolds (supplementary to Paper II). 
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4.2.3 Weight-related anthropometrics and activity level as risk 
factors for atopy by late childhood (Paper III) 
BMI SDS at 1 year of age was positively associated with atopic sensitization at 12.8 
years of age (OR: 1.22, 95 % CI: 1.00, 1.49). 
Changes in BMI SDS at 1–4 years of age and BMI SDS at 4 years of age were 
positively associated with ever being diagnosed with atopic dermatitis by the time of 
the first follow-up (OR: 1.46, 95% CI: 1.11, 1.92 and OR: 1.32, 95% CI: 1.06, 1.65, 
respectively). 
Low level of physical activity at 3–6 years of age was positively associated with 
atopic sensitization at 12.8 years of age (OR: 2.36, 95% CI 1.15, 4.81).  
High level of physical activity at 6–10 years of age was positively associated with 
ever being diagnosed with atopic dermatitis by the time of the first follow-up (OR: 
1.94, 95% CI: 1.16, 3.24). 
Low levels of physical activity at both 3–6 and 6–10 years of age were positively 
associated with ever having doctor-diagnosed asthma by the first follow-up (OR: 
3.61, 95% CI: 1.56, 8.36 and OR: 2.52, 95% CI: 1.24, 5.12, respectively). 
We did not find associations of birthweight/BMI SDS and changes in weight or BMI 
SDS with allergic rhinoconjunctivitis (Paper III, Tables 2 and 3) or asthma (Paper III, 
Table 4 and Supplementary to Paper III). We did not find associations of waist 
circumference, waist-to-height ratio or skinfolds with atopic sensitization, allergic 
rhinoconjunctivitis, atopic dermatitis or asthma in late childhood (Supplementary to 
Paper III). 
We did not find any non-straight-line associations between weight-related 
anthropometric measurements and atopy. 
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4.2.4 Weight-related anthropometrics as risk factors for changed 
lung function in late childhood (Paper IV) 
Children with current asthma in late childhood had similar FVC % and FEV1 % but 
lower FEF25-75%/FVC and a tendency for lower FEV1/FVC %, than children without 
asthma. 
Birthweight and BMI at different ages throughout childhood were positively 
associated with FVC % and FEV1 % in late childhood. BMI, waist circumference, 
waist-to-height ratio and skinfolds at 12.8 years of age and the change in BMI from 
early to late childhood were positively associated with FVC % and FEV1 % and 
negatively associated with FEV1/FVC and FEF25-75%/FVC. Interaction analyses 
showed that positive associations between anthropometrics other than BMI and lung 
function were mostly present in girls (Paper IV, Tables 4 and 5). We found inverse 
U-shaped associations between BMI at the ages of 10.8/11.8 (girls/boys) and 12.8 
years (both genders) and FVC % and FEV1 % at 12.8 years of age (Paper IV, Figure 
1). After gender stratification, these associations were not significant, except for girls 





5.1 Methodological considerations 
5.1.1 Study design 
As described in Chapter 3.1, the Stavanger Study was a follow-up of a nested case 
control study on preeclampsia. The design of the original study was also used in my 
first two studies (Paper I and II) to answer the research questions with preeclampsia 
as a predictor, and it showed associations with atopy, lung function and childhood 
growth. In Papers III and IV, childhood growth and physical activity were the 
predictors and atopy and lung function were the outcomes. Thus, Papers III and IV 
were not designed according to the original study but as a historical/retrospective 
cohort, and consequently, bias by preeclampsia might be an issue in these papers. 
However, preeclampsia was considered a confounder and adjusted for in the analyses 
in the last two studies. No confounding by preeclampsia was found. Therefore, bias 
by preeclampsia in Papers III and IV may not be very likely. This matter is discussed 
further in Chapter 5.1.4. 
The sample population in Papers III and IV is biased because it consists of several 
children exposed to preeclampsia, and therefore, it consists of several prematurely 
born children. As Papers III and IV aim to show the associations between childhood 
growth/physical activity and atopy and lung function, a general population cohort 
would be better suited to answer the research questions. 
The study population was homogeneous in terms of socio-economic status and 
ethnicity, which is an advantage of our study design, and these factors reduce the risk 
of bias. 
The average BMI of the girls who assented to the first but not the second follow-up 
was higher than that of the girls who assented to both follow-ups; this might have 
caused a bias in the analyses in all the studies. We do not know why more girls with a 
higher BMI did not assent to the second follow-up; girls with the highest BMI might 
have disliked being weighed in the first follow-up and in anticipation of being 
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weighed, they did not assent to the second follow-up. Preeclampsia was, in general, 
positively associated with weight and BMI in girls. However, there is no reason to 
think that the girls with the higher BMI who were lost to the second follow-up were 
overrepresented in any particular exposure group. Therefore, the association between 
preeclampsia and growth would not be expected to be biased by the change in the 
BMI of the girls from the first to the second follow-up. 
Other weight-related anthropometric measurements than BMI at both follow-ups 
were not related to atopy (Paper III) but they were associated with lung function 
(Paper IV). These two associations were similar in both follow-ups, although there 
was a difference in average BMI in the girls participating in the two follow-ups. 
Therefore, the bias may have only negligible consequences for the results. 
Owing to the study design, atopic sensitization and atopic disease were assessed at 
two different follow-ups; however, this should not bias the independent associations 
found for the various outcomes of atopy. 
There were fewer children ever diagnosed with atopic dermatitis in the second than in 
the first follow-up. The reason for this discrepancy is unknown, and it might bias the 
results in Papers I and III, in which atopy was an outcome. As atopic dermatitis was 
an outcome only at the first follow-up, the associations between the predictors of 
Papers I and III and atopic dermatitis may not be affected. However, atopic dermatitis 
is correlated with atopic sensitization. Thus, the number of sensitized children in the 
second follow-up that were ready for analyses of atopic sensitization may be lower 
than the number of sensitized children in the first follow-up. The results may 
therefore underestimate the associations of preeclampsia, anthropometry and physical 
activity with atopic sensitization. 
The participation rate at the second follow-up was lower than at the first follow-up. 
Furthermore, there was a low response rate for the outcomes of asthma in the second 
follow-up. Together, these two issues decrease the power of the studies and increase 
the risk of false negative results. 
The study was longitudinal with a long follow-up time, which is an advantage over 
cross-sectional studies. However, the outcomes (diagnoses of atopy and measures of 
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lung function) in Papers I, III and IV were assessed only at follow-ups; therefore, the 
age of onset is unknown. In Paper I, preeclampsia occurs before any of the outcomes 
of atopy and lung function. In Paper II, preeclampsia precedes childhood growth, and 
therefore, the models in these two studies are predictive, and the direction of the 
associations must be from preeclampsia to the outcomes. 
Only the predictors and not the outcomes were assessed longitudinally in Papers III 
and IV; therefore, the potential causality and its direction must be interpreted with 
care. Furthermore, Papers III and IV had a retrospective design, which may be 
inferior to a prospective one. 
Some outcomes of atopy and lung function were assessed at the first follow-up and 
others, at the second follow-up. Ideally, all variables should have been assessed at the 
second follow-up. The questionnaire completed by the mothers at the first follow-up 
included questions about all three atopic diseases in the offspring. The questionnaire 
completed by the children at the second follow-up included questions about asthma 
(ISAAC). Therefore, the outcome of asthma ever from the second follow-up could 
have been used in analyses. However, to assess asthma ever at the same time as 
atopic dermatitis ever and allergic rhinoconjunctivitis ever, we had to use the 
available information from the first follow-up. An advantage of using the diagnosis of 
asthma ever from the first and not the second follow-up was that several responses 
were missing from the second follow-up, and we had to use interpreted values which 
were possibly not as reliable as the maternal responses from the first follow-up. To 
assess current asthma in late childhood, however, the only available information was 
from the ISAAC questionnaire completed at the second follow-up. 
5.1.2 Validity of diagnoses 
Atopic sensitization 
A specific IgE toward a particular allergen with a cut-off at 0.35 kU/l (also used in 
our studies) is normally used for the diagnosis of atopic sensitization, and it provided 
a good measure of atopic sensitization (171). However, low-grade sensitization just 
above the cut-off is less likely to be clinically relevant. Some authors define atopic 
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sensitization conservatively as a radio-allergo-sorbent test (RAST) class 2 or a 
specific IgE >0.7 kU/l (172, 173). The cut-off at 3.9 kU/l corresponds to the lower 
quartile of the sensitized children in our study. The cut-off was used in the present 
studies to include more clinically relevant atopic sensitizations, and it is supported by 
a previous study suggesting a positive predictive value of allergy to be 97% if 
specific IgE levels are 3.5 kU/l (171). 
Allergic rhinoconjunctivitis, atopic dermatitis and asthma ever 
These diagnoses were determined at the first follow-up and were based on maternal 
questionnaires. The conditions assessed by questionnaires could over- or 
underestimate the diagnoses owing to recall bias. The reported diagnoses may not be 
as accurate as those examined at follow-ups. Furthermore, two unknown issues 
regarding these diagnoses are the age of onset and continued symptoms at the first 
follow-up. However, the high proportion of allergic sensitization (94.4%) in children 
with rhinoconjunctivitis suggests a high degree of diagnostic accuracy. Although 
some children reported allergic rhinoconjunctivitis without having sensitization (5%), 
other studies have reported that allergic rhinoconjunctivitis could be due to local and 
not systemic sensitization (174), which supports our findings.  
Atopic dermatitis was diagnosed at several primary care clinics without following 
any predefined criteria, so the diagnosis must be interpreted with care. Atopic 
dermatitis comprises both cases with IgE-associated mechanisms and around 20% of 
cases without (96, 175), and therefore, it may not always contribute to the ‘atopic 
march’. 
The diagnosis of asthma is not always based on objective measures. In particular, in 
children <5 years of age, the diagnosis is based on the evaluation of symptoms and 
associated factors such as atopy. During these years wheezing episodes may represent 
asthma or transient conditions, and the diagnosis of asthma may be used variously 




This was assessed from an ISAAC form included in questionnaires completed by the 
children themselves at the second follow-up. Several children who answered the other 
questions in the questionnaire did not answer the ISAAC form. A missing response in 
the ISAAC form was therefore interpreted as a negative response. To what degree a 
positive answer in the ISAAC questionnaire was reliable is unknown, but the 
responses from the children may be less reliable than those of the mothers in the first 
follow-up. 
Spirometry 
Spirometry was performed under the guidance of experienced and trained paediatric 
nurses in the outpatient department of Stavanger University Hospital under the 
surveillance of a consultant paediatrician. 
Seven of the 470 children who assented to the second follow-up were not able to 
perform a satisfactory spirometry, and they were excluded from the analyses in Paper 
IV. Owing to the personnel’s expertise and the exclusion of unsatisfactory 
spirometries, the lung function testing in our study may be considered to have high 
quality and reliability. A recent study showed that the GLI-2012 reference values for 
lung function tests (which we used for the analyses in Paper IV) fit the Norwegian 
data, and therefore, they are recommended for use in Norway (176). 
Preeclampsia 
The diagnosis of preeclampsia was divided into none, mild, moderate and severe. 
Owing to pathophysiological similarities, the mild and moderate categories were 
combined (30). This classification affords the advantage of distinguishing the effects 
of preeclampsia from prematurity on offspring outcomes later in life. 
Preeclampsia may also be classified as early or late onset, where early onset begins at 
<34–35 weeks of gestation (depending on country) and is often of the more severe 
type (29). 
Because most cases of severe preeclampsia occur early (as also reported in Paper II) 
whereas mild/moderate preeclampsia occurs later during pregnancy and close to term, 
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the two types of classification do not differ substantially. One advantage of 
classifying preeclampsia according to severity might be that pathophysiological 
differences due to severity more likely affect the health of the offspring, whereas the 
classification based on gestational age may affect offspring health indirectly owing to 
gestational age or indirectly due to a correlation with severity. 
The CLASP criteria are considered conservative, and the advantage of using such a 
classification is that all the cases are certain to have preeclampsia, and no cases will 
be falsely diagnosed with preeclampsia (26). 
Anthropometric measurements 
The anthropometric measurements used in our study may be considered to have high 
quality. Routine measurements at the well-child clinics are standardized. Trained 
paediatric nurses performed the measurements at the first and second follow-ups.  
The repeatedly sampled measurements of length/height and weight yielded 
calculations of a predictive model of growth by preeclampsia exposure status; they 
may be advantageous in this study. The sampling of the growth variables as 
predictors enabled the window of time in childhood with the possibility of affecting 
the development of atopy and lung function to be examined. On the other hand, the 
measurements were not performed at every age during childhood. In the longitudinal 
analyses, only length/height, weight and BMI were available, and no other 
anthropometric measurements were. BMI may have a limited correlation with 
childhood adiposity (177). As both predictors and outcomes, waist circumference and 
skinfolds could have added valuable information to our studies, however, they were 
not measured at the well-child clinics, and therefore, they are impossible to collect 
retrospectively. 
Physical activity 
A validated questionnaire for adults was used for the Stavanger Study (164). A 
validated questionnaire for children would have been more appropriate. To the best of 
our knowledge, no validated recall questionnaire for physical activity for this age 
existed at the time the Stavanger Study was conducted. The response to this 
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questionnaire provided the only available data for physical activity in the age groups 
3–6 and 6–10 years. Therefore, the associations between physical activity and atopy 
must be interpreted with care. 
5.1.3 Sample size 
The statistical analyses included several covariates, and owing to the complexity, it 
would have been difficult to estimate sample sizes. Power is the probability of 
rejecting the null hypothesis in a future study. Once the study has been conducted, 
this probability is either 1 or 0. Therefore, post hoc power calculations are not 
recommended (178). Instead, CIs and p-values are meaningful quantifications of 
uncertainty after the study has been conducted (179).  
Because our studies were included in an established follow-up study, no power 
calculations targeted for our studies were performed to determine the necessary 
sample size. Instead, we had to interpret our results with care. Owing to the possibly 
of low power, we have to be aware of the possibility of false negative results. 
Therefore, the width of the CIs was of importance, especially when interpreting 
negative results. If the CIs included both no associations and clinically relevant effect 
measurements, the sample size may have been too small to detect these associations 
and to confirm that there are no associations between predictors and outcomes. 
5.1.4 Statistical considerations 
Information may be lost when grouping continuous variables into categorical 
variables, because similar data appear different if they happen to fall into different 
categories. Therefore, methods allowing the use of continuous variables are superior 
to those using categories, and the use of continuous variables should generally be 
attempted. 
Atopic sensitization was analysed as an ordinal variable instead of as a continuous 
variable. Although specific IgE is a continuous variable, atopic sensitization is 
generally considered a dichotomous condition with a cut-off at 0.35 kU/l. We further 
introduced the term high-level atopic sensitization to differentiate between those who 
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merely had sensitization and those who were more likely to have a clinical allergy, 
thereby providing an ordinal variable for atopic sensitization which, in the context of 
our studies, was likely to be the most appropriate.
Anthropometric measurements were used as continuous variables and were not 
categorized. For BMI, there are specific IOTF categories for three underweight 
categories, and for normal weight, overweight and obesity (66). These could have 
been used in the analyses; however, IOTF classes are not available before 2 years of 
age. The age data of our participants consisted of five measurements before and only 
three after 2 years of age. Therefore, IOTF classes could not have been used in the 
GEE analyses (including all the ages of the participants from birth onwards). MFPR 
analyses were used to study non-straight-line associations between predictors and 
anthropometry or between anthropometry and outcomes. MFPR analyses have the 
advantage over simpler models of showing linear associations that may take any form 
or any equation, including U-shaped associations, while keeping continuous variables 
continuous. 
A backward stepwise selection in logistic regression is not always reliable. The 
model might change simply because the number of variables is reduced, and not 
because there is confounding. We did check for confounding in backward stepwise 
selection by keeping the same analytic sample as in fully adjusted analyses; however, 
we could not rule out residual confounding. 
Therefore, after the first paper, we began using DAGs. DAGs are causal diagrams, 
and by using the DAGitty software, we selected potential confounding variables. 
Using DAGs helps to avoid using variables that are intermediate on the causal 
pathway between the predictor and the outcome. Furthermore, using DAGs may help 
to avoid adjusting for variables that are common effects of both the predictor and the 
outcome either directly or indirectly (colliders). Adjusting for intermediate variables 
might falsely reduce the association between the predictor and the outcome (180). 
Adjusting for colliders might give rise to spurious associations between the predictor 
and the outcome (181, 182). 
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Therefore, for some of the models, especially with an adequate n in fully adjusted 
analyses, we chose not to use backward stepwise selections; instead, we obtained 
results through fully adjusted analyses containing variables as selected by using 
DAGitty (170), and we consider this as a strength of our analyses. 
The variables gestational age and birthweight are intermediary on the pathway 
between preeclampsia and outcomes in the present studies. The group of participants 
exposed to severe preeclampsia showed lower gestational age and birthweight than 
the group of participants exposed to mild/moderate preeclampsia and the unexposed 
group. Therefore, gestational age and birthweight may confound the results in Papers 
I and II, in which preeclampsia was used as the predictor. As described above, in the 
section about intermediate variables and colliders, these could not be adjusted for. 
One method to reduce confounding from the variables gestational age and 
birthweight would be to match the participants on these variables, which was not 
done in the original study. 
Wald-test P-values were used in Paper I. F-test and Wald-test P-values are identical 
for variables that are not represented by at least two indicator variables in the model. 
The Wald-test gives the P-values for each b in the model, whereas the F-test gives the 
P-values for all types of variables. In Papers II and IV F-test P-values were used, 
showing the overall significance level for ordinal explanatory variables as well. This 
is a better method, and it could also have been used in Paper I. 
5.2 Discussion of results 
In the studies, we found that exposure to severe preeclampsia in utero was positively 
associated with subsequent high-level atopic sensitization and allergic 
rhinoconjunctivitis in late childhood; however, preeclampsia was not associated with 
atopic dermatitis, asthma or lung function. Exposure to mild/moderate preeclampsia 
was positively associated with linear growth in boys, and with weight and BMI in 
both boys and girls. Exposure to preeclampsia was negatively associated with linear 
growth in girls. Exposure to severe preeclampsia was negatively associated with 
linear growth, weight and BMI in boys. Severe preeclampsia was positively 
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associated with waist-to-height ratio in late childhood. Preeclampsia exposure was 
not associated with waist circumference or skinfolds in late childhood. 
BMI and accelerated weight gain in early childhood was positively associated with 
atopic sensitization and atopic dermatitis in late childhood. Low physical activity 
during childhood was positively associated with atopic sensitization and ever being 
diagnosed with asthma in late childhood. High physical activity during childhood was 
positively associated with atopic dermatitis in late childhood. BMI and physical 
activity were not associated with allergic rhinoconjunctivitis or current asthma in late 
childhood. Weight-related anthropometrics during childhood were positively 
associated with FVC % and FEV1 % in late childhood; however, BMI, waist 
circumference and waist-to-height ratio in late childhood were negatively associated 
with FEV1/FVC % and FEF25-75%/FVC. BMI in late childhood showed an inverse U-
shaped association with FVC % and FEV1 %. 
5.2.1 Preeclampsia, atopy and lung function 
A few studies on the associations of preeclampsia with atopy and lung function have 
been published after Paper I was published. A recent publication from Stokholm et al. 
(183) included two studies: one study of 411 Danish children born of mothers with 
asthma, where the children were examined at several occasions until 7 years of age 
and 5.6% were exposed to preeclampsia; and one registry-based cohort of 1.7 million 
children of which 3.7% were exposed to preeclampsia. Preeclampsia exposure was 
associated with atopic sensitization and allergic rhinoconjunctivitis in both cohorts, in 
accordance with our results. The authors also found positive associations of 
preeclampsia exposure with asthma treatment and bronchial responsiveness in the 
cohort of 411 children, which we did not study. Preeclampsia was associated with 
asthma and eczema in the registry-based cohort with adjusted Incidence Risk Ratio of 
1.09 (1.05, 1.12) (183). The discrepancy of the registry-based cohort with our study 
and the cohort of 411 Danish children may be due to false negative results in smaller 
studies. In a study of 115 222 children, all of who were diagnosed with asthma, 
preeclampsia was positively associated with asthma (184). In a recent publication 
from the Avon Longitudinal Study of Parents and Children including more than 5000 
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children, hypertension before pregnancy was positively associated with asthma in 
children at 7 years of age with OR 1.34 (1.00, 1.79) and preeclampsia was negatively 
associated with FEV1 at 8 years of age with an adjusted mean difference in SDS of -
0.14 (-0.33, 0.06) (185). The difference from our results may arise from a tendency of 
false negative results in studies with fewer participants. In a recent Norwegian 
publication of two studies, a registry-based study of 406 907 children showed an 
association between preeclampsia and asthma at 7 years of age, whereas in a 
subsample of children participating in the Norwegian Mother and Child Cohort Study 
(n = 45 028), preeclampsia was not associated with asthma. Adjustments for 
prematurity yielded significant associations between preeclampsia and asthma, which 
may, as the authors noted, be due to collider bias. Furthermore, when a sibling 
comparison was performed, no association remained between preeclampsia and 
asthma (186). 
Most children exposed to severe preeclampsia were born prematurely. Adjustment for 
prematurity in the statistical analyses was not appropriate because prematurity is an 
intermediate variable on the causal pathway between preeclampsia and the outcomes 
of atopy and lung function. A Swedish national cohort study showed a negative 
association between prematurity and allergic rhinitis, possibly owing to the protective 
effect of earlier exposure to pathogens (187). In a Norwegian register study of 9349 
children with severe asthma and 6930 children with severe atopic dermatitis, preterm 
birth was positively associated with severe asthma and negatively associated with 
severe atopic dermatitis (188). As preeclampsia is positively associated with both 
prematurity and allergic rhinitis, our results may underline the importance of 
preeclampsia as a possible risk factor for allergic rhinitis independent of the effect of 
prematurity. 
Antibiotics are frequently prescribed to prematurely born infants during the neonatal 
period; this may cause a delay in intestinal bacterial colonization, and therefore, it 
may pose a risk of developing allergic disorders (189). As preeclampsia is associated 
with allergy and prematurity, antibiotic use may contribute to the development of 
allergy in this group. However, we were not able to adjust our analyses for 
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intermediate variables on the causal pathway between preeclampsia and allergy, such 
as antibiotics. 
Preeclampsia is a condition involving several pro-inflammatory cytokines in maternal 
circulation, which may initiate the development of immunological conditions such as 
atopy in the foetus. The cytokines of maternal circulation are reflected in those of the 
offspring until the age of 1 year (17, 190-192). 
In the registry-based cohort study in the above-mentioned publication from Stokholm 
et al., the associations between preeclampsia and atopy were especially pronounced 
with longer duration of preeclampsia, suggesting a mechanism of in utero
inflammation causing lasting immune dysregulation in the offspring (183). The 
possible impact on the foetus may be facilitated by foetal immune cell maturation. 
Immune tolerance is partly mediated by thymus-derived Tregs, and the foetal thymus 
is smaller in foetuses exposed to preeclampsia (193). 
During normal pregnancy, but not in preeclampsia, there are increased levels of Th2 
and Tregs, this, in turn, promotes maternal immune responses to avoid the rejection 
of the foetus (194). The levels of Th2 cells and Tregs are lower in blood from women 
with preeclampsia (195) and in cord blood in new-borns exposed to preeclampsia 
(196). Studies have shown the transplacental regulation of cellular immunity between 
the mother and the foetus (197), underlining the possibility of maternal immunity 
affecting that of the foetus. The proliferative responses of T-cells derived from cord-
blood in children who later become allergic are reduced (198) and atopy has been 
associated with altered cytokine profile in neonates (199). 
In a recent study, Herzog et al. reported that early-onset preeclampsia was associated 
with a derangement in foetal haematopoiesis (200). This underlines the importance of 
how preeclampsia may give rise to epigenetic changes in the offspring, especially 
immunological ones. 
5.2.2 Preeclampsia and childhood growth 
As described in Chapter 1.3.5, apart from one publication from the original nested 
case control study (25) and one publication from the Stavanger Study (24), six other 
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studies on childhood growth after preeclampsia exposure exist. In these studies, 
preeclampsia was examined as one entity rather than by severity, although in the 
smallest study, preeclampsia was differentiated by gestational age of onset (32, 75-
77, 79, 80). These studies show conflicting results of weight and BMI development 
after preeclampsia exposure, and two of these studies found no association between 
preeclampsia and linear growth. The discrepancies across studies are possibly 
attributable to different designs including age and gender at participation. 
In our study, severe preeclampsia was negatively associated with linear growth in 
boys but not in girls, in contrast to studies on foetal growth retardation showing a 
postnatal catch-up in linear growth (201, 202). Studies on very premature children 
born SGA show results similar to ours, as very premature children are less likely to 
show catch-up growth, or catch-up growth only after the age of 6 years (203). IGF-1 
is lower in placental tissues and cord blood in pregnancies with severe, but not mild, 
preeclampsia (204). IGF-1 is one of the most important regulators of postnatal growth 
(205). Poor linear growth in children exposed to severe preeclampsia might therefore 
be due to effects on the growth hormone IGF-1 axis (206-208). Preeclampsia is a 
condition characterized by inflammation, especially severe preeclampsia, and the 
cytokines of pregnancy correlate with those in the offspring until 1 year of age (190, 
191). This inflammatory status may induce apoptosis of the growth plate cartilage 
both prenatally and during infancy, thus explaining poor linear growth in children 
exposed to severe preeclampsia in utero (209).
In the current study, weight and BMI were initially lower in children exposed to 
mild/moderate preeclampsia and in girls exposed to severe preeclampsia; however, it 
was increased and was higher from preschool age and onwards compared to the 
unexposed children. Children born small for their gestational age and prematurely 
born children show similar development of weight and BMI (201, 210, 211). 
Preeclampsia, especially in the severe form, may cause starvation in the foetus; this, 
in turn, may lead to epigenetic changes causing a tendency for energy conservation 
throughout life and therefore cause overweight or obesity (212, 213). Children with 
catch-up growth postnatally show increased insulin sensitivity, and they show 
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favourable linear growth and weight development (214). Children born SGA 
frequently show catch-up in weight and length before the age of 1 year (203). 
However, in our study, catch-up growth, and only in weight, occurred at a later age. 
This difference suggests that preeclampsia affects weight and BMI independently 
whether the children were born SGA. In the current study, boys exposed to severe 
preeclampsia had a low weight and BMI throughout childhood, as opposed to 
children born SGA. Low levels of IGF-1 mediated through prematurity and 
inflammation may be a common pathophysiology of linear growth and weight 
development in boys exposed to severe preeclampsia (215). 
The result of high waist-to-height ratio in children exposed to severe preeclampsia is 
in accordance with studies showing that children born SGA continue to gain excess 
body fat even after catch-up in weight is completed (203). As a high waist-to-height 
ratio is a risk factor for insulin resistance and metabolic syndrome (211), severe 
preeclampsia is an inflammatory condition (14, 216) and an association between 
inflammatory disorders in adults and metabolic syndrome has been suggested (217), 
severe preeclampsia may indirectly and/or via inflammation be a risk factor for 
metabolic syndrome in offspring. 
The current study showed different effects of mild/moderate and severe preeclampsia, 
and as explained in Chapter 1.2.3, these may be considered two distinct 
pathophysiological entities with implications for child growth (14, 30). 
There were different effects of preeclampsia exposure on childhood growth 
depending on the gender of the child. Generally, severe preeclampsia exposure was 
negatively associated with linear growth, weight and BMI development in boys 
throughout childhood. Mild/moderate preeclampsia was positively associated with 
linear growth in boys, negatively in girls, and it was positively associated with weight 
and BMI development in both boys and girls. Severe preeclampsia was positively 
associated with weight and BMI development in girls, but negatively associated in 
boys. Although previous publications have reported inconsistent results about gender 
differences in growth after preeclampsia exposure (32, 79, 80), boys are generally 
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more prone to neonatal complications (218). Boys are more likely to be affected by 
extreme prematurity or being born SGA than girls; even when born to term and being 
of adequate birthweight, boys are more prone to neonatal complications than girls 
(219, 220). 
5.2.3 Preeclampsia as a marker of placental dysfunction and 
inflammation 
Preeclampsia may be regarded as a syndrome rather than as one entity, with many 
pathways leading to the symptoms that are defined as preeclampsia. The cause of 
preeclampsia seems to be the placenta, and poor placentation means that poor 
uteroplacental circulation occurs secondary to inadequate remodelling of the spiral 
arteries between weeks 8 and 18 during pregnancy (221). Preeclampsia may only be 
one of several related causes of disease in the offspring. The international Human 
Placenta Project aims to study these issues (222). 
Preeclampsia is only one of several causes of placental dysfunction. Placental 
abruption and placenta previa are two conditions with placental dysfunction that may 
be caused by preeclampsia as well as by high maternal age, multiparity, cigarette 
smoking, drug abuse, rapid uterine decompression, short umbilical cord, prolonged 
premature rupture of membranes, chorioamnionitis, folate deficiency, chronic 
hypertension, preeclampsia, and previous placental abruption or placenta previa (223-
225). 
One Norwegian study suggested that placental dysfunction may be represented as a 
range of clinical expressions such as pregnancy-induced hypertension, intrauterine 
growth retardation, preterm delivery and placental abruption and they may all share 
an etiological factor such as lesions in the utero-placental arteries (226). 
Preeclampsia is characterized by inflammation which may be the common pathway 
to both altered growth and atopy development. However, the inflammatory status of 
preeclampsia may not affect childhood growth after the first few years. 
Microchimerism is increased during preeclampsia (38), and it may give rise to several 
inflammatory conditions in the offspring (37). Furthermore, inflammatory conditions 
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may affect normal growth (209), and therefore, it is possible to speculate over the 
possibility that maternal microchimerism after preeclampsia exposure, especially 
after long-lasting or severe preeclampsia, plays a role in the association between 
preeclampsia and childhood growth beyond infancy and early childhood and into 
puberty. 
Preeclampsia may be a trigger for prenatal stress. In a recent metaanalysis by van de 
Loo et al., 10 studies showed that prenatal stress was positively associated with 
respiratory morbidity in the children. General stress components released by 
preeclampsia and other triggers may be direct causes of asthma (227), and therefore, 
preeclampsia as well as all other triggers of prenatal stress may have similar effects. 
5.2.4 Weight-related anthropometrics and physical activity and 
associations with atopy 
Weight-related anthropometrics and atopy 
Previous studies on the association between BMI and atopic sensitization have shown 
conflicting results; furthermore, studies showing an association have mainly been 
cross-sectional, and therefore, they cannot be used to assess whether obesity precedes 
sensitization (140). BMI at 1 year was positively associated with atopic sensitization 
at 12.8 years in our cohort, and most children were sensitized to airborne allergens. 
Sensitization to airborne allergens is uncommon in Scandinavian children before the 
age of 1 year (228); therefore, the high BMI at 1 year probably preceded airborne 
sensitization. However, we did not assess sensitization during the first year of life, 
and therefore, we cannot exclude sensitization to food allergens during this period. 
An animal study showed that obesity in mice lowered the threshold for atopic 
sensitization, suggesting that obesity causes atopy (229). High BMI is associated with 
higher body fat and altered adipokines and, in turn, inflammatory changes; these, in 
turn, might predispose one to atopic sensitization (230). Our results indicate that BMI 
at 1 year of age is of importance. 
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On the other hand, animal studies have shown that allergen exposure induces adipose 
tissue inflammation and insulin resistance, indicating that allergen exposure may be a 
common cause of both allergy and overweight/obesity (231). 
A change in BMI SDS from 1 to 4 years and BMI at 4 years of age was positively 
associated with ever being diagnosed with atopic dermatitis by the age of 10.8/11.8 
years (girls/boys), which confirms previous results (135, 232). If the association is 
causal, reverse causality may be possible. Atopic dermatitis frequently begins during 
the first year of life and therefore precedes the age of any potential overweight or 
obesity (233). However, overweight/obesity may cause atopic dermatitis. First, 
obesity is associated with an increased risk of dry skin, thereby aggravating 
underlying skin defects (234). Second, a positive association of BMI increase and 
high BMI during preschool years with atopic dermatitis could be explained by 
immunological changes due to increased body fat, and an association between 
adipokines and atopic dermatitis has been reported (235). Third, not all atopic 
dermatitis begins in infancy. As shown in Chapter 1.5.2, 17% of 2-year-old children 
and 21%–33% of 9-to11-year-old children in Norway have atopic dermatitis 
(Norwegian Institute of Public Health, 2014 report). We did not find any association 
between weight-related anthropometrics and asthma, unlike previous large studies 
(138, 236). Our results do not contradict the fact that an association may be present, 
as we may have too few participants to show a significant association of a low 
magnitude, as reflected in the CIs that include effect measures similar to those in 
larger studies (138). 
Physical activity and atopy 
Low physical activity at 3–6 years in our cohort was positively associated with atopic 
sensitization at 12.8 years. To the best of our knowledge, this is the first publication 
showing such an association. A cross-sectional study of 2000 Spanish adolescents 
using questionnaires showed no association between physical activity and allergy at 
13–17 years of age (237). 
92 
In our analyses, we adjusted for BMI; however, BMI may underestimate the relative 
amount of fat tissue in the body composition of children (68). The association 
between low activity and atopic sensitization may therefore be due to relatively more 
body fat in children with a low activity level independent of weight status, with 
subsequent changes in adipokines and, in turn, development of sensitization (230). 
We found that a high activity level at 6–10 years of age was positively associated 
with atopic dermatitis at 10.8/11.8 years (girls/boys), in accordance with ISAAC 3; it 
showed that vigorous physical activity at 13–14 years was positively associated with 
atopic dermatitis at the same age, which was possibly attributable to sweat-induced 
itch (135). Natural killer cell cytotoxicity could be increased after long-lasting 
physical activity (92), and a positive association between natural killer cell 
cytotoxicity and atopic dermatitis has been suggested (238). 
Low activity levels at 3–6 and 6–10 years of age were positively associated with ever 
being diagnosed with asthma by 10.8/11.8 years (girls/boys) in our cohort. There was 
no association with current asthma at 12.8 years of age. In ISAAC 3, Mitchell et al. 
found that several hours of TV viewing was positively associated with current asthma 
in adolescents (135). Other studies have indicated a protective effect of physical 
activity against asthma development (141). 
We found no significant association between physical activity and allergic 
rhinoconjunctivitis; however, the CIs did include clinically relevant values. 
Therefore, our results did not contradict those of the ISAAC 3 study, where both 
vigorous physical activity and a sedentary lifestyle at 13 years of age were positively 
associated with allergic rhinoconjunctivitis with ORs of 1.25 and 1.17, respectively 
(135). 
5.2.5 Weight-related anthropometrics and associations with lung 
function 
The positive associations between weight-related anthropometrics and lung function 
are consistent with results from other studies in children (139, 152-155, 157, 239). 
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A negative association between BMI and FEV1/FVC has been interpreted as flow 
limitation (153, 240). However, there is a positive association between BMI and 
FEV1 and a stronger association between BMI and FVC within the normal range of 
BMI (139, 152). A disproportionate growth between lung size and airway calibre 
during childhood has been called ‘dysanapsis’, by many considered a physiological 
phenomenon and without clinical relevance for airflow limitation in individuals 
(241). Recently, the results of studies suggest that dysanapsis (defined as a normal 
FVC and FEV1 and a low FEV1/FVC ratio) is associated with respiratory symptoms 
and disease severity in obese children with asthma, suggesting that dysanapsis is not 
normal (242, 243).  
As mentioned in Chapter 5.2.4, we found no association between weight-related 
anthropometrics and asthma. Together with a negative association with the 
FEV1/FVC ratio, our results are similar to those of a cross-sectional study of 2393 
children at the ages of 10–17 years, where a negative association between weight and 
FEV1/FVC ratio was independent of respiratory disease or symptoms (152). 
However, as discussed in Chapter 5.1.6, larger studies have shown positive 
associations of rapid weight gain (138, 139) and overweight/obesity with childhood 
asthma (134, 236). 
As mentioned above, our and other studies of children show positive associations of 
weight-related anthropometrics with FEV1 and FVC, whereas studies of adults show 
negative associations (161, 244). A longitudinal study interpreted that an initial 
positive association between childhood BMI and FEV1 and FVC was likely 
attributable to greater childhood lean body mass and not adiposity (161). BMI in 
normal-weight children may be a surrogate marker of relatively more lean body mass 
than fat mass, suggesting that the increase in muscle mass in parallel with BMI could 
explain the different results in children and adults (245). Skinfolds and waist 
circumference may be better markers of body fat mass than BMI in children (168, 
169, 246). However, we found similar associations between BMI and waist 
circumference and skinfolds with lung function, suggesting that BMI also partly 
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reflects body fat in these children, and may contradict that the association between 
childhood BMI and lung volumes is only a result of lean body mass. 
Inverse U-shaped associations were found between BMI SDS and FEV1 % and FVC 
% in late childhood, and the breakpoint toward a negative association is around the 
BMI SDS corresponding to overweight. This is in accordance with other studies 
suggesting that BMI beyond a threshold is associated with reduced lung function 
(153, 157, 247). In the large PIAMA study including measurements at 8 and 12 years 
of age, perseverance of high BMI or large waist circumference was positively 
associated with FEV1 at 12 years of age and showed a small inverse U-shaped 
association with lung function only in obese boys (153). The authors suggested that 
the transition from childhood association (i.e., BMI positively associated with lung 
volumes) to adult association (i.e., BMI negatively associated with lung volumes) 
occurs at a later age (153). In a cross-sectional study of 6784 students of age 8–20 
years, BMI showed an inverse U-shaped association with FEV1 only in children older 
than 12 years of age (247). Our results indicate that the transition from a positive to a 
negative association between BMI and lung function may appear some years earlier. 
Together, these results support that the negative impact of overweight/obesity 
depends on the duration of the overweight, where late childhood is of importance 
(159). 
It is important to consider the composition of excess weight when studying the 
associations between weight-related anthropometrics and lung function (159). We 
found an inverse U-shaped association between subscapular skinfold and FEV1 %, 
indicating that the inverse U-shaped associations may be due to fat and not lean mass. 
However, this should be interpreted with caution owing to the lack of similar findings 
for triceps skinfolds. 
Internal fat deposition may reduce chest wall compliance and impede diaphragmatic 
descent, thus explaining the association between obesity and lung volumes as a 
mechanical effect (248). A negative association of leptin or leptin/adiponectin ratio 
with lung function suggests an effect mediated by a low-grade systemic inflammation 
95 
(159); this is supported by studies showing an association between adiposity and 
asthma in children (159) and adults (236). 
We found positive straight-line associations, but no U-shaped associations for 
birthweight and change in BMI from 1–4 and 4 years to first follow-up and lung 
function at 12.8 years of age in accordance with another study reporting a positive 
association between rapid weight gain from 3–7 years of age and FEV1 and FVC at 
15 years of age (139). However, in a study of 1740 children followed from birth to 21 
years of age, catch-up growth until 5 years of age was positively associated with lung 
function at 21 years of age but negatively associated with lung function in men if the 
weight gain or obesity started after 5 years of age (157), in contrast to our results. 
Finally, results from our and from other studies indicate that the association between 
anthropometrics and lung function may differ between boys and girls. We found that 
the associations between anthropometrics other than BMI and FVC % and FEV1 % 
were mainly found in girls, which is consistent with other studies (154, 249). When 
stratifying by gender, the inverse U-shaped associations persisted only for girls at 
10.8 years of age, but this may possibly be owing to loss of power. Gender specific 
differences could be owing to differences in fat accumulation during and after 
puberty, with a peripheral fat deposition in girls and an abdominal fat deposition in 
boys, leading to reduction in lung function in boys (154).  
5.3 Clinical implications 
We found a positive association of severe preeclampsia with allergic 
rhinoconjunctivitis and high-level atopic sensitization, which emphasizes the possible 
early origin of atopic disease. 
The trajectories of growth after preeclampsia exposure were partly of a large enough 
magnitude to be clinically relevant. Our predictive model of growth after 
preeclampsia exposure may have implications for targeted approaches for healthy 
growth and development. 
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The positive associations (1) of BMI with atopic sensitization and atopic dermatitis, 
(2) of low physical activity with atopic sensitization and asthma and (3) of high 
physical activity with atopic dermatitis were of both high and low effect measures; 
thus, some of the results could be clinically relevant. 
We found positive associations between weight-related anthropometrics and FVC % 
and FEV1 %, but negative associations between weight-related anthropometrics and 
FEV1/FVC % and FEF25-75%/FVC. Whereas these could be physiological phenomena, 
increasing weight might also influence the diameter of the airways, thereby 
contributing to airflow limitation. The inverse U-shaped association of BMI in late 
childhood with lung function suggests that the impact of body composition on lung 
function is higher in obese children. The positive and negative regression coefficients 
between the weight-related anthropometrics and lung function in the present study 
were small, varying from approximately one to three. Therefore, if the predictors 
increase by one unit, the predicted lung function values increase or decrease by 1%–
3%, making the clinical relevance of the results less substantial. However, the inverse 
U-shaped associations between weight-related anthropometrics and lung function at 
10.8–12.8 years of age could suggest that the greater impact of airway obstruction 
occurs in children with the highest body fat mass. 
Our studies do not have direct clinical implications and do not identify new 
preventive measures. Our studies mainly contribute to understanding associations and 
possible early risk factors for atopy, lung function and growth, thereby providing an 




Based on the results of the studies in this thesis and considering the methodological 
limitations, the following answers can be provided for the study objectives. 
Preeclampsia exposure in utero by increasing severity was (positively) associated 
with allergic rhinoconjunctivitis and high-level atopic sensitization in late childhood. 
We did not find any associations of preeclampsia with atopic dermatitis, asthma or 
lung function. 
From birth to adolescence, linear growth, weight and BMI trajectories differed among 
children exposed to preeclampsia by severity of preeclampsia, age and gender 
compared with unexposed children. Exposure to mild/moderate preeclampsia was 
positively associated with linear growth in boys, and it was positively associated with 
weight and BMI in both genders. Exposure to severe preeclampsia was negatively 
associated with linear growth in both genders, and it was negatively associated with 
weight and BMI trajectories in boys, but in girls, it was positively associated with 
weight and BMI after preschool age. Exposure to severe preeclampsia was positively 
associated with waist-to-height ratio in late childhood; however, we did not find any 
associations with waist circumference, triceps skinfolds or subscapular skinfolds. 
BMI and increase in BMI were positively associated with atopic sensitization and 
atopic dermatitis; however, we did not find any association with asthma or allergic 
rhinoconjunctivitis. Furthermore, low physical activity was associated with atopic 
sensitization and asthma ever. High physical activity was associated with atopic 
dermatitis. We did not find any association between physical activity and allergic 
rhinoconjunctivitis. 
Different weight-related anthropometric measurements from birth throughout 
childhood were positively associated with FVC % and FEV1 % and negatively 
associated with FEV1/FVC % and FEF25-75%/FVC in late childhood. BMI in late 
childhood showed an inverse U-shaped association with FVC % and FEV1 %. 
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7. Future perspectives 
Larger studies are needed to further explore the role of preeclampsia in the 
development of atopic disease. 
Our study was the first to provide a predictive model for growth after preeclampsia 
exposure. Similar studies will be needed to confirm our results. Larger studies on a 
population-based cohort with anthropometric measurements every third month until 2 
years of age, and thereafter, every year until adulthood (167), would be necessary to 
further explore this issue. 
The overall aim was to study early-life determinants of atopic diseases. To further 
clarify this topic, large prospective studies would need to be conducted to confirm the 
results of the studies included in this thesis and to identify other risk factors for atopic 
diseases. Such a cohort should be population-based instead of being a preeclampsia 
cohort. 
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9.1 Paper I 
9.1.1 Abstract 
Severe maternal preeclampsia was associated with high level allergic 
sensitization (sum of specific IgE in serum  3.9 kU/l; the 25 percentile for all 
children being sensitized); odds ratio (OR): 3.79; 95 % confidence interval (CI): 
(1.54, 9.32); LR-p: 0.015 and with allergic rhinoconjunctivitis offspring; OR: 2.22; 
95 % CI: (1.19, 4.14); LR-p: 0.047; should be: 
Severe maternal preeclampsia was associated with high-level allergic sensitization 
(sum of specific IgE in serum 3.9 kU/l; the 25th percentile for all children being 
sensitized); odds ratio (OR): 4.05; 95% confidence interval (CI): (1.62, 10.1); LR-p: 
0.010 and with allergic rhinoconjunctivitis offspring; OR: 2.23; 95% CI: (1.20, 4.17); 
LR-p: 0.046. 
9.1.2 Table 1 and Figure 1 
n was not correct; however, the results did not change significantly when n was 
corrected as shown in Paper II, Table 1. Owing to the wrong merging of files, three 
participants were coded two times in the data file used for Paper I; however, this was 
corrected in Paper II. Therefore, it appeared to be 617in the first follow-up and 470 
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Birth after preeclamptic pregnancies: association
with allergic sensitization and allergic
rhinoconjunctivitis in late childhood; a historically
matched cohort study
Kristine Kjer Byberg1*, Bjorn Ogland1,2, Geir Egil Eide3,4 and Knut Øymar1,5
Abstract
Background: The development of allergic sensitization and allergic disease may be related to factors during
intrauterine life, but the role of maternal preeclampsia is not known.
We studied if maternal preeclampsia is associated with long-term allergic sensitization, allergic rhinoconjunctivitis,
atopic dermatitis, asthma and with altered lung function in late childhood.
Methods: 617 children participated in a 1:2 matched and controlled historical cohort study; 230 born after
preeclamptic pregnancies and 387 born after normotensive pregnancies. Specific IgE in serum and lung function
were measured at the age of 12.8 years and questionnaires on maternal and adolescent data were completed at
the ages of 10.8 years (girls) and 11.8 years (boys), and at 12.8 years (both genders). The association between birth
after preeclampsia and the main outcome measures allergic sensitization, allergic rhinoconjunctivitis, atopic
dermatitis, asthma and lung function in late childhood were analysed with multiple regression analyses, including
possible confounders.
Results: Severe maternal preeclampsia was associated with high level allergic sensitization (sum of specific IgE in
serum ≥ 3.9 kU/l; the 25 percentile for all children being sensitized); odds ratio (OR): 3.79; 95% confidence interval
(CI): (1.54, 9.32); p = 0.015 and with allergic rhinoconjunctivitis in offspring; OR: 2.22, 95% CI: (1.19, 4.14), p = 0.047.
Preeclampsia was not associated with atopic dermatitis, asthma or altered lung function in late childhood.
Conclusion: Maternal preeclampsia was associated with allergic sensitization and allergic rhinoconjunctivitis in
offspring in late childhood, but not with other atopic diseases.
Keywords: Childhood, Allergy, Allergic rhinoconjunctivitis, Allergic sensitization, Asthma, Atopic dermatitis, Atopy,
Child, Lung function, Preeclampsia
Background
The prevalence of allergy and asthma has been increas-
ing in both adults and children during the last decades
[1]. There is also increasing evidence that early life
events including intrauterine factors are important for
the development of atopic disease [2-4].
Atopic diseases are associated with an inhibition of the
transition towards an increased T-helper cell type 1
(Th1)/Th2 balance after birth, resulting in Th2 cytokine
predominance [4,5]. Maternal inflammatory cytokines
during pregnancy have been shown to correlate with
corresponding cytokines in offspring at the age of one
[6], and an association between an altered maternal
cytokine profile and subsequent atopic disease in off-
spring has been suggested [7].
Preeclampsia is a common and potentially serious com-
plication of the second half of pregnancy affecting both
mother and child, characterised by maternal hypertension
and proteinuria, and occasionally foetal growth restriction
[8,9]. Preeclampsia is associated with an increase in
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several circulating maternal cytokines, and a skewed ma-
ternal immune response towards an increased Th1/Th2
balance [10]. This could potentially skew the child’s cyto-
kine balance after birth in the same direction, and thereby
protect against the development of atopic disease [6].
However, clinical studies have suggested that complica-
tions during pregnancy may rather increase the risk of
childhood asthma and allergic rhinoconjunctivitis [11,12],
and an association between maternal preeclampsia and
subsequent allergic sensitization in offspring during ado-
lescence has been suggested [13].
Preeclampsia has also been associated with an in-
creased risk of RDS and BPD in preterm infants and to
recurrent wheezing in a general population of pre-
school children [14]. This association might either be
due to an increased soluble antiangiogenic factor [15], or
a congenital reduction in airways calibre and compliance
in particular in infants with intrauterine growth restric-
tion [16]. However, no studies have evaluated a possible
long-term association between maternal preeclampsia
and asthma or lung function in offspring.
In a long–term follow-up of children of preeclamptic
and normal pregnancies, the aim was to study if mater-
nal preeclampsia is associated with allergic sensitization,
allergic rhinoconjunctivitis, atopic dermatitis, asthma,
and lung function in late childhood.
Methods
Study population and design
The study was a part of “the Stavanger study” described
in detail elsewhere [17]. In short, cord blood was drawn
from all newborns at Stavanger University Hospital dur-
ing 1993–1995, during which 12 804 deliveries took
place. The Medical Birth Registry of Norway was used to
identify offspring exposed to maternal preeclampsia and
unexposed offspring, and information was verified and
supplemented with data from hospital records. All off-
spring of preeclamptic pregnancies were defined as ex-
posed. For each exposed, two matched unexposed
offspring were selected as follows: one was defined as
the next delivery in the hospital and one as the next
delivery matched on maternal age. Exposed and unex-
posed offspring were invited to participate in a follow-
up (FU) study at the target ages of 10.8 years (girls)
and 11.8 years (boys) (FU1), and a second follow-up at
the target age of 12.8 years (FU2) (Figure 1). The target
ages at FU1 were selected to also be able to collect pu-
berty stage data at an age presumed to represent the
start of puberty development in the children [17]. If
unexposed offspring did not respond, no substitutes
were invited. Consequently, the study design was a his-
torically matched cohort with 1025 children; 366 in
the preeclampsia cohort and 659 in the control cohort.
The study was approved by the Norwegian Data In-
spectorate, the Regional Committee for Ethics in medical
research and the Institutional Review Board of the Na-
tional Cancer Institute of the United States. Written
consent was obtained from all participating children and
mothers at follow-up.
Data collection and definitions
Preeclampsia was defined as a diastolic blood pres-
sure increased by ≥ 25 mmHg to a persistent pressure
of ≥ 90 mmHg and proteinuria with dipstick ≥ +1 present
in at least one urine sample after 20 weeks of gestation.
Preeclampsia was further divided into mild, moderate and
severe. Moderate preeclampsia was defined as proteinuria





n = 287 (44%)
(136 (40%) / 151 (47%))
Participants
n = 183 (50%)




n = 387 (59%)




n = 230 (63%)







n = 136 (37%)
(69 (39%) / 67 (36%))
Missing
n = 230 (63%)
(109 (61%) / 121 (64%))
Missing
n = 183 (50%)
(82 (46%) / 101 (54%))
Missing
n = 372 (56%)
(202 (60%) / 170 (53%))
n=179 n=279
Figure 1 Number of participants invited to the Stavanger study, and numbers that consented to first and second follow-up.
Abbreviations: FU1 = First follow-up at the ages of 10.8 years (girls) and 11.8 years (boys); FU2 = Second follow-up at the age of 12.8 years (both
genders); Preeclampsia = children born after pregnancies with preeclampsia; Normal = children born after pregnancies without preeclampsia.
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proteinuria with dipstick ≥ + 3 and diastolic blood pres-
sure of ≥110 mmHg.
Maternal body mass index (BMI, kg/m2) was calcu-
lated using weight measurement at the first antenatal
visit at primary healthcare examination during the first
trimester of pregnancy and height measurement from
FU1. Maternal smoking in pregnancy was recorded at
the same antenatal visit. Data on gestational age at birth
and mode of delivery were extracted from hospital re-
cords. Birth weight for gestational age was calculated as
z-scores based on Scandinavian normal standards [18].
Weight and height in offspring were recorded at FU1,
and z-scores for BMI were calculated using the latest
growth references for Norwegian children [19].
Questionnaires
At FU1, the questions included the birth order of the
child, parental asthma, and atopic disease of the child.
The mothers were asked as follows: Has your child ever
had asthma (diagnosed by physician), allergy in nose/
eyes (hay fever) or atopic dermatitis (childhood eczema)?
At FU2, the children answered a questionnaire from the
International Study of Asthma and Allergies in Childhood
(ISAAC) translated into Norwegian [20]. Reported asthma
symptoms and asthma medication during the last year
and asthma diagnosis ever were recorded. Missing an-
swers were interpreted as negative. Current asthma at
FU2 was defined as asthma ever, in addition to asthma
symptoms or the use of asthma medication during the last
12 months.
Laboratory methods
At FU2 blood was drawn from the children, centrifuged
and aliquoted, and serum stored at -80°C. Allergic
sensitization was determined by serum specific immuno-
globulin E (IgE) antibodies using Phadiatop® and fx5E®
(ImmunoCAP® 250, Phadia AB, Uppsala, Sweden). If
Phadiatop® was positive, serum was further analysed for
specific IgE against Dermatophagoides pteronyssinus, cat,
horse, dog, timothy, common silver birch, mugwort and
Cladosporium herbarum. If fx5E® was positive, serum
was further analysed for specific IgE against egg white,
milk, fish (cod), wheat, peanut and soya bean. Allergic
sensitization was defined as specific IgE ≥ 0.35 kU/l for
at least one allergen. The levels of specific IgE ≥ 0.35
were added together, and high level allergic sensitization
was defined as a sum > 3.9 kU/l; the 25 percentile for all
children being sensitized.
At FU2, lung function measures were performed by
spirometry according to standard quality criteria [21]
with a Vmax Encore spirometer (Sensor Medics Inc.,
Anaheim, USA).
Statistics
Groups were compared with Pearson’s chi-square exact
test for the dichotomous outcomes and independent t-
tests (Gosset’s t-test) and one way analysis of variance
for the continuous outcomes. Bonferroni-correction of
p-values was applied to adjust for multiple testing.
Before analyses, the variable preeclampsia was cate-
gorised into none, mild/moderate (combined) and se-
vere. Risk associations between preeclampsia and related
pregnancy variables with outcomes in late childhood
were analysed by multiple logistic and linear regression
analyses, including the covariates gender, birthweight
z-score for gestational age, being firstborn, maternal
smoking during pregnancy, maternal age at birth, cae-
sarean section, gestational age, maternal BMI and ma-
ternal asthma. Paternal asthma was not included as a
covariate due to low response rate. Each variable was
first entered separately into simple regression models.
Covariates significant at the 10% level and those con-
sidered important were included in backward stepwise
logistic and linear regression analyses. Final models in-
cluded the remaining covariates significant at the 5%
level and the covariates gender and maternal asthma,
considered as biologically important. Analysing the or-
dinal variable preeclampsia as were it a continuous
variable with scores 0, 1 and 2 for the three levels, ORs
showing a trend have been calculated by multiple lo-
gistic regression analysis.
From logistic regression odds ratios (OR) with 95% con-
fidence interval (CI) and likelihood ratio p-value (LR-p) for
each exposure are reported. From linear regression the es-
timated coefficients (b), 95% CI and F-test p-value are re-
ported. Interactions between preeclampsia and all other
risk factors remaining in the final models were tested. Also
interactions between preeclampsia and gender were tested.
All tests were 2-tailed and p-values ≤ 0.05 were consid-
ered statistically significant. Due to missing data, match-
ing was not included in the analyses, but the matching
variables were adjusted for. SPSS for Windows (version
18.0.0, Chicago, Ill., USA) was used for all analyses.
Results
Characteristics of the participants
The number of children invited and participating in FU1
and FU2 are shown in Figure 1. Table 1 shows the char-
acteristics of children who consented to FU1, and those
who did not consent. There were no significant differ-
ences in perinatal characteristics of children who con-
sented and those who did not consent.
At FU1, the age of the girls was 10.8 (±0.22) years
(mean, SD), and for boys 11.8 (±0.18) years. At FU2 the
age for both genders was 12.8 (±0.19) years.
BMI z-score at FU1 was higher in children who only
consented to FU1 than in children who consented to both
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FU1 and FU2 (mean difference BMI z-score: 0.31 kg/
m2; 95% CI: 0.13 to 0.49; p = 0.001). When analysed
separately for girls and boys, the difference persisted
for girls only (mean difference BMI: 0.44 kg/m2; 95%
CI: 0.20 to 0.68; p < 0.001). More children had atopic
dermatitis of those who only consented to FU1 (48/
150; 32%), than those who consented to both FU1 and
FU2 (100/445; 22.5%); p = 0.022. No other variables
differed significantly between those who consented to
FU1 only and those who consented to both FU1 and
FU2.
Preeclampsia and outcomes
The outcome in children according to maternal pre-
eclampsia status is shown in Table 2. A greater proportion
of offspring from pregnancies with severe preeclampsia
had allergic rhinoconjunctivitis and high level allergic
sensitization than offspring from pregnancies with mild/
moderate or no preeclampsia.
Among children with any allergic sensitization, 50%
had symptoms of allergic rhinoconjunctivitis, whereas
5.6% of children with allergic rhinoconjunctivitis did not
have any allergic sensitization.
Table 1 Initial characteristics of 1025 Norwegian children born in 1993–1995 and invited to the Stavanger study
according to consenting or not to the first follow-up 11–12 years latera)
Consented (n = 617) Did not consent (n = 409)
Variable n n p
Gender: boys, n (%) 617 296 (48.0) 408 220 (53.9) 0.065b)
Preeclampsia, n (%) 617 230 (37.3) 409 137 (33.5) 0.231b)
Maternal age, years, mean, 95% CI 610 28.0 (27.7, 28.4) 408 27.6 (27.2, 28.1) 0.194c)
Gestational age, weeks; mean, 95% CI 604 39.3 (39.1, 39.5) 343 39.2 (39.0, 39.5) 0.855c)
Birth weight z-scored) 590 −0.17 (−0.27, −0.07) 339 −0.06 (−0.18, 0.06) 0.169c)
Abbreviations: CI confidence interval.
a)Follow-up at the ages of 10.8 years (girls) and 11.8 years (boys);
b)Exact chi-square test;
c)Gosset’s t-test;
d)Number of standard deviations from mean.















54 19 (35.2) 161 36 (22.4) 371 71 (19.1) 0.018 0.822 0.015
Atopic dermatitis, n (%) 54 15 (27.8) 163 37 (22.7) 369 92 (24.9) 1.476 1.172 1.000




39 15 (38.5) 112 40 (36.3) 230 72 (31.3) 0.918 0.924 0.296
High level allergic
sensitization, n (%)c)
39 15 (38.5) 112 28 (25.0) 230 50 (21.7) 0.056 1.166 0.042
Current asthma, n (%) 46 6 (13.0) 123 12 (9.8) 279 19 (6.8) 0.454 0.630 0.126
FEV1%, mean, 95% CI 45 89.7 (87.0, 92.5) 126 91.0 (89.0, 93.0) 272 91.1 (90.0, 92.2) 1.000 1.000 0.682
FVC%, mean, 95% CI 45 99.2 (95.5, 102.8) 126 100.0 (97.7, 102.3) 272 101.1 (99.8, 102.4) 0.965 1.000 0.489
FEV1/FVC, mean, 95% CI 45 84.6 (82.7, 86.5) 126 85.3 (83.9, 86.6) 272 84.9 (84.1, 85.7) 1.000 1.000 0.482
FEF25–75%, mean, 95% CI 45 84.9 (79.4, 90.3) 126 89.6 (85.9, 93.4) 272 87.4 (85.1, 89.6) 1.000 0.827 0.317
FEF25–75/FVC, mean,
95% CI
45 54.5 (50.0, 59.0) 126 57.3 (54.7, 59.9) 272 55.7 (54.1, 57.4) 1.000 0.906 0.429
Abbreviations: FU1 first follow-up at the ages of 10.8 years (girls) and 11.8 years (boys), FU2 second follow-up at the age of 12.8 years (both genders), FEV1% forced
expiratory volume in first second predicted, CI Confidence interval, FVC% forced vital capacity predicted, FEF25–75% forced expiratory flow between 25% and 75% of the
forced vital capacity, predicted.
a)Pearson’s exact chi-square test (dichotomous variable) and one way analysis of variance (continuous variable) with Bonferroni corrections;
b)Cochran-Armitage test for dichotomous outcomes and one way analysis of variance for continuous outcomes;
c)Sum of specific IgE > 3.9 kU/l.
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In the unadjusted logistic regression analyses, severe
preeclampsia was a risk factor for allergic rhinoconjunc-
tivitis; OR: 2.29; 95% CI: 1.24 to 4.24; LR-p = 0.036.
Table 3 shows the results of adjusted logistic regression
analyses with different atopic diseases as outcomes ac-
cording to maternal preeclampsia status. In fully ad-
justed analyses, severe preeclampsia was a significant
risk factor for high level allergic sensitization, but not so
for any other outcomes of atopic disease.
In the backward stepwise regression analysis of high
level allergic sensitization the final model included pre-
eclampsia as a significant risk factor, in addition to male
gender, maternal smoking during pregnancy, gestational
age in weeks and maternal asthma (Table 3). Specifically,
birth after severe preeclampsia gave 4.05 times higher
odds for high level allergic sensitization than birth after
non-preeclampsia, adjusted for the other variables.
In a backward stepwise regression analysis of allergic
rhinoconjunctivitis the final model included preeclamp-
sia in addition to male gender and maternal asthma
(Table 3). Specifically, severe preeclampsia gave 2.23
times higher odds for allergic rhinoconjunctivitis than
no preeclampsia, adjusted for the other variables.
Adjusted for the same covariates as in final analysis,
there was a trend of an increasing effect of preeclampsia
(none, mild/moderate, severe) on both high level allergic
sensitization (OR = 1.88; 95% CI: (1.23, 2.86); LR-p = 0.003)
and on allergic rhinoconjunctivitis (OR = 1.42; 95% CI:
(1.07, 1.89); LR-p = 0.018).
Preeclampsia was not a significant risk factor for other
outcomes of atopic disease in the final models.
Preeclampsia was not a risk factor for any outcomes of
lung function in unadjusted or fully adjusted linear re-
gression analyses. Table 4 shows the results of linear re-
gression analyses of lung function variables according to
maternal preeclampsia status.
Discussion
In the present study we found positive associations be-
tween severe maternal preeclampsia and both high level
allergic sensitization and allergic rhinoconjunctivitis in
adolescent offspring. This is to our knowledge showed
for the first time. Preeclampsia was not associated with
subsequent atopic dermatitis, asthma or alterations in
lung function.
Preeclampsia and atopic disease
Few other studies have evaluated preeclampsia as a pos-
sible risk factor for subsequent allergic sensitization or
atopic disease in a long-term perspective. Keski-Nisula
et al. found an association between maternal preeclamp-
sia and severe atopy in children. However, in that study
only women who underwent caesarean section were in-
cluded, and a very high percentage of children were sen-
sitized [13]. Nafstad et al. found a relation between
uterus-related complications during pregnancy and aller-
gic rhinoconjunctivitis and asthma, but not for children
born after preeclamptic pregnancies [11]. To our know-
ledge, no other studies have evaluated the risk for aller-
gic rhinoconjunctivitis after preeclamptic pregnancies.
A possible causal relation between preeclampsia and
atopic disease in offspring could be linked to the
Table 3 Summary of logistic regression analyses of atopic diseases in late childhood in 586 Norwegian children according to
mother’s preeclampsia status
Effects of maternal preeclampsia













Outcome variable OR 95% CI OR 95% CI
p
OR 95% CI OR 95% CI
p
FU1 variables
Allergic rhinoconjunctivitis 514 1.21 (0.70, 2.07) 2.10 (0.86, 5.11) 0.268 586 1.25 (0.79, 1.97) 2.23 (1.20, 4.17) 0.046
Atopic dermatitis 513 0.90 (0.54, 1.50) 0.97 (0.39, 2.39) 0.914 ____
Asthma 506 0.87 (0.38, 1.97) 0.72 (0.19, 2.77) 0.878 ____
FU2 variables
Allergic sensitization 329 1.49 (0.84, 2.63) 2.44 (0.93, 6.42) 0.138 ____
High level allergic sensitizationc) 329 1.64 (0.87, 3.11) 4.42 (1.58, 12.3) 0.015 347 1.60 (0.88, 2.91) 4.05 (1.62, 10.1) 0.010d)
Current asthma 388 1.11 (0.45, 2.73) 0.69 (0.15, 3.18) 0.802 ____
Abbreviations: OR Odds ratio, CI Confidence interval, FU1 first follow-up at the ages of 10.8 years (girls) and 11.8 years (boys), FU2 second follow-up at the age of 12.8 years
(both genders); Likelihood-ratio-p refers to exposure only.
a)Adjusted for gender, birth weight z-score adjusted for gestational age, being firstborn, Caesarean section, maternal smoking during pregnancy, gestational age in weeks,
maternal age, maternal body mass index (kg/m2) and maternal asthma;
b)After backward stepwise selection from fully adjusted model with p≤ 0.05; all final analyses include the covariates gender and maternal asthma as default.
c)High level allergic sensitization = Sum of specific IgE > 3.9 kU/l; the 25 percentile of sensitized children.
d)Adjusted for gender, maternal smoking during pregnancy, gestational age in weeks and maternal asthma. No significant interaction effects were found in final analyses.
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inflammatory changes observed during preeclampsia. If
the tendency for preeclampsia to skew the cytokine pro-
file of the mother towards an increased Th1/Th2 ratio is
reflected in the cytokine pattern of the offspring during
pregnancy and early life, it could potentially protect the
child from the development of Th2 driven atopic disease
[6,22]. However, preeclampsia is a complex inflammatory
condition characterised by a variety of pro-inflammatory
cytokines beyond the Th1 type of cytokines [10,23]. Pro-
inflammatory cytokines, chemokines and adhesion mol-
ecules appear to be increased in maternal circulation
during preeclampsia [13], and could potentially initiate
the development of immunological conditions in the
foetus, such as atopic sensitization or diseases [6].
The association between preeclampsia and atopy could
be due to shared genetic or environmental factors in
pregnancy. Preeclampsia is more common in nulliparous
[24] and pregnancies with a male foetus [25], and atopic
disease is more common in first-born-children [26] and
boys up to adolescence [27]. According to the hygiene
hypothesis, the birth order effect on atopy may be ex-
plained by a reduced tendency for Th2 deviation due to
greater exposure to pathogens from older siblings [28].
However, recent studies have demonstrated a birth order
effect on cord blood IgE and food allergy in very early
life, suggesting a prenatal origin of this effect [29,30].
Our analyses were controlled for birth order, suggesting
that preeclampsia may be a risk factor for atopy in the
offspring unrelated to birth order. However, as this is an
observational study, the possibility of residual confound-
ing cannot be excluded.
Finally, maternal conditions prior to pregnancy could
increase the risk for both preeclampsia and atopic dis-
ease in offspring. Maternal asthma has been shown as a
risk factor for preeclampsia [31]. To our knowledge, no
studies have shown any association between maternal al-
lergy and preeclampsia.
There was a trend of an increased risk of atopic disease
in the child by an increasing severity of the maternal pre-
eclampsia. Moreover, preeclampsia was not associated
with low level allergic sensitization, asthma or atopic
dermatitis. Low level allergic sensitization may be unspe-
cific and less related to clinical atopic disease compared to
higher levels of sensitization [32]. The pathophysiology of
asthma and atopic dermatitis is more multifactorial than
the specific allergy driven pathophysiology of rhinocon-
junctivitis. Our results may therefore suggest that the
association between severe preeclampsia and atopic
disease in offspring is related to specific Th2-mediated
mechanisms [29].
Preeclampsia, asthma, wheezing and lung function
Some studies have shown an association between differ-
ent complications of pregnancy and asthma in offspring,
but preeclampsia was not shown to be a risk factor in
these studies [12,33]. In a large population-based study
using a questionnaire, an association between maternal
preeclampsia and wheezing in the offspring was shown
[34]. A possible explanation for this association could be
that hypertension in pregnancy is related to fetal growth
restriction and hence altered airway function [35]. Our
results do not contradict this. Although we could not
find any association between preeclampsia and asthma
ever, current asthma or lung function in late childhood,
we did not investigate wheezing disorders in the first
years of life. However, the present study had a longer
follow-up than in the studies mentioned above, and may
therefore be better suited to study any long time effect
of preeclampsia on asthma and lung function in late
childhood.
One limitation of the study is the rather low rate of
participation, especially in FU2. It is not known whether
there was a difference in prevalence of asthma or atopy
between those who consented and those who didn’t con-
sent to overall follow-up. Especially for the outcomes of
asthma, there was a rather low response rate which in-
creases the risk of a type 2 error. Furthermore, children
who participated in FU1 but not in FU2 had a higher
BMI and more atopic dermatitis. This may have biased
our results, as both overweight and atopic dermatitis
may be associated with allergic sensitization and other
atopic disease.
Another limitation may be that that allergic rhinocon-
junctivitis, asthma and atopic dermatitis were defined only
by questionnaire. However, allergic sensitization was
found in 94.4% of children diagnosed with rhinoconjuncti-
vitis, suggesting a high degree of diagnostic accuracy.
Some children reported allergic rhinoconjunctivitis
Table 4 Summary of linear regression analyses of lung
function in late childhood in 395 Norwegian children
according to mother’s preeclampsia status







b 95% CI p b 95% CI p
FEV1% 381 0.57 (−1.86, 2.99) 0.647 1.27 (−2.95, 5.49) 0.555
FVC% 381 −1.47 (−4.36, 1.42) 0.317 −2.24 (−7.28, 2.79) 0.381
FEV1/FVC 381 1.28 (−0.35, 2.92) 0.124 2.79 (−0.06, 5.64) 0.055
Abbreviations: FEV1% forced expiratory volume in first second predicted,
FVC% Forced vital capacity predicted, FEV1/FVC Ratio of actual FEV1 over FVC,
n number of participants, b regression coefficient, CI confidence interval,
a)Adjusted for gender, birth weight z-score adjusted for gestational age,
being firstborn, Caesarean section, maternal age, maternal smoking during
pregnancy, gestational age in weeks, maternal body mass index (kg/m2)
and maternal asthma.
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without having sensitization, but this is also seen in other
studies and does not rule out allergic rhinoconjunctivitis
[36]. Due to study design, allergic rhinoconjunctivitis and
allergic sensitization were assessed at two different
ages. However, this should not affect that independent
associations were found between preeclampsia preg-
nancies and allergic rhinoconjunctivitis and allergic
sensitization respectively.
In the multivariate analyses we included a set of vari-
ables possibly influencing the outcomes. The covariates
gestational age, birthweight z-score and caesarean sec-
tion could be considered as intermediate variables be-
tween preeclampsia and the outcomes, but may also be
independent risk factors for subsequent allergy and
atopic disease and were therefore included as covariates
in the analyses. Given the lack of complete ascertain-
ment of causal links, one cannot exclude the possibility
of collider bias and therefore biased associations be-
tween exposures and outcomes [37].
The only data on family atopy available were on ma-
ternal and paternal asthma. Paternal asthma was not
considered to be a possible confounder for the relation-
ship between maternal preeclampsia and subsequent
atopy, asthma or lung function in offspring and not in-
cluded as a covariate.
Conclusion
The results of this study suggest that severe maternal pre-
eclampsia may be associated with allergic sensitization and
allergic rhinoconjunctivitis in late childhood. This empha-
sizes the possible early origin of atopic disease, but larger
studies are needed to further explore the role of pre-
eclampsia in the development of atopic disease. No other
significant associations between maternal preeclampsia
and atopic dermatitis, asthma or lung function were found.
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An adverse intrauterine environment may affect offspring growth and development. Our aim
was to explore whether preeclampsia (PE) exposure in utero influences growth from birth to
13 years.
Methods
In a nested case-control study, 229 children were exposed to PE (mild/moderate: n = 164,
severe: n = 54) and 385 were unexposed. Length/height and weight were abstracted from
records at birth, 3 and 6 months, 1 and 4 years, and measured along with waist circumfer-
ence and skinfolds at follow-up at 11/12 (girls/boys) and 13 years (both sexes). Associations
between PE and z-scores for growth were analyzed by multiple linear and fractional polyno-
mial regression with adjustment for potential confounders.
Results
In boys, exposure to mild/moderate PE was positively associated with linear growth after 0.5
years, but severe PE was negatively associated with linear growth in all ages. In girls, both
exposure to mild/moderate and severe PE were negatively associated with linear growth.
Exposure to PE was negatively associated with weight and body mass index (BMI) during
infancy, but positively associated with weight and BMI thereafter, except that boys exposed
to severe PE consistently had a lower weight and BMI compared to the unexposed.
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Exposure to severe PE only was positively associated with waist-to-height ratio at 11/12
(girls/boys) and 13 years (both sexes).
Conclusions
From birth to adolescence, linear growth, weight and BMI trajectories differed between the
sexes by severity of exposure to PE. In general, PE exposure was negatively associated
with linear growth, while in girls; positive associations with weight and BMI were observed.
This underlines fetal life as a particularly sensitive period affecting subsequent growth and
this may have implications for targeted approaches for healthy growth and development.
Introduction
Preeclampsia (PE) is diagnosed in 3–5% of pregnancies and may be a serious complication of
the second half of pregnancy affecting both mother and child. It is characterized by maternal
hypertension and proteinuria, and associated in its severe form with fetal growth restriction
[1–3]. PE is classified by severity into mild, moderate and severe forms, with differences in
pathophysiology, gestational age at diagnosis, fetal growth and outcomes [4].
According to the Barker hypothesis, a hostile intrauterine environment may be associated
with low birth weight, with increased risk for having a shorter adult height, metabolic disor-
ders, obesity, diabetes and cardiovascular diseases [5–7]. Children born small for gestational
age frequently experience catch-up growth, although more catch-up in weight than in height
[8].
PE has been associated with low birthweight, catch-up growth in infants and a high body
mass index (BMI, kg/m2) during adolescence [9, 10]. Delay of thelarche but accelerated pub-
arche and increased risk for obesity in late childhood with subsequent metabolic anomalies
and altered risk for cancer in adulthood, have also been reported in offspring exposed to PE
compared to the unexposed [10–12].
The present study is a part of “The Stavanger study”, which has previously shown that expo-
sure to PE is associated with a low birthweight, especially after severe PE [3], large waist cir-
cumference and a high BMI in girls at the onset of puberty [10]. However, there are limited
data on longitudinal growth patterns of children exposed to PE from birth to late childhood.
The aim of the present study was therefore to explore whether length/height, weight and BMI
trajectories from birth to late childhood and waist circumference and skinfolds in late child-
hood vary by severity of PE and the child’s sex and differ in comparison with the unexposed.
We specifically hypothesized that exposure to severe PE in utero, a known risk factor for small
for gestational age, contributes to compromised linear growth and accelerated weight gain
during childhood and that the pathways to growth may differ by severity of PE and by child’s
sex.
Methods
Study population and design
From a population-based cohort including 12 804 deliveries during 1993–1995 at Stavanger
University Hospital [3], the Medical Birth Registry of Norway was used to identify mothers
with PE (n = 366) and controls (n = 659) to conduct a nested case control study: For each case,
two matched controls were selected; one was the next delivery in the hospital (i.e. a birth date
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match) and one was the next born matched on maternal age (i.e. a risk factor for PE). The pres-
ent study, “The Stavanger Study” described in detail elsewhere [10], was a follow-up of the
nested case control study, aiming to study anthropometry, blood pressure and pubertal devel-
opment in children after PE exposure in utero. The cases and controls were invited to partici-
pate in a first follow-up study. The ages at follow-up were selected to coincide with the age of
pubertal onset (first follow-up) and menarche (second follow-up) of the children [10, 12].
Thus the mean age was 10.8 years (girls) and 11.8 years (boys) at the first follow-up, and at the
second follow-up it was 12.8 years (both sexes), as shown previously [13]. As there were more
missing participants in the controls than the case group, the original matching on maternal
age and birth date was compromised, and maternal age was included as a potential confounder
in the analyses. The analyzed sample included all children who participated in both follow-
ups.
The study was approved by the Norwegian Data Inspectorate, the Regional Committee for
Ethics in Medical Research Western Norway (Reference Numbers: First: 078–03, Second:
2010/1375) and the Institutional Review Boards of the National Cancer Institute (Reference
Number: LAB09-0139) and University of Texas at Austin, United States (Reference Number:
2013-04-0036). At follow-up, participating mothers and children signed an informed consent/
assent form.
Exposures
PE was diagnosed based on blood pressure and proteinuria levels at gestational age (GA) 20
weeks on and further classified as mild, moderate or severe according to the Collaborative
Low-dose Aspirin Study in Pregnancy (CLASP) criteria as specified previously [10, 14]. How-
ever, due to the pathophysiological similarity between mild and moderate PE, these two condi-
tions were combined into one category for analyses [15].
Outcomes
Birth length and weight were abstracted from hospital records for consenting participants.
In Norway, all children receive healthcare at well baby clinics with routine measurements
of recumbent length (or standing height from 2 years of age) and weight from infancy to
school age. At first follow-up, length/height and weight measurements from routine visits at
well baby clinics at the target ages of 3, 6 and 12 months and 4 years were abstracted from clin-
ical records. If a measurement was missing, the value from the closest visit in time was used
and the exact age was recorded for all visits. Height, weight, triceps skinfold and waist circum-
ference in offspring were measured twice each at both follow-ups, and subscapular skinfold at
second follow-up, with the average used in the analyses. The measurements at follow-ups were
performed by three specially trained nurses, as described previously [10]. Standard deviation
scores (SDS) for height, weight, BMI, skinfold and waist measurements including the waist-to-
height ratio, relative to sex and age, were calculated in R version 2.6.2 (R Development Core
Team, Vienna, Austria). Calculating SDS according to WHO standards could put the data into
an international perspective. However, growth of Norwegian children has been shown to devi-
ate significantly from the WHO standards [16]. We have therefore used SDS based on the Nor-
wegian growth reference in our calculations [17–19].
Confounders
The potential confounders including categorical and continuous variables are presented
below, and illustrated in a directed acyclic graph (S1 Fig):
Child’s sex: Frommedical records.
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Birth order (recoded to firstborn or not): Frommaternal questionnaire at first follow-up.
Maternal BMI: Calculated from pre-pregnancy weight measurement at the first antenatal
visit at primary healthcare examination during the first trimester of pregnancy and height
measurement from first follow-up.
Maternal smoking in pregnancy (yes/no): Recorded at first antenatal visit.
Maternal age at delivery: Design variable.
Maternal education at time of delivery (< 9 years, 9–12 years,> 12 years): Frommaternal
questionnaire at first follow-up.
GA and puberty staging were not adjusted for, as these are intermediate variables between
the exposures and outcomes.
The questionnaires used have been shown as supporting information in a recent publica-
tion by Alsnes et al [20].
Statistics
For descriptive statistics we used the mean and 95% confidence interval (CI) as well as median
and lower and upper quartiles (Q1, Q3). For comparison between groups by severity of PE
exposure Kruskal-Wallis one way analysis of variance and Mann-Whitney U-test were used
for continuous variables that were not normally distributed, and compared by Gosset’s
unpaired t-tests (Student, 1908) for approximately normally distributed variables.
Multiple linear regression analysis of growth (SDS for length/height, weight and BMI) over
time,.i.e. at birth, 3 and 6 months, 1 and 4 years, and both follow-ups was computed using gen-
eralized estimating equations (GEE) taking into account correlations between repeated mea-
surements in each child. To identify potential non-straight line effects of PE on growth, we
used multiple fractional polynomial regression (MFPR) [21] adjusted for repeated measure-
ments in each child by use of the mfpr and xtgee procedures in GEE of Stata 14. The effect of
maternal PE (no, mild/moderate, and severe) on growth was studied using regression models
with adjustment for potential confounders. Interactions with sex and age were tested using the
likelihood ratio test. Finally, the identified fractional polynomials were plotted using R (version
3.2.1)
Also, associations between the severity of PE and SDS for skinfolds, waist circumference
and waist-to-height ratio were analyzed by separate multiple linear regression analyses (gen-
eral linear model: GLM) including the covariates above. A backward stepwise selection of con-
founders at P-values of< 0.05 was performed, with child’s sex and maternal smoking forced
into the final model with adjustment for significant confounders.
The estimated coefficients (b), 95% CI and P-values fromWald’s chi-square-test (GEE) and
the F-test (GLM) are reported. All tests were 2-tailed and P-values 0.05 were considered sta-
tistically significant.
STATA SE14 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX:
StataCorp LP.) was used for the GEE analyses, and IBM SPSS for Windows (version 22.0.0,
Chicago, Ill., USA) was used for the GLM analyses.
Results
Characteristics of the participants
A detailed description of the cohort is previously published [13]. Briefly, out of 366 exposed
and 659 unexposed invited children, 229 (63%) of the exposed (mild/moderate: n = 164,
severe: n = 54) and 385 (59%) of the unexposed children assented to the first follow-up. 182
(50%) of the exposed (mild/moderate: n = 127, severe: n = 46) and 286 (43%) of the unexposed
children assented to the second follow-up. Information about PE severity was missing for 11
Preeclampsia exposure and subsequent growth throughout childhood
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children at the first follow-up, and for 9 children at the second follow-up. Maternal age at
delivery was greater in children who did than did not assent to the second follow-up. Other-
wise, there were no significant differences in perinatal characteristics between children who
did and did not assent to the first and the second follow-ups (Table 1) [13]. GA at birth differed
between the three PE exposure groups (Kruskal-Wallis test: P< 0.001). Pairwise comparisons
showed that children exposed to severe PE had a lower GA at birth than those exposed to
mild/moderate PE and the unexposed (Mann-Whitney U-test for both comparisons:
P< 0.001) and that children exposed to mild/moderate PE had a lower GA at birth than the
unexposed (Mann-Whitney U-test: P< 0.001). Median weeks (Q1, Q3) were, respectively; 36.1
(32.0, 38.6), 39.1 (37.6, 40.1) and 40.1 (39.3, 41.0). BMI SDS at the first follow-up was higher in
girls who only assented to first follow-up than in those who assented to both follow-ups (mean
difference BMI: 0.44 kg/m2; 95% CI: 0.20 to 0.68; unpaired t-test P< 0.001).
PE and outcomes
The growth curves for height, weight and BMI by sex and severity of PE as developed by frac-
tional polynomial regression are shown in Figs 1 and 2. The corresponding regression models
appear in Table 2.
The results of fully adjusted analysis of the interaction between sex, age and PE and the
effect on height, weight and BMI appear in Table 2 and are described below.
Length/Height SDS (Fig 1A–1D, Table 2)
In utero exposure to PE was associated with linear growth. Specifically, boys exposed to mild/
moderate PE had an increased linear growth above 0.5 years compared to the unexposed. Boys
exposed to severe PE had a decreased linear growth trajectory compared to the unexposed
boys across all ages. As an example, boys exposed to severe PE were approximately 3 cm
shorter than the unexposed boys at 2 years of age. Girls exposed to PE had a decreased linear
growth trajectory until 12 years of age (non-significant difference between boys and girls;
Table 1. Comparison of invited children to the Stavanger Study (n = 1025) according to assenting status to follow-upsa).
Variable First follow-upa) Second follow-upa)
Assented (n = 617) Did not assent
(n = 408)
Assented (n = 470) Did not assent
(n = 555)
n n p n n p
Gender: boys, n (%) 613 293 (47.8) 408 220 (53.4) 0.056b) 468 230 (49.1) 553 283 (51.2) 0.530b)
Preeclampsia, n (%) 614 229 (37.3) 438 165 (37.7) 0.676b) 469 182 (38.8) 583 212 (36.4) 0.184b)
































Abbreviations: CI = confidence interval
a) First follow-up at the ages of 10.8 years (girls) and 11.8 years (boys); Second follow-up at 12.8 years;
b) Exact chi-square test;
c) Gosset’s t-test;
d) Q1, Q3 = Lower and upper quartiles;
e) Mann-Whitney U Test;
f) SDS = standard deviation score
https://doi.org/10.1371/journal.pone.0176627.t001
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P< 0.290, Table 2). Girls exposed to severe PE were approximately 2 cm shorter than the
unexposed girls at 2 years of age.
Weight SDS (Fig 1E–1H, Table 2)
Weight SDS in children exposed to mild/moderate PE, and in girls exposed to severe PE, was
lower than in the unexposed from birth through preschool age and higher thereafter, but the
Fig 1. Plots of predicted length/height standard deviation score (SDS) (A-D) and weight SDS (E-H) vs. age according to sex
and severity of preeclampsia. Key to figures: Solid line = Unexposed, Dash-dot line = mild/moderate preeclampsia, Dashed
line = Severe preeclampsia. Each figure represents the fractional polynomial (FP) with the best fit for each measure (X), i.e. FP (0, 3)
= b1ln(X) + b2X
3; FP (0, 0.5) = b1ln(X) + b2
p
X. The plots are adjusted for sex, age, birth order, maternal age, smoking, BMI, education
and an interaction between preeclampsia and age. Details appear in Table 2.
https://doi.org/10.1371/journal.pone.0176627.g001
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differences were maximally equivalent to 0.5 kg. Weight SDS in boys exposed to severe PE was
lower than in the unexposed across all ages in childhood (non-significant difference between
boys and girls; P = 0.299, Table 2). As an example, weight in boys exposed to severe PE was
approximately on1 kg lower than in the unexposed boys at 2 years of age.
BMI SDS (Fig 2I–2L, Table 2)
BMI SDS in boys exposed to mild/moderate PE was lower than in the unexposed from infancy
through 7 years, e.g. at 6 months of age, BMI in boys exposed to mild/moderate PE was
approximately 0.8 kg/m2 lower than in the unexposed boys. Boys exposed to severe PE experi-
enced a lower BMI SDS than the unexposed boys across all ages, e.g. BMI in boys exposed to
severe PE was approximately 0.1 kg/m2 lower than in the unexposed boys at 12 years of age.
BMI SDS in girls exposed to mild/moderate PE was higher than in the unexposed from 1 year
of age. Girls exposed to severe PE experienced a lower BMI SDS than the unexposed from
infancy, but higher after 4 years of age, with the maximum difference of 1.5 kg/m2 at 12.8 years
of age (significant difference between boys and girls; P = 0.020, Table 2).
Other measurements
At both 10.8/11.8 (girls/boys) and 12.8 years, severe PE was positively associated with waist-to-
height ratio SDS (Table 3). Finally, in multiple linear regression analyses, there were no associ-
ations between PE (both categories) and waist circumference SDS, triceps or scapular skinfold
SDS at any age (S1, S2 and S3 Tables).
Discussion
In the present study of children exposed and unexposed to PE in utero, absolute values for and
trajectories in length/height, weight and BMI from birth to late childhood differed by sex and
Fig 2. Continued from Fig 1. Plots of predicted BMI SDS (I-L) vs. age according to sex and severity of preeclampsia. Key to
figures: Solid line = Unexposed, Dash-dot line = mild/moderate preeclampsia, Dashed line = Severe preeclampsia. Each figure
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severity of PE. Mild/moderate PE was in general positively associated with the development of
length/height in boys, and with weight and BMI for both sexes. Severe PE was in general nega-
tively associated with the development of length/height, weight and BMI except in girls, where
severe PE was positively associated with weight and BMI after preschool ages. Severe PE was
also associated with a larger waist-to-height ratio in late childhood in both sexes.
Apart from the Stavanger Study [3, 10], three earlier studies examined the association
between PE and childhood growth. In all of those three studies, PE was examined as one entity
Table 2. Multiple fractional polynomial regression of growth from birth to 13 years of agea) using generalized estimating equations analyses in
Norwegian children born in 1993–1995 according to mother’s preeclampsia status and interaction with age and sex.
Independent variables Outcome variable
Length/height SDS n = 502 Weight SDS n = 502 BMI SDS n = 501
b 95% CI P b 95% CI P b 95% CI P
Preeclampsia (No = reference)
Mild/Moderate -0.20 (-0.47, 0.08) 0.08 (-0.16, 0.33) 0.21 (-0.01, 0.44)
Severe -0.54 (-0.99, -0.08) -0.19 (-0.59, 0.21) 0.14 (-0.24, 0.52)
Age
FP1 0.21 (0.16, 0.26) 0.30 (0.15, 0.44) -0.23 (-0.34, 0.13)
FP2 -0.22 (-0.31, -0.12) -1.32 (-1.87, -0.76) -0.44 (-0.58, -0.30)
Sex (male) -0.19 (-0.41, 0.04) -0.07 (-0.27, 0.13) 0.05 (-0.14, 0.23)
Preeclampsia Age
Mild/Moderate FP1 -0.05 (-0.14, 0.04) 0.03 (-0.20, 0.26) 0.13 (0.01, 0.26)
Mild/Moderate FP2 0.12 (-0.04, 0.28) 0.34 (-0.57, 1.24) 0.27 (0.09, 0.46)
Severe FP1 -0.07 (-0.21, 0.07) -0.05 (-0.39, 0.29) 0.23 (0.01, 0.45)
Severe FP2 0.30 (0.03, 0.57) 1.08 (-0.30, 2.44) 0.47 (0.14, 0.80)
Preeclampsia sex
Mild/Moderate sex 0.43 (0.02, 0.84) -0.09 (-0.45, 0.27) -0.32 (-0.65, 0.02)
Severe sex -0.39 (-1.00, 0.22) -0.38 (-0.91, 0.15) -0.31 (-0.82, 0.20)
Sex Age
Sex FP1 -0.04 (-0.12, 0.04) -0.12 (-0.33, 0.10) 0.10 (-0.05, 0.26)
Sex FP2 0.05 (-0.08, 0.19) 0.54 (-0.28, 1.35) 0.19 (-0.02, 0.39)
Sex Preeclampsia Age 0.290 0.299 0.020
Sex Mild/Moderate FP1 0.13 (-0.01, 0.27) -0.06 (-0.41, 0.30) -0.001 (-0.23, 0.23)
Sex Mild/Moderate FP2 -0.12 (-0.36, 0.12) 0.31 (-1.07, 1.68) 0.03 (-0.29, 0.35)
Sex Severe FP1 0.01 (-0.17, 0.19) 0.04 (-0.35, 0.43) -0.24 (-0.53, 0.07)
Sex Severe FP2 -0.05 (-0.38, 0.29) -0.66 (-2.27, 0.94) -0.52 (-0.97, -0.08)
Birth order (firstborn) -0.03 (-0.20, 0.13) 0.698 -0.04 (-0.20, 0.11) 0.558 0.01 (-0.14, 0.17) 0.873
Maternal age at delivery (years) 0.01 (-0.01, 0.02) 0.486 -0.002 (-0.02, 0.01) 0.794 -0.002 (-0.02, 0.01) 0.819
Maternal smoking (yes) -0.24 (-0.41, -0.06) 0.007 -0.16 (-0.33, -0.002) 0.047 0.03 (-0.13, 0.19) 0.719
Maternal BMI (kg/m2) 0.02 (0.002, 0.04) 0.029 0.05 (0.03, 0.07) 0.001 0.05 (0.03, 0.07) 0.001
Maternal educationb) -0.05 (-0.15, 0.06) 0.364 -0.05 (-0.14, 0.05) 0.356 -0.01 (-0.10, 0.09) 0.920
Intercept -0.22 (-0.97, 0.52) -0.76 (-1.44, -0.07) -1.21 (-1.90, -0.52)
Abbreviations: n = number of participants; CI = confidence interval; BMI = body mass index; SDS = standard deviation score; P =Wald chi-square test for
interaction between preeclampsia and age; FP = fractional polynomial. FP1 (length/height SDS) = ln(X) + 0.8368401723; FP2 (length/height SDS) = X3
0.0812259488; where: X = (Age + 0.258516924726631)/10. FP1 (weight SDS) = ln(X) + 0.8404720262; FP2 (weight SDS) =
p
X 0.6568917665; where:
X = (Age + 0.258516924726631)/10. FP1 (BMI) = 1/
p
X 1.435656586; FP2 (BMI) = ln(X) + 0.7232445915; where: X = Age/10.
a) Calculated from measurements at birth and the target ages of 3, 6 months, 1, 4, 10.8 (girls)/11.8 (boys) and 12.8 years;
b) Maternal education at delivery:9 years, 9–12 years, 12 years.
For all the interactions involving preeclampsia, the category “no” preeclampsia is the reference.
https://doi.org/10.1371/journal.pone.0176627.t002
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rather than by severity. First, in a Norwegian study of 4096 girls aged 13–19 years PE was posi-
tively associated with BMI, and our results are in accord [12]. Second, in a large cohort of
Israeli adolescents, exposure to PE (n = 428) was positively associated with weight and BMI at
17 years of age in boys but not girls [22]. This corresponds to our findings in boys exposed to
mild/moderate preeclampsia, but not severe preeclampsia. Third, in a study of three cohorts
with a total of 4622 children, those exposed to PE had low birthweight, but catch-up growth
postnatally [9]. This corresponds to our results in children exposed to mild/moderate PE, and
girls, but not boys, exposed to severe PE. The discrepancies across studies may be due to differ-
ent designs namely different ages at assessment and because in the other three studies [9, 12,
22] PE was not differentiated by severity.
To our knowledge, no previous publications exist on the associations between PE exposure
and linear growth. In our study, boys exposed to mild/moderate PE had a recumbent length at
birth similar to that of unexposed, but exceeded linear growth during preschool age, while
those exposed to severe PE had a decreased linear growth compared to unexposed at all ages.
PE had less impact on linear growth in girls, however both mild/moderate and severe PE was
negatively associated with linear growth in girls. The decreased linear growth after exposure to
severe PE is in contrast with studies on fetal growth retardation where postnatal catch-up in
linear growth is reported [23, 24]. However, studies on very premature children born small for
gestational age have reported that they may be less likely to have catch-up in linear growth, or
only after 6 years of age [25]. IGF-I is one of the most important regulators of postnatal growth
and is known to be lower in placental tissues and cord blood in women with severe, but not
mild, PE [26, 27]. Therefore, poor linear growth in children exposed to severe PE might be
due to effects on the growth hormone- IGF-1 axis [28–30], an effect that might be mediated
through inflammation or perhaps the result of fetal programming. PE is characterized by
inflammation and the cytokines of pregnancy could correlate with those in offspring until the
age of 1 year [31, 32]. Furthermore, a pro-inflammatory status might induce apoptosis of the
growth plate cartilage both prenatally and during infancy [33].
Weight and BMI were lower in children exposed to mild/moderate PE, and girls exposed to
severe PE, but weight and BMI in these children were higher from school age and onwards
when compared to unexposed children. This effect is similar to what is found in other children
Table 3. Multiple linear regression analysis of waist-to-height ratio SDS in 586 Norwegian children born in 1993–1995 according to mother’s pre-
eclampsia status.
Independent variables 10.8/11.8 yearsa), n = 519 12.8 years, n = 390
b 95% CI F-test Pb) b 95% CI F-test Pb)
Intercept -1.57 (-2.15, -0.98) 0.001 -0.93 (-1.53, -0.33) 0.002
Preeclampsia 0.011 0.019
None 0.00 Reference 0.00 Reference
Mild/moderate 0.16 (-0.06, 0.38) -0.03 (-0.25, 0.20)
Severe 0.47 (0.15, 0.79) 0.44 (0.12, 0.75)
Sex (male) -0.07 (-0.26, 0.11) 0.435 -0.15 (-0.35, 0.04) 0.124
Maternal BMI (kg/m2) 0.07 (0.04, 0.09) 0.001 0.06 (0.03, 0.08) 0.001
Maternal smoking (yes) 0.25 (0.03, 0.47) 0.024 0.21 (-0.02, 0.45) 0.072
Abbreviations: n = number of participants; CI = Confidence interval; SDS = Standard deviation scores; F-test P refers to exposure only; BMI = body mass
index (kg/m2).
Bold numbers indicate statistical significance
a) 10.8 years for girls, 11.8 years for boys
b) After backward stepwise selection from fully adjusted model.
https://doi.org/10.1371/journal.pone.0176627.t003
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born small for gestational age [25, 34] and in prematurely born children [35]. Prenatal starva-
tion is associated with epigenetic changes that could persist throughout life, causing a tendency
for energy conservation and thus overweight [36, 37]. Children with catch-up growth postna-
tally have better insulin sensitivity than other children, so these children will have a favorable
linear growth and weight development [38]. However, most children born small for gestational
age catch up in weight and length before 12 months of age [25], but this was not the case in
our study subjects who experienced catch-up at a later age. This difference suggests that PE
affects weight and BMI independently of small for gestational age status. Boys exposed to
severe PE had lower weight and BMI during infancy and childhood when compared to the
unexposed. These results are different from children born prematurely or small for gestational
age. The effects of severe PE on weight trajectories in boys could be influenced by some of the
same mechanisms as those for linear growth, like low levels of IGF-1, mediated through pre-
maturity and inflammation [39].
Children exposed to severe PE had a higher waist-to-height ratio than the unexposed chil-
dren in late childhood. Similar results have been found in children born small for gestational
age, who continue to gain excess body fat even after catch-up in weight [25]. A high waist-to-
height ratio is a known risk factor for insulin resistance and metabolic syndrome [34]. As
severe PE is characterized by inflammation [40, 41], and studies indicate an association
between inflammatory disorders in adults and metabolic syndrome [42] one can speculate that
exposure to severe PE might indirectly and via inflammation be a risk factor for metabolic
syndrome.
The current study shows different effects of mild/moderate and severe PE on childhood
growth. This might be explained by different pathophysiology of the two conditions. Mild/
moderate PE more often appears late whereas severe PE appears early in pregnancy. Early and
late-onset PE differ by maternal age, pre-pregnancy BMI, maternal cardiac output, vascular
resistance and endothelial damage [15, 41, 43]. Further, only early onset PE is associated with
fetal growth restriction, due to incomplete invasion of trophoblast into the maternal spiral
arteries, and changes in blood flow in umbilical arteries [4, 41]. Mild/moderate PE is more
common in overweight mothers with metabolic syndrome, while severe PE is more common
in normal weight women, but possibly characterized by more inflammation; thereby reflecting
different maternal phenotypes by severity of PE with implications for child growth [15, 40].
There were differences between the sexes regarding the effect of PE on length/height and
weight, and significant differences between the sexes regarding the effect of PE on BMI. While
PE exposure in girls had some negative effects on linear growth, in boys mild/moderate PE
exposure was generally positively associated, and severe PE negatively associated with linear
growth. PE was generally positively associated with weight and BMI in boys and girls, while in
boys only, severe PE was generally negatively associated with weight and BMI. Although there
are inconsistencies in the literature regarding sex differences in growth after exposure to PE
[10, 12, 22], boys are generally more prone to neonatal complications [44]; whether born to
term and of adequate birthweight, small for gestational age [45] and extreme prematurity
affects boys more severely than it does to girls [46].
Statistical considerations
We did not adjust for gestational age or birthweight in the analyses because they are intermedi-
ary variables on the causal pathway from PE to growth in childhood, and adjusting for them
could attenuate the association between PE and growth. Further, as gestational age and birth-
weight may be influenced by unknown factors, adjusting for them could give rise to spurious
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associations between PE and growth. Therefore, modeling conditional growth (and thereby
correcting for the regression to the mean) was not feasible.
Other strategies to compare growth between the three groups unexposed, exposed to mild/
moderate and exposed to severe PE could have been pursued if we wanted to separate from the
effects of gestational age and child’s birth weight. Stratification is a statistically inferior method
of adjusting, and as explained, adjustment for these variables cannot be done. Further, stratifi-
cation would lead to a loss of power if used.
For the same reasons, we did not adjust for pubertal status. Some effects of PE could be
indirect and mediated through prematurity and being born small for gestational age, but the
distinct differences in growth between children exposed to PE from those who are otherwise
born small for gestational age indicates that PE has effects on growth other than through path-
ways related to gestational age or birthweight.
The extremes of Figs 1 and 2 should be interpreted with caution. The mathematical model
attempting to predict the best curve might be influenced by very few observations of length
SDS and weight SDS before age 0.0 years, particularly in the group of mild/moderate PE and
in the unexposed group.
Strengths and limitations
An advantage of the study population is its homogeneity of socio-economic status and ethnic-
ity. Furthermore, the measurements of height and weight were sampled repeatedly during
childhood, enabling the possibility of calculating a predictive model of growth, i.e., the length/
height, weight or BMI of a child at a given age, by sex or PE exposure status.
The study also has some limitations. The original matching on maternal age and birth date
in the analyses was compromised due to more missing participants in the unexposed than the
exposed group, which may be a source of bias. However, we adjusted for maternal age in the
statistical analyses to avoid confounding bias. We described above why the analyses could not
be adjusted for gestational age or birthweight; therefore, the study might be biased. A matching
of participants on gestational age and birthweight could have reduced bias. The anthropomet-
ric measurements from the well-baby clinics were not measured by the research team; how-
ever, routine measurements at well-baby clinics are standardized. Repeated measurements of
waist circumference (a more accurate measurement of adiposity) and skinfolds were not per-
formed at well-baby clinics [17]. Furthermore, we do not have consecutive anthropometric
measurements across ages in childhood. There was a considerable attrition at the second fol-
low-up of around 50%, which may be a source of selection bias. However, there were no
known perinatal differences between those who assented to the first follow-up and those who
did not assent, and most baseline characteristics between those who participated in the first
and the second follow-ups did not differ. The average BMI of girls who participated in the first
but not the second follow-up was higher than the BMI of girls who participated in both follow-
ups. However, there is no reason to assume that the girls with the higher BMI who were lost to
the second follow-up were overrepresented in any particular exposure group. Therefore, the
association between PE and growth would not be expected to be biased by the change in BMI
of the girls from the first to the second follow-up.
Conclusions
From birth to adolescence, linear growth, weight and BMI trajectories differed among the PE
exposed children by severity of PE, age and sex compared with the unexposed. In general, PE
exposure was negatively associated with linear growth, while in girls positive associations with
weight and BMI were observed. The trajectories might differ from those found in studies of
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children born small for gestational age. The present results underline that fetal life is a particu-
larly sensitive period regarding growth, supporting the hypothesis that an adverse intrauterine
environment may affect postnatal development, anthropometry throughout childhood and
probably also the metabolic phenotype. Our results may have implications for targeted
approaches for healthy growth and development.
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S1 Fig. Directed acyclic graph of the association between preeclampsia and 
growth with confounders.  
Green with arrowhead = exposure 
Blue with black bar = outcome 
Red = ancestor of exposure and outcome  
Blue = ancestor of outcome  
Green arrows = causal path 
Red arrows = biasing path 

S1 table. Multiple linear regression analyses of waist circumference SDS at 10.8/11.8 and 12.8 
years of age in 593 children according to mother’s preeclampsia status 
 10.8/11.8 yearsa), n = 519 12.8 years, n = 390 
Independent variables b 95 % CI F-test P b 95 % CI F-test P
Intercept -1.71 (-2.29, -1.13) < 0.001 -1.09 (-1.70, 0.48) 0.001 
Preeclampsia   0.098   0.344 
     None 0.00 Reference  0.00 Reference  
     Mild/moderate 0.18 (-0.04, 0.40)  0.04 (-0.19, 0.27)  
     Severe 0.27 (-0.14, 0.53)  0.24 (-0.08, 0.56) 
Sex (male) -0.09 (-0.28, 0.10) 0.352 -0.19 (-0.39, 0.01) 0.056 
Maternal BMI (kg/m2) 0.08 (0.05, 0.10) < 0.001 0.06 (0.04, 0.09) < 0.001 
Maternal smoking (yes) 0.11 (-0.10, 0.33) 0.301 0.12 (-0.12, 0.36) 0.331 
S2 table. Multiple linear regression analyses of triceps skinfold SDS at 10.8/11.8 and 12.8 years 
of age in 589 children according to mother’s preeclampsia status 
 10.8/11.8 yearsa), n = 515 12.8 years, n = 389 
Independent variables b 95 % CI F-test P b 95 % CI F-test P
Intercept -1.72 (-2.31, -1.13) < 0.001 -1.31 (-1.97, -0.66) < 0.001 
Preeclampsia   0.388   0.903 
     None 0.00 Reference  0.00 Reference  
     Mild/moderate 0.15 (-0.07, 0.37)  -0.03 (-0.27, 0.22)  
     Severe 0.03 (-0.29, 0.34)  0.06 (-0.29, 0.41) 
Sex (male) 0.20 (0.02, 0.39) 0.031 0.02 (-0.19, 0.24) 0.835 
Maternal BMI (kg/m2) 0.06 (0.03, 0.08) < 0.001 0.05 (0.02, 0.08) < 0.001 
Maternal smoking (yes) 0.06 (-0.15, 0.28) 0.570 -0.10 (-0.36, 0.16) 0.437 
S3 table. Multiple linear regression analyses of waist circumference SDS at 12.8 years of age in 
487 children according to mother’s preeclampsia status 
12.8 years, n = 380 
Independent variables b 95 % CI F-test P
Intercept -2.13 (-2.74, -1.52) < 0.001 
Preeclampsia   0.384 
     None 0.00 Reference  
     Mild/moderate 0.15 (-0.07, 0.38)  
     Severe 0.10 (-0.22, 0.43)  
Sex (male) 0.12 (-0.08, 0.31) 0.241 
Maternal BMI (kg/m2) 0.07 (0.04, 0.10) < 0.001 
Maternal smoking (yes) 0.13 (-0.11, 0.37) 0.284 
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Body mass index and physical activity 
in early childhood are associated with  
atopic sensitization, atopic dermatitis 
and asthma in later childhood
Kristine Kjer Byberg1* , Geir Egil Eide2,3, Michele R. Forman4, Pétur Benedikt Júlíusson5,6 and Knut Øymar1,6
Abstract 
Background: The results of studies on the associations of childhood excessive weight/obesity and physical activ-
ity with atopic sensitization and atopic diseases are inconsistent. We studied the associations of anthropometry and 
physical activity in childhood with atopic sensitization and atopic diseases in late childhood.
Methods: In a cohort study including cases exposed to preeclampsia during pregnancy and controls, anthropom-
etry and physical activity were assessed at several ages in 617 children. Associations with atopic sensitization and 
atopic diseases in late childhood were analysed using multiple logistic regression.
Results: Body mass index standard deviation score (BMI SDS) at 1 year and low physical activity at 3–6 years were 
positively associated with atopic sensitization at 12.8 years [adjusted odds ratio (OR) 1.22; 95 % confidence interval 
(1.00, 1.49) and OR 2.36; (1.15, 4.81), respectively]. Change in BMI SDS from 1 to 4 years, BMI SDS at 4 years, and high 
physical activity at 6–10 years were positively associated with atopic dermatitis by 10.8 years [OR 1.46; (1.11, 1.92); OR 
1.32; (1.06, 1.65) and OR 1.94; (1.16, 3.24); respectively]. Low physical activity at 3–6 and 6–10 years were positively 
associated with asthma by 10.8 years [OR 3.61; (1.56, 8.36) and OR 2.52; (1.24, 5.12), respectively].
Conclusions: BMI and physical activity in early childhood were associated with atopic sensitization, atopic dermatitis 
and asthma in later childhood. Larger cohorts with repeated measurements of both predictors and outcomes are 
required to further elucidate this issue.
Trial registration Our study was observational without any clinical intervention on the participants. Therefore, no trial 
registration number is available
Keywords: Allergic rhinitis, Anthropometry, Asthma, Atopic dermatitis, Child
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Background
The prevalence of obesity, allergy and asthma has 
increased worldwide during the last decades [1, 2]. An 
association between obesity and asthma has been sug-
gested both in early and late childhood [3], where obesity 
precedes asthma in prospective studies [4]; the associa-
tion between obesity and allergy is inconsistent [5].
High birth weight or body mass index (BMI; kg/m2) 
in early childhood is associated with obesity into later 
childhood [6]. Atopic sensitization and atopic disease 
commonly start in early childhood [7], and associations 
between accelerated weight gain in early childhood and 
subsequent atopic sensitization, allergic rhinitis [8] and 
asthma [9], have been suggested, but not for atopic der-
matitis. Physical activity during childhood may also be 
associated with atopy, either directly or due to an influ-
ence on body composition [10].
Many of these associations of childhood obesity and 
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studies [5, 10, 11]. Few longitudinal studies exist, mainly 
from registers [4, 5, 11].
It is unknown if an accelerated weight gain from birth is 
associated with an increased risk of atopy. Furthermore, 
it is unknown if a positive association between BMI and 
asthma in children is limited to those with atopy.
The present cohort study was derived from a case con-
trol study nested within three birth cohorts that focused 
on preeclampsia, that had repeated anthropometric 
measurements, linked information across childhood, and 
measures of atopic disease at clinical follow-ups. The aim 
was to study whether weight-related anthropometrics, 
changes in BMI SDS and physical activity at different 
ages in childhood are associated with atopic sensitization 
and atopic disease by late childhood. We hypothesized 
that childhood excessive weight/obesity or accelerated 
weight gain is positively associated and physical activity 




The study was a part of “the Stavanger study” described 
in detail previously [12]. From a population-based 
cohort, a nested case–control study was conducted, 
where offspring exposed to maternal preeclampsia and 
unexposed offspring were identified from all births deliv-
ered in Stavanger University hospital in 1993–1995. For 
each exposed offspring, two matched unexposed off-
spring were selected: one as the next born in the hospi-
tal (i.e. a birth match) and one as the next born matched 
on maternal age (i.e. a risk factor for preeclampsia). 1025 
children, 366 in the preeclampsia and 659 in the con-
trol group, were invited to participate in a first follow-
up study at 10.8 years (girls) and 11.8 years (boys), and a 
second follow-up at 12.8 years (both sexes) [13]. The ages 
at follow-up were selected to coincide with the ages of 
pubertal onset and menarche of the children. Our anal-
yses disregarded the matched pairs due to missing par-
ticipants. Therefore, in our study, data were analysed as a 
historical cohort adjusting for preeclampsia and maternal 
age, including all the children who participated in both 
follow-ups, with predictors as listed.
The study was approved by the Norwegian Data Inspec-
torate, the Regional Committee for Ethics in medical 
research Western Norway, and the Institutional Review 
Boards of the National Cancer Institute and University 
of Texas at Austin, United States. Mothers and children 
signed an informed consent/assent form at follow-up.
Outcomes
The outcomes allergic rhinoconjunctivitis, atopic der-
matitis, asthma ever (evaluated at first follow-up), atopic 
sensitization and current asthma (evaluated at second 
follow-up) were defined as follows:
Atopic sensitization Blood specific immunoglobulin 
E (IgE)  ≥  0.35  kU/l for at least one common allergen. 
Blood was drawn at second follow-up and analysed by 
Phadiatop®, fx5E® and by specific IgE when positive [13]. 
Included allergens are shown in Fig. 1. The levels of spe-
cific IgE ≥ 0.35 were added, and high grade sensitization 
was defined as a sum >3.9  kU/l: above the lower quar-
tile of all children being sensitized. The ordinal outcome 
variable atopic sensitization was categorized as: no, low 
grade and high grade sensitization.
Atopic disease: Asthma ever, allergic rhinoconjunctivitis 
or atopic dermatitis At first follow-up, questions on 
atopic disease of the child were asked to the mothers: 
“Has your child ever had doctor-diagnosed asthma or 
ever diagnosed with allergy in nose/eyes (hay fever) or 
atopic dermatitis (childhood eczema)?” Response of “yes” 
was classified as having the respective diagnosis.
Current asthma At second follow-up, the children 
answered a questionnaire on reported asthma symptoms 
and medication during the last year according to the 
International Study of Asthma and Allergies in Child-
hood (ISAAC) and asthma ever was recorded [14]. Cur-
rent asthma at second follow-up was defined as asthma 
ever, in addition to asthma symptoms or the use of 
asthma medication the last 12 months (Additional file 1).
Predictors
Birthweight and gestational age were abstracted from 
hospital records. Recordings of length/height and weight 
measurements were collected from well-baby clinics at 
the target ages of 3, 6 and 12 months and 4 years. Trained 
nurse researchers measured height, weight, triceps skin-

















Fig. 1 Percent of children with sensitization (specific IgE > 0.35 kU/l) 
to common allergens, measured at 12.8 years (n = 388). D: der-
matophagoides, C: cladosporium
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follow-ups, and subscapular skinfold was measured twice 
at second follow-up; the average of each was used in the 
analysis [12]. Skinfolds were measured with Harpenden 
Skinfold Calliper®.
Change in weight and BMI SDS was calculated as the 
difference between weight and BMI SDS from each target 
age to the next.
At the first follow-up, the “Stanford Brief Activity Sur-
vey”, a questionnaire validated for adults, was admin-
istered to the mothers requesting responses about 
physical activity of the child. Specifically the answers 
to the following questions were extracted: “How active 
was your child at 3–6 years?” and “How active was your 
child at 6–10  years?” The response categories were cat-
egorized as: passive and/or not so active =  low activity, 
active = normal, very active = high activity [15].
Confounders
Potential confounders included categorical and continu-
ous variables, i.e. sex; gestational age; birth order (first-
born or not); duration of breastfeeding (categories: none; 
<3; >3  months. This information was extracted from 
maternal questionnaire, and used in analyses for pre-
dictors at target ages ≥6  months); mother’s preeclamp-
sia (none, mild/moderate, severe) [16]; mother’s BMI 
(weight at first antenatal visit and height at first follow-
up); mother’s smoking (at first antenatal visit); mother’s 
doctor-diagnosed asthma [13]; mother’s education (from 
maternal questionnaire: <9; 9–12; >12 years) and moth-
er’s age. This is illustrated in a Directed Acyclic Graph 
(Additional file 1: Figure S1) [17].
Statistical methods
Descriptive statistics were analysed as means, standard 
deviations, numbers and percentages for the main pre-
dictors and outcomes.
There was a wide range of gestational ages at birth due 
to the inclusion of offspring of preeclampsia and normo-
tensives and a wide age range at later well-child visits, 
analysing actual values for anthropometrics as predictors 
would therefore not be appropriate. Instead, standard 
deviation scores (SDS) based on anthropometric values 
and actual ages were computed from validated references 
[18–21]. Conversions into SDS were done using R version 
2.6.2 (R Development Core Team, Vienna, Austria).
The associations between anthropometrics and physi-
cal activity for each target age (see predictors), and out-
comes of atopic sensitization and atopic diseases in late 
childhood were analysed using multiple binary and ordi-
nal logistic regression analyses (the latter for outcome of 
atopic sensitization). Separate analyses of the predictors 
were done for each follow-up time.
Each variable was entered separately into simple 
regression models. Next, all potential confounders 
were included in fully adjusted models. Backward step-
wise selections were performed to remove non-signif-
icant confounders, unless there was ≥15  % change in 
effect size upon removal of the confounder. Last, final 
models for each target age included anthropometrics, 
physical activity, sex of the child and all remaining 
confounders.
For each predictor, odds ratios with p-values from 
likelihood ratio tests and 95  % confidence intervals are 
reported. Interactions between anthropometrics and 
physical activity with potential confounders were tested. 
The significance level was 0.05 for all tests.
Also, to study possible non-straight-line associations 
between BMI SDS and the outcomes, multiple fractional 
polynomial regression (MFPR) was used with the con-
servative requirement of p  ≤  0.01 for non-straight-line 
terms.
Due to missing values the number of participants var-
ied between the different analyses.
IBM SPSS for windows (version 22.0.0, Chicago, Ill., 
USA) was used for descriptive statistics and logistic 
regression, and Stata SE 14 for MFPR.
Results
Characteristics of the participants
The numbers of participants in each follow-up have been 
published previously [13]. Briefly, 617 children assented 
to participate at the first follow-up and 470 at the sec-
ond follow-up. There were more girls with high BMI in 
the first than second follow-up, and more children with 
atopic dermatitis in the first than the second follow-up. 
Otherwise, baseline characteristics were similar between 
those who assented to the first follow-up only and those 
who assented to both follow-ups [13]. The percentages 
of children sensitized to different allergens appear in 
Fig. 1. Clinical characteristics of the participants appear 
in Table 1.
Impact of anthropometrics (Tables 2, 3, 4)
BMI SDS at 1 year was positively associated with atopic 
sensitization at 12.8 years with a borderline significance 
(Table 2). Change in BMI SDS from 1 to 4 years and BMI 
SDS at 4 years were positively associated with atopic der-
matitis ever at the first follow-up (Tables 2, 3).
Birthweight/BMI SDS and changes in weight or BMI 
SDS were not associated with allergic rhinoconjunctivitis 
(Tables 2, 3) or asthma (Table 4 and Additional file 2: Table 
S1). Skinfolds, waist circumference and waist-to-height 
ratio at the follow-ups were not associated with atopic sen-
sitization or atopic disease (Additional file 2: Table S2).
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Impact of physical activity (Tables 2, 4)
Low physical activity at 3–6  years was positively asso-
ciated with atopic sensitization at 12.8  years (Table  2). 
High physical activity at 6–10 years was positively asso-
ciated with atopic dermatitis ever at the first follow-up 
(Table  2). Low physical activity at 3–6 and 6–10  years 
were positively associated with asthma ever at the first 
follow-up (Table 4). Physical activity was not associated 
with allergic rhinoconjunctivitis.
In the MFPR analyses, no non-straight-line associations 
were found for anthropometrics or physical activity with 
atopic sensitization or atopic diseases (data not shown).
Discussion
In this cohort study of children followed from birth to 
12.8 years, after adjusting for potential confounders, BMI 
in childhood was positively associated with atopic sensi-
tization and atopic dermatitis in late childhood. High and 
Table 1 Descriptive statistics for predictors and outcomes for 617a children included in a matched cohort study with fol-
low-up from birth to 12–13 years in the Stavanger area, Norway
SD standard deviation, BMI body mass index (kg/m2)
a Due to missing values and variation in response, the number of participants varied between the different predictors and outcomes
b First follow-up: 10.8 years (girls), 11.8 years (boys)
c Second follow-up: 12.8 years
d 99 (25.5 %) had high grade atopic sensitization (sum of specific IgE ≥ 3.9 kU/l)
Predictors n Mean SD
Birthweight (kg) 606 3.37 0.71
BMI 3 months 541 16.4 1.52
BMI 6 months 559 17.2 1.53
BMI 1 year 559 17.2 1.49
BMI 4 years 477 15.9 1.43
BMI first follow-upb 610 18.0 2.91
BMI second follow-upc 466 18.8 3.00
Waist circumference (cm) first follow-up 610 63.5 7.80
Waist circumference (cm) second follow-up 466 68.0 7.72
Triceps skinfold (mm) first follow-up 605 11.7 4.63
Triceps skinfold (mm) second follow-up 465 12.1 4.81
Waist-to-height ratio first follow-up 610 0.42 0.04
Waist-to-height ratio second follow-up 466 0.43 0.05
Subscapular skinfold (mm) second follow-up 450 8.21 3.24
n %
Physical activity 3-6 years 601
 Low 72 12
 Normal 370 62
 High 159 26
Physical activity 6–10 years 596
 Low 99 17
 Normal 376 63
 High 121 20
Outcome
Atopic sensitization at second follow-upd 133/388 34
Allergic rhinoconjunctivitis ever by first follow-up 131/595 22
Atopic dermatitis ever by first follow-up 149/596 25
Asthma ever by first follow-up 53/590 9
Current asthma at second follow-up 37/458 8
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low physical activity during childhood was differentially 
associated with atopic sensitization, atopic dermatitis and 
asthma assessed in late childhood. BMI and physical activ-
ity were not associated with allergic rhinoconjunctivitis.
Anthropometrics and outcomes
In this cohort BMI at 1  year was positively associated 
with atopic sensitization at 12.8 years with borderline sig-
nificance. As recently reviewed by Boulet [5], some stud-
ies are consistent with and others conflict our results, 
which may be due to differences in the study design. 
Studies showing an association have been cross-sectional 
and therefore unable to assess whether obesity precedes 
sensitization [5]. In our study, the majority of children 
were sensitized to airborne allergens. Sensitization to 
airborne allergens is uncommon in Scandinavian chil-
dren before the age of 1 year [22]. It is therefore probable 
that the high BMI at 1 year preceded airborne sensitiza-
tion. However, sensitization to food allergens may have 
been present in the first year of life, which we did not 
assess. In mice, obesity lowered the threshold for atopic 
sensitization, suggesting that obesity causes atopy [23].
Several mechanisms explaining the association 
between obesity and atopic sensitization have been sug-
gested [5]. In addition to hormonal and genetic factors, 
a high BMI is associated with higher body fat and altered 
adipokines, and in turn might predispose to atopic sensi-
tization through inflammatory changes [24]. Our results 
could indicate that a high BMI at the age of 1 year is of 
importance.
Table 2 The adjusted odds ratios of  atopic sensitization and  atopic disease in  adolescence in  617 Norwegian children 
by weight/BMI SDS and physical activity after backward stepwise selection of potential confounders (one model for each 
predictor variable)
First follow-up: 10.8 years (girls) and 11.8 years (boys); Second follow-up: 12.8 years (both sexes)
Italics numbers indicate statistically significant results
n number of participants, OR odds ratio, CI confidence interval, LR-p (likelihood ratio-test p-value) refers to predictor only, BMI body mass index (kg/m2), SDS standard 
deviation score, N.A. not applicable
a Adjusted for sex, preeclampsia and gestational age
b n = 388. Ordinal response: none, low grade, high grade (sum of specific IgE ≥ 3.9 kU/l; above the lower quartile of all children being sensitized)
c Adjusted for sex, mother’s asthma and mother’s smoking
d Also adjusted for physical activity at 3–6 years
e Also adjusted for physical activity at 6–10 years
f Also adjusted for BMI SDS at 4 years
g Also adjusted for BMI SDS at the first follow-up
Predictor Outcome variable (final analyses)
Atopic sensitizationa,b Allergic rhinoconjunctivitisa Atopic dermatitisc
Age n OR 95 % CI LR-p n OR 95 % CI LR-p n OR 95 % CI LR-p
Weight SDS
Birth 380 1.05 (0.87, 1.26) 0.609 580 0.92 (0.77, 1.10) 0.338 544 1.04 (0.88, 1.22) 0.638
BMI SDS
3 months 353 1.13 (0.90, 1.41) 0.315 521 0.91 (0.73, 1.14) 0.427 487 1.04 (0.84, 1.30) 0.694
6 months 363 1.15 (0.93, 1.42) 0.205 537 0.91 (0.74, 1.12) 0.390 503 1.05 (0.86, 1.28) 0.654
1 year 363 1.22 (1.00, 1.49) 0.050 537 0.97 (0.80, 1.18) 0.795 503 1.06 (0.87, 1.28) 0.557
4 yearsd 320 1.01 (0.80, 1.27) 0.934 456 0.86 (0.69, 1.08) 0.191 427 1.32 (1.06, 1.65) 0.012
First follow-upe 358 0.95 (0.79, 1.15) 0.612 562 0.87 (0.73, 1.04) 0.126 527 1.11 (0.93, 1.33) 0.225
Second follow-upe 354 0.96 (0.79, 1.17) 0.680 N.A. N.A.
Physical activity
At 3–6 yearsf 320 0.039 456 0.157 427 0.519
 Normal 192 1.00 Reference 277 1.00 Reference 259 1.00 Reference
 Low 40 2.36 (1.15, 4.81) 57 1.60 (0.83, 3.09) 57 1.30 (0.65, 2.61)
 High 88 0.90 (0.50, 1.61) 122 0.77 (0.44, 1.35) 111 1.34 (0.78, 2.30)
At 6–10 yearsg 358 0.773 562 0.126 527 0.033
 Normal 234 1.00 Reference 353 1.00 Reference 333 1.00 Reference
 Low 57 1.05 (0.57, 1.96) 93 1.67 (0.97, 2.87) 89 1.49 (0.87, 2.56)
 High 67 0.82 (0.45, 1.49) 116 1.15 (0.68, 1.93) 105 1.94 (1.16, 3.24)
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In this cohort, change in BMI SDS from 1 to 4  years 
and BMI at 4 years were positively associated with atopic 
dermatitis ever at first follow-up. In the ISAAC 3 study, 
overweight and obesity at 13–14  years was associated 
with current atopic dermatitis [10]. In a meta-analysis, 
mainly of cross-sectional studies, a high BMI in child-
hood, adolescence and adulthood was also associated 
with atopic dermatitis [25].
Atopic dermatitis usually has its debut in the first years 
of life and normally precedes any potential overweight 
or obesity [7]. Therefore, there may be reverse causal-
ity, but it may also be possible that overweight/obesity 
causes atopic dermatitis. Firstly, obesity is associated 
with an increased risk of dry skin, aggravating underly-
ing skin defects [26]. Secondly, the positive association of 
a change in BMI SDS and overweight in preschool years 
with atopic dermatitis could be explained by immuno-
logical changes due to increased body fat, and an associa-
tion between adipokines and atopic dermatitis has been 
reported [27].
Anthropometric measures were not associated with 
allergic rhinoconjunctivitis in accordance with previous 
studies [28].
In the present study, there was no association between 
anthropometric measures during childhood and asthma 
in late childhood, without variation by sex. In 2013, six 
studies were included in a meta-analysis showing that 
overweight and obesity in childhood is associated with 
subsequent asthma. However, the results were incon-
sistent regarding sex [4]. Recently, in a study including 
>24,000 children, accelerated weight gain from birth to 
3 years was positively associated with asthma by 3 years 
with risk ratio of 1.22 and at 7 years with risk ratio of 1.13 
[9]. Our results do not contradict this, as we may have 
too few participants to show a significant association of a 
similar low magnitude.
Physical activity and outcomes
In this cohort, low preschool activity level was positively 
associated with atopic sensitization at 12.8 years. To our 
knowledge, this is the first study to show such an asso-
ciation. In a cross-sectional study of 2000 Spanish ado-
lescents using questionnaires, there was no association 
between physical activity and allergy at 13–17 years [29].
In our study we adjusted for BMI, but BMI underesti-
mates the relative amount of fat tissue in the body com-
position of children [30]. Thus, the association between 
low activity and atopic sensitization might be due to a 
higher body fat percentage in children with a low activ-
ity level, independent of weight status, with subsequent 
changes in adipokines that may influence the develop-
ment of sensitization [24].
In this cohort, a high level of physical activity at 
6–10 years was associated with atopic dermatitis ever at 
Table 3 The adjusted odds ratios of  atopic sensitization and  atopic disease in  adolescence in  617 Norwegian children 
by changes in weight/BMI SDS after backward stepwise selection of potential confounders (one model for each predictor 
variable)
First follow-up: 10.8 years (girls) and 11.8 years (boys); Second follow-up: 12.8 years (both sexes)
Italics numbers indicate statistically significant results
n number of participants, OR odds ratio, CI confidence interval, LR-p likelihood ratio-test p-value refers to predictor only, BMI body mass index (kg/m2), SDS standard 
deviation score, N.A. not applicable
a Adjusted for sex, weight/BMI SDS at start of interval, gestational age, preeclampsia (none/mild or moderate/severe)
b n = 388. Ordinal response: none, low grade, high grade (sum of specific IgE ≥ 3.9 kU/l; above the lower quartile of all children being sensitized)
c Adjusted for sex, weight/BMI SDS at start of interval, mother’s asthma and mother’s smoking
d Also adjusted for physical activity at 3–6 years
e Also adjusted for physical activity at 6–10 years
Predictor Outcome variable (final analyses)
Atopic sensitizationa,b Allergic rhinoconjunctivitisa Atopic dermatitisc
Age n OR 95 % CI LR-p n OR 95 % CI LR-p n OR 95 % CI LR-p
Weight SDS
Birth to 3 months 361 1.10 (0.87, 1.38) 0.408 534 0.90 (0.74, 1.09) 0.292 500 0.98 (0.80, 1.17) 0.835
BMI SDS
3–6 months 351 1.15 (0.83, 1.60) 0.413 519 0.96 (0.71, 1.30) 0.794 485 1.15 (0.85, 1.56) 0.363
6 months to 1 year 360 1.30 (0.95, 1.76) 0.100 534 1.11 (0.83, 1.48) 0.470 500 1.07 (0.81, 1.42) 0.638
1–4 years 325 0.82 (0.62, 1.09) 0.173 456 0.82 (0.63, 1.07) 0.150 427 1.46 (1.11, 1.92) 0.005
4 years to first follow-upd 315 0.99 (0.78, 1.26) 0.940 450 1.01 (0.80, 1.28) 0.917 422 0.87 (0.70, 1.09) 0.223
First to second follow-upe 349 0.96 (0.65, 1.43) 0.843 N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A
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first follow-up. This is in accordance with the findings 
in ISAAC 3, where vigorous physical activity in children 
13–14  years was associated with current atopic der-
matitis, and was attributed to sweat-induced itch [10]. 
One possible explanation for an association is that after 
long-term physical activity, natural killer cell cytotoxic-
ity could be increased, which in turn has been associated 
with atopic dermatitis [31, 32].
We report an association of low physical activity at 
both 3–6 and 6–10  years with asthma ever, but not cur-
rent asthma, in late childhood. In the ISAAC 3 study, sev-
eral hours of TV viewing was associated with symptoms 
of current asthma in adolescents [10]. Similarly, studies 
indicate that physical activity could be protective against 
the development of asthma [11]. We found no association 
between physical activity and allergic rhinoconjunctivitis. 
In ISAAC 3, both associations of vigorous physical activity 
and a sedentary lifestyle at 13 years with allergic rhinocon-
junctivitis were found with odds ratios at 1.25 and 1.17, 
respectively [10]. With the low number of participants in 
our study, our results do not contradict these results.
Strengths and limitations
Strengths: The study population is homogeneous regard-
ing socio-economic status and ethnicity. Further, the 
predictor variables have been sampled by repeated meas-
urements from several ages to examine the window of 
time in childhood the predictors could possibly affect the 
development of atopic sensitization and atopic diseases.
However, the study also has some limitations. The pre-
sent study was not primarily designed to answer the cur-
rent research questions, but this has been accounted for by 
including the design variable preeclampsia as a potential 
confounder, and no confounding was present. BMI may 
Table 4 The adjusted odds ratios of asthma in adolescence in 617 Norwegian children by weight/BMI SDS and physical 
activity after backward stepwise selection of potential confounders (one model for each predictor variable)
First follow-up: 10.8 years (girls) and 11.8 years (boys); Second follow-up: 12.8 years (both sexes)
Italics numbers indicate statistically significant results
n number of participants, OR Odds ratio, CI confidence interval, LR-p likelihood ratio-test p-value refers to predictor only, BMI body mass index (kg/m2), SDS standard 
deviation score, N.A. not applicable
a After stepwise backward selection, adjusted for sex, gestational age, mother’s preeclampsia and asthma
b After stepwise backward selection, adjusted for sex, mother’s preeclampsia and mother’s asthma
c Also adjusted for physical activity at 3–6 years
d Also adjusted for physical activity at 6–10 years
e Also adjusted for BMI SDS at 4 years
f Also adjusted for BMISDS at the first follow-up
Predictor Outcome variable (final analyses)
Asthma ever by first follow-upa Current asthma at second follow-upb
Age n OR 95 % CI LR-p n OR 95 % CI LR-p
Weight SDS
Birth 580 0.93 (0.72, 1.20) 0.587 439 0.95 (0.71, 1.27) 0.716
BMI SDS
3 months 520 0.88 (0.64, 1.21) 0.437 411 0.96 (0.67, 1.38) 0.835
6 months 536 1.06 (0.79, 1.41) 0.707 425 0.86 (0.61, 1.20) 0.370
1 year 536 1.00 (0.76, 1.32) 0.998 424 0.78 (0.57, 1.08) 0.127
4 yearsc 454 1.09 (0.80, 1.47) 0.596 361 0.91 (0.63, 1.32) 0.627
First follow-upd 558 1.02 (0.79, 1.33) 0.849 426 1.10 (0.81, 1.49) 0.561
Second follow-upd N.A. N.A. N.A. N.A. 421 1.25 (0.90, 1.72) 0.176
Physical activity
At 3–6 yearse 454 0.014 361 0.475
 Normal 275 1.00 Reference 220 1.00 Reference
 Low 57 3.61 (1.56, 8.36) 48 1.92 (0.66, 5.59)
 High 122 1.34 (0.61, 2.97) 93 1.40 (0.55, 3.55)
At 6–10 yearsf 558 0.038 426 0.177
 Normal 351 1.00 Reference 274 1.00 Reference
 Low 92 2.52 (1.24, 5.12) 69 1.98 (0.80, 4.85)
 High 115 1.02 (0.46, 2.28) 83 1.97 (0.83, 4.67)
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have limited correlation with childhood adiposity [3], and 
we did not have other adiposity measurements available 
from the visits at the well-baby clinics. Children who par-
ticipated in the first follow-up but not in the second fol-
low-up had a higher BMI and more atopic dermatitis. This 
may have biased our results, as both overweight and atopic 
dermatitis may be associated with atopic sensitization and 
other atopic disease. Only the predictors and not the out-
comes were measured longitudinally, thus we cannot know 
if the associations reveal causality, or the direction of the 
causality. Lastly, due to several statistical analyses, the sta-
tistically significant results must be interpreted with care.
Conclusions
The results of this study suggest that BMI and physical activ-
ity in early childhood are associated with atopic sensitiza-
tion, atopic dermatitis and asthma in later childhood. Larger 
cohorts with repeated measurements of both predictors and 
outcomes are needed to further elucidate this issue.
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